{ "instance": { "mor-20221231.htm": { "axisCustom": 8, "axisStandard": 36, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 41, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 1765 }, "contextCount": 917, "dts": { "calculationLink": { "local": [ "mor-20221231_cal.xml" ] }, "definitionLink": { "local": [ "mor-20221231_def.xml" ] }, "inline": { "local": [ "mor-20221231.htm" ] }, "labelLink": { "local": [ "mor-20221231_lab.xml" ] }, "presentationLink": { "local": [ "mor-20221231_pre.xml" ] }, "schema": { "local": [ "mor-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd" ] } }, "elementCount": 1151, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 329, "keyStandard": 283, "memberCustom": 184, "memberStandard": 45, "nsprefix": "mor", "nsuri": "http://www.morphosys.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.morphosys.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:NotesToTheBalanceSheetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Notes to the Balance Sheet", "menuCat": "Notes", "order": "10", "role": "http://www.morphosys.com/role/NotestotheBalanceSheet", "shortName": "Notes to the Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:NotesToTheBalanceSheetTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i700f3dcf0a81408480224e130c3f8092_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000102 - Disclosure - RS - Summary of equity-settled 2019 Long-term Incentive Plan MOR AG (Details)", "menuCat": "Details", "order": "100", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "shortName": "RS - Summary of equity-settled 2019 Long-term Incentive Plan MOR AG (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i700f3dcf0a81408480224e130c3f8092_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4602ec1a3e114539bb62cf4922c587e6_I20190401", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000103 - Disclosure - RS - Summary of equity-settled 2019 Long-term Incentive Plan MOR US (Details)", "menuCat": "Details", "order": "101", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "shortName": "RS - Summary of equity-settled 2019 Long-term Incentive Plan MOR US (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4602ec1a3e114539bb62cf4922c587e6_I20190401", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfTheLTIPlansTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i305a49f012374c68bdbc304cf89d3b6d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000104 - Disclosure - RS - Summary of Development of equity-settled Long-term Incentive Plans (Details)", "menuCat": "Details", "order": "102", "role": "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "shortName": "RS - Summary of Development of equity-settled Long-term Incentive Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfTheLTIPlansTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i305a49f012374c68bdbc304cf89d3b6d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfFairValueOfPerformanceSharesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "id207435ef5864df0bd38ab28caf588c3_D20190401-20190430", "decimals": "2", "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "reportCount": 1, "unique": true, "unitRef": "eurPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000105 - Disclosure - RS - Summary of Fair Value of equity-settled Long-term Incentive Plan (Details)", "menuCat": "Details", "order": "103", "role": "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "shortName": "RS - Summary of Fair Value of equity-settled Long-term Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfFairValueOfPerformanceSharesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "id207435ef5864df0bd38ab28caf588c3_D20190401-20190430", "decimals": "2", "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "reportCount": 1, "unique": true, "unitRef": "eurPerShare", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000106 - Disclosure - RS - Summary of equity-settled 2020 Restricted Stock Unit Plans (Details)", "menuCat": "Details", "order": "104", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "shortName": "RS - Summary of equity-settled 2020 Restricted Stock Unit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ie0388c98ecec44dba9e10cab7409b320_I20200401", "decimals": "0", "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i889ea14ec0344e1abdf34deaf1e80d8b_I20210401", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000107 - Disclosure - RS - Summary of equity-settled 2021 Restricted Stock Unit Plans (Details)", "menuCat": "Details", "order": "105", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "shortName": "RS - Summary of equity-settled 2021 Restricted Stock Unit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i889ea14ec0344e1abdf34deaf1e80d8b_I20210401", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "id1e15cc9bf764f5ebd46e3d408b645be_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "share_unit_type", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000108 - Disclosure - RS - Summary of equity-settled 2022 Restricted Stock Unit Plan (Details)", "menuCat": "Details", "order": "106", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "shortName": "RS - Summary of equity-settled 2022 Restricted Stock Unit Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "iadeba9f112da43478c559655b697dcec_I20221231", "decimals": "2", "lang": "en-US", "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "reportCount": 1, "unique": true, "unitRef": "eurPerShare", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4bae006e5d6345adb7c2340929daff38_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000109 - Disclosure - RS - Summary of Development of equity-settled Restricted Stock Unit Plans (Details)", "menuCat": "Details", "order": "107", "role": "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "shortName": "RS - Summary of Development of equity-settled Restricted Stock Unit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4bae006e5d6345adb7c2340929daff38_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000110 - Disclosure - RS - Summary of cash-settled 2019 Restricted Stock Unit Plan (Details)", "menuCat": "Details", "order": "108", "role": "http://www.morphosys.com/role/RSSummaryofcashsettled2019RestrictedStockUnitPlanDetails", "shortName": "RS - Summary of cash-settled 2019 Restricted Stock Unit Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4bae006e5d6345adb7c2340929daff38_I20221231", "decimals": "2", "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ib5a105060b0e4ee6b072d932f8921499_I20200601", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000111 - Disclosure - RS - Summary of cash-settled 2020 Performance Share Unit Program (Details)", "menuCat": "Details", "order": "109", "role": "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "shortName": "RS - Summary of cash-settled 2020 Performance Share Unit Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ib5a105060b0e4ee6b072d932f8921499_I20200601", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DisclosureOfRemunerationSystemForManagementBoardAndEmployeesOfGroupExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Remuneration System for the Management Board and Employees of the Group", "menuCat": "Notes", "order": "11", "role": "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroup", "shortName": "Remuneration System for the Management Board and Employees of the Group", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DisclosureOfRemunerationSystemForManagementBoardAndEmployeesOfGroupExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i38196aea0ee94ab28daefeaee39c20cc_I20210401", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000112 - Disclosure - RS -Summary of cash-settled Performance Share Unit Program (Details)", "menuCat": "Details", "order": "110", "role": "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "shortName": "RS -Summary of cash-settled Performance Share Unit Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i38196aea0ee94ab28daefeaee39c20cc_I20210401", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ide3dcaa4acf94f84979a3ea2d4fbc848_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000113 - Disclosure - RS - Summary of cash-settled 2022 Performance Share Unit Program (Details)", "menuCat": "Details", "order": "111", "role": "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "shortName": "RS - Summary of cash-settled 2022 Performance Share Unit Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ide3dcaa4acf94f84979a3ea2d4fbc848_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000114 - Disclosure - RS - Summary of cash-settled Long-term Incentive Cash Plan (Details)", "menuCat": "Details", "order": "112", "role": "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "shortName": "RS - Summary of cash-settled Long-term Incentive Cash Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i3afe604f32324fa6b4ff008fd68bae97_I20200430", "decimals": "3", "lang": "en-US", "name": "mor:PercentageOfSharesVested", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfCashSettledProgramsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ibb969bc5fb1348169f1a6dce80c7925a_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000115 - Disclosure - RS - Summary of Development of cash-settled Performance Share Unit Programs (Details)", "menuCat": "Details", "order": "113", "role": "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "shortName": "RS - Summary of Development of cash-settled Performance Share Unit Programs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfCashSettledProgramsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ibb969bc5fb1348169f1a6dce80c7925a_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i7dfc56f42fc245298f406ff4580ac16e_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "reportCount": 1, "unique": true, "unitRef": "eurPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000116 - Disclosure - RS - Summary of Fair Value of cash-settled Performance Share Unit Programs (Details)", "menuCat": "Details", "order": "114", "role": "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "shortName": "RS - Summary of Fair Value of cash-settled Performance Share Unit Programs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i7dfc56f42fc245298f406ff4580ac16e_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "reportCount": 1, "unique": true, "unitRef": "eurPerShare", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000117 - Disclosure - RS - Summary of Related Parties (Details)", "menuCat": "Details", "order": "115", "role": "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "shortName": "RS - Summary of Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfSharesOfRelatedPartiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i27ce3a6b334741fdbf9ff81ab896c311_I20221231", "decimals": "0", "lang": "en-US", "name": "mor:NumberOfSharesIssuedToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i27ce3a6b334741fdbf9ff81ab896c311_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000118 - Disclosure - RS - Summary of Stock Options of Related Parties (Details)", "menuCat": "Details", "order": "116", "role": "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "shortName": "RS - Summary of Stock Options of Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i27ce3a6b334741fdbf9ff81ab896c311_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPerformanceSharesOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i600f2719f6834fdb8922f372c6c89f46_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000119 - Disclosure - RS - Summary of Performance Shares of Related Parties (Details)", "menuCat": "Details", "order": "117", "role": "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "shortName": "RS - Summary of Performance Shares of Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPerformanceSharesOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i600f2719f6834fdb8922f372c6c89f46_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000120 - Disclosure - RS - Summary of Remuneration of Key Management Personnel (Details)", "menuCat": "Details", "order": "118", "role": "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails", "shortName": "RS - Summary of Remuneration of Key Management Personnel (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfRemunerationOfSupervisoryBoardTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i6c4108fe66d14c59a074684695128d38_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:RemunerationOfSupervisoryBoard", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000121 - Disclosure - RS - Summary of Remuneration of Supervisory Board (Details)", "menuCat": "Details", "order": "119", "role": "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "shortName": "RS - Summary of Remuneration of Supervisory Board (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfRemunerationOfSupervisoryBoardTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i6c4108fe66d14c59a074684695128d38_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:RemunerationOfSupervisoryBoard", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Additional Notes", "menuCat": "Notes", "order": "12", "role": "http://www.morphosys.com/role/AdditionalNotes", "shortName": "Additional Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:KeyManagementPersonnelCompensation", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000122 - Disclosure - RS - Related Parties - Additional Information (Details)", "menuCat": "Details", "order": "120", "role": "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "shortName": "RS - Related Parties - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInAccruedIncomeOtherThanContractAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:FutureMinimumLeasesPaymentsOfLowValueAssetsAndOtherShortTermLeases", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000123 - Disclosure - Additional Notes - Summary of Obligations arising from Leases (Details)", "menuCat": "Details", "order": "121", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "shortName": "Additional Notes - Summary of Obligations arising from Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:FutureMinimumLeasesPaymentsOfLowValueAssetsAndOtherShortTermLeases", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R122": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "iac00bafc26164e0c9459c5e32a918a19_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:MilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000124 - Disclosure - Additional Notes - Summary of Contingent Liabilities (Details)", "menuCat": "Details", "order": "122", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesDetails", "shortName": "Additional Notes - Summary of Contingent Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "iac00bafc26164e0c9459c5e32a918a19_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:MilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R123": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000125 - Disclosure - Additional Notes - Summary of Fair Value Level of Financial Assets and Liabilities (Details)", "menuCat": "Details", "order": "123", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "shortName": "Additional Notes - Summary of Fair Value Level of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFairValueOfFinancialAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "lang": "en-US", "name": "mor:OtherReceivablesFinancialAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R124": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000126 - Disclosure - Additional Notes - Carrying Amount of Financial Instruments (Details)", "menuCat": "Details", "order": "124", "role": "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails", "shortName": "Additional Notes - Carrying Amount of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R125": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfInvestmentAtFairValueAdivoGmbHTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i9a1586d70b7046eaba547afaa51efc39_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000127 - Disclosure - Additional Notes - Summary of Investment adivo GmbH (Details)", "menuCat": "Details", "order": "125", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails", "shortName": "Additional Notes - Summary of Investment adivo GmbH (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfInvestmentAtFairValueAdivoGmbHTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i9a1586d70b7046eaba547afaa51efc39_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R126": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfChangeInInvestmentInAdivoGmbHTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000128 - Disclosure - Additional Notes - Summary of Changes Investment Adivo GmbH (Details)", "menuCat": "Details", "order": "126", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInvestmentAdivoGmbHDetails", "shortName": "Additional Notes - Summary of Changes Investment Adivo GmbH (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfChangeInInvestmentInAdivoGmbHTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R127": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfNetGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:GainLossOnFinancialInstruments", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000129 - Disclosure - Additional Notes - Net Gains or Losses from Financial Instruments (Details)", "menuCat": "Details", "order": "127", "role": "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "shortName": "Additional Notes - Net Gains or Losses from Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfNetGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:GainLossOnFinancialInstruments", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R128": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfGrossGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000130 - Disclosure - Additional Notes - Summary of Interest Income and Expense of Financial Instruments (Details)", "menuCat": "Details", "order": "128", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails", "shortName": "Additional Notes - Summary of Interest Income and Expense of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfGrossGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R129": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfImpairmentLossesOnFinancialAssetsAndProvisionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4be094a035f54042b227e1965eedbb11_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:ImpairmentLossOnFinancialAsset", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000131 - Disclosure - Additional Notes - Summary of Changes in Impairment Losses for Credit Risk (Details)", "menuCat": "Details", "order": "129", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "shortName": "Additional Notes - Summary of Changes in Impairment Losses for Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfImpairmentLossesOnFinancialAssetsAndProvisionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4be094a035f54042b227e1965eedbb11_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:ImpairmentLossOnFinancialAsset", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DescriptionOfAccountingPolicyForBASISOFANDCHANGESINACCOUNTINGSTANDARDSPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "13", "role": "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DescriptionOfAccountingPolicyForBASISOFANDCHANGESINACCOUNTINGSTANDARDSPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R130": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfGrossCarryingAmountsOfFinancialAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0b92a3e158e1494097e8d0a3fac49488_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:InternalCreditRating", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000132 - Disclosure - Additional Notes - Summary of Gross Carrying Amount of Financial Assets by Credit Risk (Details)", "menuCat": "Details", "order": "130", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "shortName": "Additional Notes - Summary of Gross Carrying Amount of Financial Assets by Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfGrossCarryingAmountsOfFinancialAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0b92a3e158e1494097e8d0a3fac49488_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:InternalCreditRating", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R131": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:MaximumExposureToCreditRiskOnDebtInstruments", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000133 - Disclosure - Additional Notes - Summary of Credit risk - Additional Information (Details)", "menuCat": "Details", "order": "131", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "shortName": "Additional Notes - Summary of Credit risk - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:MaximumExposureToCreditRiskOnDebtInstruments", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R132": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:TradeAccountsPayable", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000134 - Disclosure - Additional Notes - Summary of Contractual Cash Flows of Financial Liabilities (Details)", "menuCat": "Details", "order": "132", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "shortName": "Additional Notes - Summary of Contractual Cash Flows of Financial Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfContractualCashFlowsOfFinancialLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i646933d55c45482ca17e59f35d6b3adc_I20221231", "decimals": "-3", "lang": "en-US", "name": "mor:TradeAccountsPayable", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R133": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000135 - Disclosure - Additional Notes - Summary of Exposure to Foreign Currency Risk (Details)", "menuCat": "Details", "order": "133", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "shortName": "Additional Notes - Summary of Exposure to Foreign Currency Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i7d025427c18441f49ae25c7e0a04c689_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R134": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfSensitivityAnalysisOfForeignExchangeRatesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i861a21be4714439081b34c208a5d374d_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:ForeignExchangeSensitivityAnalysis", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000136 - Disclosure - Additional Notes - Summary of Sensitivity Analysis of Foreign Exchange Rate (Details)", "menuCat": "Details", "order": "134", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails", "shortName": "Additional Notes - Summary of Sensitivity Analysis of Foreign Exchange Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfSensitivityAnalysisOfForeignExchangeRatesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i861a21be4714439081b34c208a5d374d_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:ForeignExchangeSensitivityAnalysis", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R135": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSensitivityAnalysisOfInterestRateRiskTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "icedf3102a8684aff988fce89916c9f5a_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:ForeignExchangeSensitivityAnalysis", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000137 - Disclosure - Additional Notes - Summary of Sensitivity Analysis of Variable Interest Rate (Details)", "menuCat": "Details", "order": "135", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails", "shortName": "Additional Notes - Summary of Sensitivity Analysis of Variable Interest Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSensitivityAnalysisOfInterestRateRiskTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "icedf3102a8684aff988fce89916c9f5a_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:ForeignExchangeSensitivityAnalysis", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R136": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000138 - Disclosure - Additional Notes - Summary of Capital Management (Details)", "menuCat": "Details", "order": "136", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails", "shortName": "Additional Notes - Summary of Capital Management (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfCapitalManagementTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "3", "lang": "en-US", "name": "mor:EquityCapitalPercentage", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R137": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfDetailedInformationOfLiabilitiesArisingFromFinancialActivitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ia602b7e804474fa8b361c7a2f90902fd_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000139 - Disclosure - Additional Notes - Summary of Net Liabilities and Other Changes which are presented in Operating Activities (Details)", "menuCat": "Details", "order": "137", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "shortName": "Additional Notes - Summary of Net Liabilities and Other Changes which are presented in Operating Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfDetailedInformationOfLiabilitiesArisingFromFinancialActivitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ia602b7e804474fa8b361c7a2f90902fd_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R138": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if356cb3164eb4044811139838a4475e2_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:NoncurrentAssetsExcludingDeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000140 - Disclosure - Additional Notes - Summary of Geographical Disclosures (Details)", "menuCat": "Details", "order": "138", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "shortName": "Additional Notes - Summary of Geographical Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if356cb3164eb4044811139838a4475e2_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:NoncurrentAssetsExcludingDeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R139": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "iea087d4da1254cbabb88ba570cb7e0fa_I20100601", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:AdditionalPayments", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000141 - Disclosure - Additional Notes - Summary of Agreements Related to Proprietary Clinical Development (Details)", "menuCat": "Details", "order": "139", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails", "shortName": "Additional Notes - Summary of Agreements Related to Proprietary Clinical Development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "iea087d4da1254cbabb88ba570cb7e0fa_I20100601", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:AdditionalPayments", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "14", "role": "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R140": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:PaymentsFromHIBio", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000142 - Disclosure - Additional Notes - Summary of Agreements Related to Clinical Development trough Partners (Details)", "menuCat": "Details", "order": "140", "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "shortName": "Additional Notes - Summary of Agreements Related to Clinical Development trough Partners (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:PaymentsFromHIBio", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:SummaryOfRevenuesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Notes to the Profit or Loss Statement (Tables)", "menuCat": "Tables", "order": "15", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables", "shortName": "Notes to the Profit or Loss Statement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:SummaryOfRevenuesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:SummaryOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Notes to the Balance Sheet (Tables)", "menuCat": "Tables", "order": "16", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetTables", "shortName": "Notes to the Balance Sheet (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:SummaryOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:SummaryOfDevelopmentOfStockOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Remuneration System for the Management Board and Employees of the Group (Tables)", "menuCat": "Tables", "order": "17", "role": "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables", "shortName": "Remuneration System for the Management Board and Employees of the Group (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:SummaryOfDevelopmentOfStockOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Additional Notes (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.morphosys.com/role/AdditionalNotesTables", "shortName": "Additional Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ie0685bd7389342139cc55bc886ed110c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:MandatoryApplicationForFinancialYearsStartingDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Summary of Significant Accounting Policies - Summary of New and Revised Standards and Interpretations (Detail)", "menuCat": "Details", "order": "19", "role": "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail", "shortName": "Summary of Significant Accounting Policies - Summary of New and Revised Standards and Interpretations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ie0685bd7389342139cc55bc886ed110c_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:MandatoryApplicationForFinancialYearsStartingDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:RevenueFromSaleOfGoods", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Consolidated Statement of Profit or Loss", "menuCat": "Statements", "order": "2", "role": "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "shortName": "Consolidated Statement of Profit or Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:RevenueFromSaleOfGoods", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfNewAndRevisedStandardsAndInterpretationsWhichWereNotYetMandatoryForFinancialYearOrWereNotYetAdoptedByEuropeanUnionWereNotAppliedExplanatoryTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i03455e4fe6714526a6675c1ed53d9d8a_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:MandatoryApplicationForFinancialYearsStartingDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies - Summary of New and Revised Standards and Interpretations, not yet Mandatorily Applicable (Detail)", "menuCat": "Details", "order": "20", "role": "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail", "shortName": "Summary of Significant Accounting Policies - Summary of New and Revised Standards and Interpretations, not yet Mandatorily Applicable (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfNewAndRevisedStandardsAndInterpretationsWhichWereNotYetMandatoryForFinancialYearOrWereNotYetAdoptedByEuropeanUnionWereNotAppliedExplanatoryTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i03455e4fe6714526a6675c1ed53d9d8a_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:MandatoryApplicationForFinancialYearsStartingDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutInSignificantInvestmentsInSubsidiariesExplanatoryTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ibff130722e0b40759e18c91471b56be7_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:PurchaseOfSharesEstablishment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies - Summary of Consolidation Methods (Detail)", "menuCat": "Details", "order": "21", "role": "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Consolidation Methods (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutInSignificantInvestmentsInSubsidiariesExplanatoryTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ibff130722e0b40759e18c91471b56be7_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:PurchaseOfSharesEstablishment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i556892dd8cdf4b7c9eed8218d5b39f26_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Property Plant and Equipment (Detail)", "menuCat": "Details", "order": "22", "role": "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Property Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i556892dd8cdf4b7c9eed8218d5b39f26_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0b3b6a1081eb4d52a8754b50bf4dc0b2_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Summary of Significant Accounting Policies - Summary Of Useful Lives Of Intangible Assets Including Goodwill (Detail)", "menuCat": "Details", "order": "23", "role": "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail", "shortName": "Summary of Significant Accounting Policies - Summary Of Useful Lives Of Intangible Assets Including Goodwill (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0b3b6a1081eb4d52a8754b50bf4dc0b2_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Revenue (Detail)", "menuCat": "Details", "order": "24", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail", "shortName": "Notes to the Profit or Loss Statement - Summary Of Revenue (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfRevenuesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i130d040cd0b948de8074a12be1e4fb5d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Regional Distribution of Revenue (Detail)", "menuCat": "Details", "order": "25", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail", "shortName": "Notes to the Profit or Loss Statement - Summary Of Regional Distribution of Revenue (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfRegionalDistributionOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i8d376794e77c44bf9dcbb9625f0b05c0_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Notes to the Profit or Loss Statement - Summary of Satisfaction of Performance Obligations (Details)", "menuCat": "Details", "order": "26", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails", "shortName": "Notes to the Profit or Loss Statement - Summary of Satisfaction of Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "mor:SatisfactionOfPerformanceObligationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:CostOfSales", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Notes to the Profit or Loss Statement - Summary of Cost of Sales (Detail)", "menuCat": "Details", "order": "27", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of Cost of Sales (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutCostOfSalesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i8e4eeeb303ed42b2bb917155b20a4d18_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:CostOfSales", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Notes to the Profit or Loss Statement - Summary of Research and Development Expenses (Detail)", "menuCat": "Details", "order": "28", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of Research and Development Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i6e4cd9869f3149a99244b3950589c057_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:SellingExpense", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Notes to the Profit or Loss Statement - Summary of Selling Expenses (Detail)", "menuCat": "Details", "order": "29", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of Selling Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfSellingExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i6e4cd9869f3149a99244b3950589c057_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:SellingExpense", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Statement of Comprehensive Income", "menuCat": "Statements", "order": "3", "role": "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome", "shortName": "Consolidated Statement of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "lang": "en-US", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:GeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Notes to the Profit or Loss Statement - Summary of General and Administrative Expenses (Detail)", "menuCat": "Details", "order": "30", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of General and Administrative Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i6e4cd9869f3149a99244b3950589c057_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:EmployeeBenefitsExpense", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Notes to the Profit or Loss Statement - Summary of Personnel Expenses (Detail)", "menuCat": "Details", "order": "31", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of Personnel Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:EmployeeBenefitsExpense", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Notes to the Profit or Loss Statement - Summary of Personnel Expenses - Additional information (Details)", "menuCat": "Details", "order": "32", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesAdditionalinformationDetails", "shortName": "Notes to the Profit or Loss Statement - Summary of Personnel Expenses - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:AverageNumberOfEmployeesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfEmployees", "reportCount": 1, "unique": true, "unitRef": "employees", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Average Number Of Employees (Detail)", "menuCat": "Details", "order": "33", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary Of Average Number Of Employees (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:AverageNumberOfEmployeesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfEmployees", "reportCount": 1, "unique": true, "unitRef": "employees", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Notes to the Profit or Loss Statement - Impairment of Goodwill (Details)", "menuCat": "Details", "order": "34", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementImpairmentofGoodwillDetails", "shortName": "Notes to the Profit or Loss Statement - Impairment of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:GainLossOnCessationOfConsolidationOfSubsidiariesDueToChangeOfInvestmentEntityStatus", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Notes to the Profit or Loss Statement - Summary of Other Income and Expenses, Finance Income and Expenses (Detail)", "menuCat": "Details", "order": "35", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of Other Income and Expenses, Finance Income and Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:GainLossOnCessationOfConsolidationOfSubsidiariesDueToChangeOfInvestmentEntityStatus", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfMajorComponentsOfIncomeTaxTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentTaxExpenseIncome", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Notes to the Profit or Loss Statement - Summary of Income Taxes (Detail)", "menuCat": "Details", "order": "36", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfMajorComponentsOfIncomeTaxTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentTaxExpenseIncome", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "mor:CorporateTaxRate", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Notes to the Profit or Loss Statement - Summary of Income Taxes - Additional Information (Detail)", "menuCat": "Details", "order": "37", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "mor:CorporateTaxRate", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfReconciliationOfExpectedIncomeTaxExpenseWithActualIncomeTaxExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Notes to the Profit or Loss Statement - Summary of Reconciliation of Expected Income Tax Expense with Actual Income Tax Expense (Detail)", "menuCat": "Details", "order": "38", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail", "shortName": "Notes to the Profit or Loss Statement - Summary of Reconciliation of Expected Income Tax Expense with Actual Income Tax Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfReconciliationOfExpectedIncomeTaxExpenseWithActualIncomeTaxExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i58a90e4733054ab6bb9ace516bb1f3fd_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:PriorYearTaxLossesCarryforwards", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Detailed Information About In Limited Unlimited Carry Forward Tax Losses (Detail)", "menuCat": "Details", "order": "39", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail", "shortName": "Notes to the Profit or Loss Statement - Summary Of Detailed Information About In Limited Unlimited Carry Forward Tax Losses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i58a90e4733054ab6bb9ace516bb1f3fd_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:PriorYearTaxLossesCarryforwards", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheet", "menuCat": "Statements", "order": "4", "role": "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "lang": "en-US", "name": "mor:TradeReceivablesAndContractAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:DeferredTaxAssets", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Notes to the Profit or Loss Statement - Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Detail)", "menuCat": "Details", "order": "40", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail", "shortName": "Notes to the Profit or Loss Statement - Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDeferredTaxAssetsAndDeferredTaxLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:DeferredTaxLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ia3e048f11ec242e59e5175f128a34814_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:DeferredTaxItemsRecognizedAgainstEquity", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Notes to the Profit or Loss Statement - Schedule of Changes in Deferred Taxes (Detail)", "menuCat": "Details", "order": "41", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "shortName": "Notes to the Profit or Loss Statement - Schedule of Changes in Deferred Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ia3e048f11ec242e59e5175f128a34814_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:DeferredTaxItemsRecognizedAgainstEquity", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Reconciliation Of Earning Per Share (Detail)", "menuCat": "Details", "order": "42", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail", "shortName": "Notes to the Profit or Loss Statement - Summary Of Reconciliation Of Earning Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfEarningsPerShareTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "lang": "en-US", "name": "mor:InterestInConnectionWithDilutiveShares", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Notes to the Profit or Loss Statement - Earnings Per Share - Additional Information (Detail)", "menuCat": "Details", "order": "43", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail", "shortName": "Notes to the Profit or Loss Statement - Earnings Per Share - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "lang": "en-US", "name": "mor:NumberOfRestrictedStockUnitsUnvested", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Notes to the Balance Sheet - Summary of Cash and Cash Equivalents (Details)", "menuCat": "Details", "order": "44", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails", "shortName": "Notes to the Balance Sheet - Summary of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i1d5590482dc9486da8935170ea3bea7b_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentFinancialAssetsAvailableforsale", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Notes to the Balance Sheet - Summary of Other Financial Assets (Details)", "menuCat": "Details", "order": "45", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "shortName": "Notes to the Balance Sheet - Summary of Other Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i1d5590482dc9486da8935170ea3bea7b_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentFinancialAssetsAvailableforsale", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialAssetsAtAmortizedCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentLoansAndReceivables", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Notes to the Balance Sheet - Summary of Other Financial Assets at Amortized Cost (Details)", "menuCat": "Details", "order": "46", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "shortName": "Notes to the Balance Sheet - Summary of Other Financial Assets at Amortized Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialAssetsAtAmortizedCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentLoansAndReceivables", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsReceivableByRegionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentTradeReceivables", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Notes to the Balance Sheet - Summary of Accounts Receivable by Region (Details)", "menuCat": "Details", "order": "47", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "shortName": "Notes to the Balance Sheet - Summary of Accounts Receivable by Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsReceivableByRegionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i8e6b3a37690248aab0ed379f9c22cfb4_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:CurrentTradeReceivables", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:AccountsReceivableNonInterestBearingPaymentTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Notes to the Balance Sheet - Summary of Accounts Receivable - Additional Information (Details)", "menuCat": "Details", "order": "48", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "shortName": "Notes to the Balance Sheet - Summary of Accounts Receivable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:AccountsReceivableNonInterestBearingPaymentTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:OtherReceivables", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Notes to the Balance Sheet - Summary of Other Receivables (Details)", "menuCat": "Details", "order": "49", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails", "shortName": "Notes to the Balance Sheet - Summary of Other Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:OtherReceivables", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ibd0512055c184077903ac2b18fc4f14d_I20191231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "shortName": "Consolidated Statement of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ifd6a7792cb394614a962cc119fdb7cd8_I20191231", "decimals": "0", "lang": "en-US", "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:Inventories", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Notes to the Balance Sheet - Summary of Inventories (Details)", "menuCat": "Details", "order": "50", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails", "shortName": "Notes to the Balance Sheet - Summary of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInventoriesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:CurrentIncomeTaxReceivables", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Notes to the Balance Sheet - Summary of Income Tax Receivables (Details)", "menuCat": "Details", "order": "51", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIncomeTaxReceivablesDetails", "shortName": "Notes to the Balance Sheet - Summary of Income Tax Receivables (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPrepaidExpensesAndOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i04adb09c99414743b09eeda4718962d7_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentPrepaidExpenses", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Notes to the Balance Sheet - Summary of Current Prepaid Expenses and Other Assets (Details)", "menuCat": "Details", "order": "52", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails", "shortName": "Notes to the Balance Sheet - Summary of Current Prepaid Expenses and Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPrepaidExpensesAndOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i04adb09c99414743b09eeda4718962d7_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentPrepaidExpenses", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfNonCurrentPrepaidExpensesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:NoncurrentPrepaidExpenses", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Notes to the Balance Sheet - Summary of Non-Current Prepaid Expenses (Details)", "menuCat": "Details", "order": "53", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails", "shortName": "Notes to the Balance Sheet - Summary of Non-Current Prepaid Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfNonCurrentPrepaidExpensesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:NoncurrentPrepaidExpenses", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:NoncurrentRestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Notes to the Balance Sheet - Summary of Prepaid Assets and Other Assets - Additional Information (Details)", "menuCat": "Details", "order": "54", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPrepaidAssetsandOtherAssetsAdditionalInformationDetails", "shortName": "Notes to the Balance Sheet - Summary of Prepaid Assets and Other Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:NoncurrentRestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ia3e048f11ec242e59e5175f128a34814_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Notes to the Balance Sheet - Summary of Property, Plant and Equipment (Details)", "menuCat": "Details", "order": "55", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails", "shortName": "Notes to the Balance Sheet - Summary of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfPropertyPlantAndEquipmentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i2e0f5817009d48d8b86a8e046860f09a_I20201231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDepreciationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:DepreciationExpense", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Notes to the Balance Sheet - Summary of Depreciation (Details)", "menuCat": "Details", "order": "56", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "shortName": "Notes to the Balance Sheet - Summary of Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDepreciationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:DepreciationExpense", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ia3e048f11ec242e59e5175f128a34814_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Notes to the Balance Sheet - Summary of Right of use Assets and Lease Liabilities (Details)", "menuCat": "Details", "order": "57", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails", "shortName": "Notes to the Balance Sheet - Summary of Right of use Assets and Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfQuantitativeInformationAboutRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:AdditionsToRightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:ComponentsOfDepreciationRightOfUseAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:DepreciationRightOfUseAssetsAfterCurrencyTranslation", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Notes to the Balance Sheet - Summary of Impact of Lease Agreements (Details)", "menuCat": "Details", "order": "58", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails", "shortName": "Notes to the Balance Sheet - Summary of Impact of Lease Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "mor:OtherInterestExpenseLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:ComponentsOfDepreciationRightOfUseAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:DepreciationRightOfUseAssetsAfterCurrencyTranslation", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Notes to the Balance Sheet - Summary of Depreciation of Right-of-Use Assets (Details)", "menuCat": "Details", "order": "59", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "shortName": "Notes to the Balance Sheet - Summary of Depreciation of Right-of-Use Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:ComponentsOfDepreciationRightOfUseAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ib05869f1848b4363af88ebfbd6371ecb_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "mor:DepreciationRightOfUseAssetsAfterCurrencyTranslation", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statement of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "shortName": "Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "lang": "en-US", "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfMaturityAnalysisOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "iab99e831ab7a431cb1bc7cff507f8d5e_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:NetLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Notes to the Balance Sheet - Summary of Maturity Analysis of Lease Liabilities (Details)", "menuCat": "Details", "order": "60", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails", "shortName": "Notes to the Balance Sheet - Summary of Maturity Analysis of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfMaturityAnalysisOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "iab99e831ab7a431cb1bc7cff507f8d5e_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:NetLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ia3e048f11ec242e59e5175f128a34814_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Notes to the Balance Sheet - Summary of Intangible Assets (Details)", "menuCat": "Details", "order": "61", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "shortName": "Notes to the Balance Sheet - Summary of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i7da8aaf9824e4cc5be636c6c2a2cff68_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAmortizationOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:AmortizationChargeForTheYear", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Notes to the Balance Sheet - Summary of Amortization of Intangible Assets (Details)", "menuCat": "Details", "order": "62", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "shortName": "Notes to the Balance Sheet - Summary of Amortization of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAmortizationOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ib05869f1848b4363af88ebfbd6371ecb_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "mor:AmortizationChargeForTheYear", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "1", "first": true, "lang": "en-US", "name": "mor:BetaFactor", "reportCount": 1, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Notes to the Balance Sheet - Summary of In process R&D Programs (Details)", "menuCat": "Details", "order": "63", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails", "shortName": "Notes to the Balance Sheet - Summary of In process R&D Programs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i155b470c18634cde8279e48edb0cc38c_I20221231", "decimals": "-5", "lang": "en-US", "name": "mor:MilestonePaymentsWereCapitalized", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Notes to the Balance Sheet - Summary of Internally generated intangible assets (Details)", "menuCat": "Details", "order": "64", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails", "shortName": "Notes to the Balance Sheet - Summary of Internally generated intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i8e6b3a37690248aab0ed379f9c22cfb4_I20221231", "decimals": "-5", "lang": "en-US", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:Goodwill", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Notes to the Balance Sheet - Summary of Goodwill (Details)", "menuCat": "Details", "order": "65", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "shortName": "Notes to the Balance Sheet - Summary of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "2", "lang": "en-US", "name": "ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentAssets", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Notes to the Balance Sheet - Summary of Investment in Associate HI-BIO (Details)", "menuCat": "Details", "order": "66", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "shortName": "Notes to the Balance Sheet - Summary of Investment in Associate HI-BIO (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "mor:MilestonePayments", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Notes to the Balance Sheet - Summary of Investments in Associates (Details)", "menuCat": "Details", "order": "67", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "shortName": "Notes to the Balance Sheet - Summary of Investments in Associates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfInvestmentsInAssociatesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ifd40f3f8ae5144afbd17219eb3401552_I20220614", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:DeferredTaxAssets", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Notes to the Balance Sheet - Summary of Deferred Tax Assets (Details)", "menuCat": "Details", "order": "68", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxAssetsDetails", "shortName": "Notes to the Balance Sheet - Summary of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:TradeAccountsPayable", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Notes to the Balance Sheet - Summary of Accounts Payables (Details)", "menuCat": "Details", "order": "69", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails", "shortName": "Notes to the Balance Sheet - Summary of Accounts Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "lang": "en-US", "name": "mor:AccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - General Information", "menuCat": "Notes", "order": "7", "role": "http://www.morphosys.com/role/GeneralInformation", "shortName": "General Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAuditFeesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:AuditFeesAndOtherAuditrelatedCosts", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Notes to the Balance Sheet - Summary of Accrued Expenses (Details)", "menuCat": "Details", "order": "70", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails", "shortName": "Notes to the Balance Sheet - Summary of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccruedExpensesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i6dca64a1571d4e1a8a3b59163f402bda_I20221231", "decimals": "-3", "lang": "en-US", "name": "mor:ExternalLaboratoryServices", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAuditFeesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:AuditFees", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Notes to the Balance Sheet - Summary of Audit fees (Details)", "menuCat": "Details", "order": "71", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails", "shortName": "Notes to the Balance Sheet - Summary of Audit fees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAuditFeesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:AuditFees", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:TaxLiabilitiesCurrentAndNonCurrent", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Notes to the Balance Sheet - Summary of Tax Liabilities and Other Provisions (Details)", "menuCat": "Details", "order": "72", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails", "shortName": "Notes to the Balance Sheet - Summary of Tax Liabilities and Other Provisions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:TaxLiabilitiesCurrentAndNonCurrent", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Notes to the Balance Sheet - Summary of Contract Liabilities (Details)", "menuCat": "Details", "order": "73", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails", "shortName": "Notes to the Balance Sheet - Summary of Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NetDeferredTaxLiabilities", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Notes to the Balance Sheet - Summary of Deferred Tax Liabilities (Details)", "menuCat": "Details", "order": "74", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxLiabilitiesDetails", "shortName": "Notes to the Balance Sheet - Summary of Deferred Tax Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:NominalAmountBond", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Notes to the Balance Sheet - Summary of Bonds (Details)", "menuCat": "Details", "order": "75", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "shortName": "Notes to the Balance Sheet - Summary of Bonds (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:NominalAmountBond", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfFinancialAssetsFromCollaborationsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "id0b1b623f94840c0b3e11531a8d81f6e_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:FinancialAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Notes to the Balance Sheet - Summary of Financial Assets from Collaborations (Details)", "menuCat": "Details", "order": "76", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails", "shortName": "Notes to the Balance Sheet - Summary of Financial Assets from Collaborations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfFinancialAssetsFromCollaborationsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "id0b1b623f94840c0b3e11531a8d81f6e_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:FinancialAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:RevenueRecognitionMilestoneMethodRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Notes to the Balance Sheet - Summary of Financial Assets from Collaborations - Additional Information (Details)", "menuCat": "Details", "order": "77", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "shortName": "Notes to the Balance Sheet - Summary of Financial Assets from Collaborations - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "mor:RevenueRecognitionMilestoneMethodRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfSensitivityAnalysisOfFairValueMeasurementDueToChangesInMulipleUnobervableInputsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if29be5a8fb424452a07d641755c85f55_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Notes to the Balance Sheet - Summary of Sensitivity Analysis Financial Assets from Collaborations (Details)", "menuCat": "Details", "order": "78", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "shortName": "Notes to the Balance Sheet - Summary of Sensitivity Analysis Financial Assets from Collaborations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:DisclosureOfSensitivityAnalysisOfFairValueMeasurementDueToChangesInMulipleUnobervableInputsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if29be5a8fb424452a07d641755c85f55_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Notes to the Balance Sheet - Summary of Financial Liabilities from Future Payments to Royalty Pharma (Details)", "menuCat": "Details", "order": "79", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "shortName": "Notes to the Balance Sheet - Summary of Financial Liabilities from Future Payments to Royalty Pharma (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "icf00c582437a47828aa506ad3d5a2572_I20221231", "decimals": "-3", "lang": "en-US", "name": "mor:CurrentPortionOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.morphosys.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ia3e048f11ec242e59e5175f128a34814_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Notes to the Balance Sheet - Summary of Royalty Pharma - Financial Liability (Details)", "menuCat": "Details", "order": "80", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails", "shortName": "Notes to the Balance Sheet - Summary of Royalty Pharma - Financial Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i678635e631cb444e8158649ce28abbaa_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfSensitivityAnalysisOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i275ebba370db4536bd01d749a3a01adb_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Notes to the Balance Sheet - Summary of Sensitivity Analysis Royalty Pharma - Financial Liability (Details)", "menuCat": "Details", "order": "81", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "shortName": "Notes to the Balance Sheet - Summary of Sensitivity Analysis Royalty Pharma - Financial Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfSensitivityAnalysisOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i275ebba370db4536bd01d749a3a01adb_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Notes to the Balance Sheet - Summary of Development Funding Bond (Details)", "menuCat": "Details", "order": "82", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "shortName": "Notes to the Balance Sheet - Summary of Development Funding Bond (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "mor:SummaryOfDevelopmentFundingBondTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ie603fa8f02fa42a3a81954ca7ed7cc35_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "mor:AdjustmentForMarketInequity", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "true" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0b2fb15b5d054cb1aeac8972817eb2fe_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:DevelopmentFundingBondMeasurementLoss", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Notes to the Balance Sheet - Summary of DFB, Initial Measurement Loss (Details)", "menuCat": "Details", "order": "83", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "shortName": "Notes to the Balance Sheet - Summary of DFB, Initial Measurement Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0b2fb15b5d054cb1aeac8972817eb2fe_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "mor:DevelopmentFundingBondMeasurementLoss", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:IssuedCapital", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Notes to the Balance Sheet - Summary of Common Stock (Details)", "menuCat": "Details", "order": "84", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "shortName": "Notes to the Balance Sheet - Summary of Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfSharesAuthorised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Notes to the Balance Sheet - Summary of Authorized Capital (Details)", "menuCat": "Details", "order": "85", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails", "shortName": "Notes to the Balance Sheet - Summary of Authorized Capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfSharesAuthorised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:NumberOfSharesOfConditionalCapital", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Notes to the Balance Sheet - Summary of Conditional Capital (Details)", "menuCat": "Details", "order": "86", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "shortName": "Notes to the Balance Sheet - Summary of Conditional Capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:NumberOfSharesOfConditionalCapital", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:NumberOfTreasuryShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - Notes to the Balance Sheet - Summary of Treasury Shares (Details)", "menuCat": "Details", "order": "87", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails", "shortName": "Notes to the Balance Sheet - Summary of Treasury Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "mor:NumberOfTreasuryShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:AdditionalPaidinCapital", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - Notes to the Balance Sheet - Summary of Additional Paid-in Capital (Details)", "menuCat": "Details", "order": "88", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "shortName": "Notes to the Balance Sheet - Summary of Additional Paid-in Capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "lang": "en-US", "name": "mor:IncreaseInCapitalReserve", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - Notes to the Balance Sheet - Summary of Accumulated Deficit (Details)", "menuCat": "Details", "order": "89", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccumulatedDeficitDetails", "shortName": "Notes to the Balance Sheet - Summary of Accumulated Deficit (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DisclosureOfAnalysisOfIncomeStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Notes to the Profit or Loss Statement", "menuCat": "Notes", "order": "9", "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatement", "shortName": "Notes to the Profit or Loss Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i5bcb2600be314d3da4706500f441408d_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mor:DisclosureOfAnalysisOfIncomeStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000092 - Disclosure - Notes to the Balance Sheet - Summary of Other Comprehensive Income Reserve (Details)", "menuCat": "Details", "order": "90", "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherComprehensiveIncomeReserveDetails", "shortName": "Notes to the Balance Sheet - Summary of Other Comprehensive Income Reserve (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ic76b8534cc324f01b0624b703dd4921d_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:ReserveOfExchangeDifferencesOnTranslation", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "mor:SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "ie94b3d4d3e404789936a822194008c95_D20220101-20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000093 - Disclosure - RS - Summary of equity-settled 2017 Stock Option Plan Group (Details)", "menuCat": "Details", "order": "91", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "shortName": "RS - Summary of equity-settled 2017 Stock Option Plan Group (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if804161c5cd24ff9b0f26552ae394330_I20221231", "decimals": "1", "lang": "en-US", "name": "mor:SubscriptionRight", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0e213e95eeda4ef7aac0c3b52c2e1164_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000094 - Disclosure - RS - Summary of equity-settled 2018 Stock Option Plan (Details)", "menuCat": "Details", "order": "92", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "shortName": "RS - Summary of equity-settled 2018 Stock Option Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i3eedeb5510194ea985d9a73d97bf621e_I20221231", "decimals": "1", "lang": "en-US", "name": "mor:SubscriptionRight", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if72c6354d85446e199ef76e723e306cd_I20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "mor:SubscriptionRight", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000095 - Disclosure - RS - Summary of equity-settled 2019 Stock Option Plan (Details)", "menuCat": "Details", "order": "93", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "shortName": "RS - Summary of equity-settled 2019 Stock Option Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if72c6354d85446e199ef76e723e306cd_I20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "mor:SubscriptionRight", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0b92895d9ba24edc8921c300e766c3bd_I20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "mor:SubscriptionRight", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000096 - Disclosure - RS - Summary of equity-settled 2020 Stock Option Plan (Details)", "menuCat": "Details", "order": "94", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "shortName": "RS - Summary of equity-settled 2020 Stock Option Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i0b92895d9ba24edc8921c300e766c3bd_I20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "mor:SubscriptionRight", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4a5cd57e462e4a4d9629840f6eb7381b_I20211001", "decimals": "2", "first": true, "lang": "en-US", "name": "mor:SubscriptionRight", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000097 - Disclosure - RS - Summary of equity-settled 2021 Stock Option Plan (Details)", "menuCat": "Details", "order": "95", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "shortName": "RS - Summary of equity-settled 2021 Stock Option Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i4a5cd57e462e4a4d9629840f6eb7381b_I20211001", "decimals": "2", "first": true, "lang": "en-US", "name": "mor:SubscriptionRight", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfStockOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if804161c5cd24ff9b0f26552ae394330_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000098 - Disclosure - RS - Summary of Development of equity-settled Stock Option Plans (Details)", "menuCat": "Details", "order": "96", "role": "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "shortName": "RS - Summary of Development of equity-settled Stock Option Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfStockOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "if804161c5cd24ff9b0f26552ae394330_I20221231", "decimals": "0", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i2cbe162ec5454cb2b47740038ac733cd_D20180401-20180430", "decimals": "2", "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "reportCount": 1, "unique": true, "unitRef": "eurPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000099 - Disclosure - RS - Summary of Fair Value of equity-settled Stock Option Plans (Details)", "menuCat": "Details", "order": "97", "role": "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "shortName": "RS - Summary of Fair Value of equity-settled Stock Option Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i2cbe162ec5454cb2b47740038ac733cd_D20180401-20180430", "decimals": "2", "first": true, "lang": "en-US", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "reportCount": 1, "unique": true, "unitRef": "eurPerShare", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i3af5b1fa607442dbba3436fd3cd603e1_I20221231", "decimals": "1", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000100 - Disclosure - RS - Summary of equity-settled 2017 Long-term Incentive Plan (Details)", "menuCat": "Details", "order": "98", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "shortName": "RS - Summary of equity-settled 2017 Long-term Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i3af5b1fa607442dbba3436fd3cd603e1_I20221231", "decimals": "1", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i1a3dfe736e6640a9804f25f2d92dcb3d_I20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000101 - Disclosure - RS - Summary of equity-settled 2018 Long-term Incentive Plan (Details)", "menuCat": "Details", "order": "99", "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "shortName": "RS - Summary of equity-settled 2018 Long-term Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mor-20221231.htm", "contextRef": "i1a3dfe736e6640a9804f25f2d92dcb3d_I20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "mor:PerformanceCriteria", "reportCount": 1, "unique": true, "unitRef": "rate", "xsiNil": "false" } } }, "segmentCount": 247, "tag": { "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "Germany [member]" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "US [member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "US [member]" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]", "terseLabel": "Business Contact" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name", "terseLabel": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard", "terseLabel": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement", "terseLabel": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report", "terseLabel": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]", "terseLabel": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]", "terseLabel": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.morphosys.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "exch_XETR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "XETRA [Member]", "terseLabel": "XETRA [Member]" } } }, "localname": "XETR", "nsuri": "http://xbrl.sec.gov/exch/2022", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccountingProfit": { "auth_ref": [ "r42", "r43" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Accounting profit", "negatedLabel": "Earnings Before Income Taxes" } } }, "localname": "AccountingProfit", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "auth_ref": [ "r48", "r57", "r94", "r103", "r106" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Accumulated depreciation, amortisation and impairment [member]" } } }, "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedImpairmentMember": { "auth_ref": [ "r191", "r203", "r302", "r316", "r320", "r345", "r350", "r353", "r354" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } }, "en-us": { "role": { "label": "Accumulated impairment [member]", "terseLabel": "Impairment [member]" } } }, "localname": "AccumulatedImpairmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r333" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated other comprehensive income [member]", "terseLabel": "Other Comprehensive Income Reserve [member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Acquisitions through business combinations, intangible assets other than goodwill", "terseLabel": "Additions through business combinations" } } }, "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Acquisitions through business combinations, property, plant and equipment", "terseLabel": "Additions through business combinations" } } }, "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination": { "auth_ref": [ "r189" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of additional contingent liabilities recognised in business combinations. [Refer: Contingent liabilities recognised in business combination; Business combinations [member]; Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Additional liabilities, contingent liabilities recognised in business combination", "terseLabel": "Additional liabilities" } } }, "localname": "AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionalPaidinCapital": { "auth_ref": [ "r336" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } }, "en-us": { "role": { "label": "Additional paid-in capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional Paid-inCapital" } } }, "localname": "AdditionalPaidinCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionalPaidinCapitalMember": { "auth_ref": [ "r333" ], "lang": { "en": { "role": { "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } }, "en-us": { "role": { "label": "Additional paid-in capital [member]", "terseLabel": "Additional paid-in capital [member]" } } }, "localname": "AdditionalPaidinCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "Additions" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustedWeightedAverageShares": { "auth_ref": [ "r80" ], "lang": { "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "verboseLabel": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } } }, "localname": "AdjustedWeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "sharesItemType" }, "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods." } }, "en-us": { "role": { "label": "Adjustments for current tax of prior periods", "terseLabel": "Current tax expense (income) and adjustments for current tax of prior periods" } } }, "localname": "AdjustmentsForCurrentTaxOfPriorPeriod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeOtherThanContractAssets": { "auth_ref": [ "r356" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for the decrease (increase) in accrued income other than contract assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Accrued income other than contract assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in accrued income other than contract assets", "terseLabel": "Accrued expenses for payments to key management personnel" } } }, "localname": "AdjustmentsForDecreaseIncreaseInAccruedIncomeOtherThanContractAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets": { "auth_ref": [ "r359" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 15.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in derivative financial assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in derivative financial assets", "terseLabel": "Net (Gain) / Loss on Derivative Financial Instruments" } } }, "localname": "AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "auth_ref": [ "r356" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 16.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other operating receivables", "terseLabel": "Inventories, Prepaid Expenses and Other Assets, Tax Receivables and Other Receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r359" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Adjustments for decrease (increase) in trade and other receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "auth_ref": [ "r357" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for depreciation and amortisation expense", "terseLabel": "Depreciation and Amortization of Tangible and Intangible Assets and of Right-of-Use Assets" } } }, "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceCosts": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance costs", "negatedTerseLabel": "Expenses from Carrying Amount Adjustments of Financial Liabilities at Amortized cost" } } }, "localname": "AdjustmentsForFinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncome": { "auth_ref": [ "r359" ], "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance income", "terseLabel": "Income from Carrying Amount Adjustments of Financial Liabilities at Amortized Cost" } } }, "localname": "AdjustmentsForFinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates": { "auth_ref": [ "r359" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals investments in subsidiaries, joint ventures and associates to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries, joint ventures and associates reported in separate financial statements; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates", "terseLabel": "Gain from Deconsolidation of Subsidiaries" } } }, "localname": "AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r359" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } }, "en-us": { "role": { "label": "Adjustments for gain (loss) on disposals, property, plant and equipment", "negatedLabel": "Net (Gain) / Loss on Sale of Property, Plant and Equipment" } } }, "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "auth_ref": [ "r357" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]" } }, "en-us": { "role": { "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss", "terseLabel": "Impairments of Assets" } } }, "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "auth_ref": [ "r112" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 14.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Income Tax Benefit" } } }, "localname": "AdjustmentsForIncomeTaxExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": { "auth_ref": [ "r356" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 18.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in deferred income including contract liabilities", "terseLabel": "Contract Liability" } } }, "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments to Reconcile Consolidated Net Profit / (Loss) to Net Cash Provided by / (Used in) Operating Activities:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r357" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based Payment" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregateOfFairValuesMember": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "This member stands for the aggregate of fair values. It also represents the standard value for the 'Fair value as deemed cost' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregate of fair values [member]", "terseLabel": "Aggregate of fair values [member]" } } }, "localname": "AggregateOfFairValuesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r101", "r105", "r146" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated measurement [member]", "terseLabel": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r22", "r159", "r170", "r171", "r198", "r235", "r236", "r237", "r243", "r274", "r304", "r306" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]", "terseLabel": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r58", "r147" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All levels of fair value hierarchy [member]", "terseLabel": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Analysis of income and expense [abstract]", "terseLabel": "Analysis of income and expense [abstract]" } } }, "localname": "AnalysisOfIncomeAndExpenseAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "Expected Tax Rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r18", "r146", "r147", "r149", "r222", "r225" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_AssociatesMember": { "auth_ref": [ "r68", "r73", "r75", "r145", "r247", "r253" ], "lang": { "en": { "role": { "documentation": "This member stands for the entities over which the investor has significant influence." } }, "en-us": { "role": { "label": "Associates [member]", "terseLabel": "Associates [member]" } } }, "localname": "AssociatesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AtFairValueMember": { "auth_ref": [ "r101", "r105", "r146" ], "lang": { "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } }, "en-us": { "role": { "label": "At fair value [member]", "terseLabel": "Fair value [member]" } } }, "localname": "AtFairValueMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AverageEffectiveTaxRate": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Average effective tax rate", "terseLabel": "Average effective tax rate" } } }, "localname": "AverageEffectiveTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "percentItemType" }, "ifrs-full_AverageNumberOfEmployees": { "auth_ref": [ "r334" ], "lang": { "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } }, "en-us": { "role": { "label": "Average number of employees", "terseLabel": "Average number of employees" } } }, "localname": "AverageNumberOfEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "decimalItemType" }, "ifrs-full_BankAndSimilarCharges": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of bank and similar charges recognised by the entity as an expense." } }, "en-us": { "role": { "label": "Bank and similar charges", "negatedLabel": "Bank Fees" } } }, "localname": "BankAndSimilarCharges", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r77", "r78" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Earnings per Share, Basic", "verboseLabel": "Basic" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "perShareItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r152", "r180", "r237", "r290", "r291", "r365" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Bottom of range [member]" } } }, "localname": "BottomOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BuildingsMember": { "auth_ref": [ "r344" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Buildings [member]", "terseLabel": "Buildings [member]" } } }, "localname": "BuildingsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BusinessCombinationsAxis": { "auth_ref": [ "r188" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Business combinations [axis]", "terseLabel": "Business combinations [axis]" } } }, "localname": "BusinessCombinationsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r48", "r54", "r94", "r98", "r102", "r103", "r104", "r105", "r106", "r191", "r203", "r204", "r367", "r368" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r54", "r98", "r102", "r104", "r105", "r191", "r203", "r204", "r316", "r319" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying amount [member]", "terseLabel": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Bank Balances and Cash in Hand" } } }, "localname": "Cash", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r13", "r118", "r138" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and Cash Equivalents at the End of the Period", "periodStartLabel": "Cash and Cash Equivalents at the Beginning of the Period", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": { "auth_ref": [ "r113" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities", "terseLabel": "Cash Receipts from Sales of Subsidiaries" } } }, "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r107", "r119" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net Cash Provided by / (Used in) Financing Activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Financing Activities:" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r107", "r119" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net Cash Provided by / (Used in) Investing Activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Investing Activities:" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r107", "r119" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net Cash Provided by / (Used in) Operating Activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Operating Activities:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "auth_ref": [ "r214" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of financial assets [axis]", "terseLabel": "Categories of financial assets [axis]" } } }, "localname": "CategoriesOfFinancialAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r69" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]", "terseLabel": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in deferred tax liability (asset) [abstract]", "terseLabel": "Changes in deferred tax liability (asset) [abstract]" } } }, "localname": "ChangesInDeferredTaxLiabilityAssetAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r82", "r84", "r151", "r169" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]", "terseLabel": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r82", "r151", "r169" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]", "terseLabel": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r208", "r209", "r234", "r244", "r245", "r246" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial assets [axis]", "terseLabel": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r208", "r209", "r234", "r245" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial liabilities [axis]", "terseLabel": "Classes of financial liabilities [axis]" } } }, "localname": "ClassesOfFinancialLiabilitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "auth_ref": [ "r351" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets and goodwill [axis]", "terseLabel": "Classes of intangible assets and goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r99" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]", "terseLabel": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfLiabilitiesAxis": { "auth_ref": [ "r151" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of liabilities [axis]", "terseLabel": "Classes of liabilities [axis]" } } }, "localname": "ClassesOfLiabilitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "auth_ref": [ "r77" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of ordinary shares [axis]", "terseLabel": "Classes of ordinary shares [axis]" } } }, "localname": "ClassesOfOrdinarySharesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r55" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]", "terseLabel": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfProvisionsAxis": { "auth_ref": [ "r90" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of other provisions [axis]", "terseLabel": "Classes of other provisions [axis]" } } }, "localname": "ClassesOfProvisionsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]", "terseLabel": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]", "terseLabel": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]", "terseLabel": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]", "terseLabel": "Items that may be reclassified to Profit or Loss" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]", "terseLabel": "Items that will not be reclassified to Profit or Loss" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r3", "r33", "r122", "r126", "r135", "r289" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "terseLabel": "Total Comprehensive Income", "totalLabel": "Total Comprehensive Income" } } }, "localname": "ComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComputerEquipmentMember": { "auth_ref": [ "r344" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Computer equipment [member]", "terseLabel": "Computer Hardware [member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_ComputerSoftwareMember": { "auth_ref": [ "r277" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Computer software [member]", "terseLabel": "Software [member]", "verboseLabel": "Software [member]" } } }, "localname": "ComputerSoftwareMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_ContingentLiabilitiesIncurredInRelationToInterestsInAssociates": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of contingent liabilities incurred relating to the entity's interests in associates. [Refer: Associates [member]; Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Contingent liabilities incurred in relation to interests in associates", "terseLabel": "Contingent liabilities incurred in relation to interests in associates" } } }, "localname": "ContingentLiabilitiesIncurredInRelationToInterestsInAssociates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContingentLiabilitiesMember": { "auth_ref": [ "r92", "r189" ], "lang": { "en": { "role": { "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used." } }, "en-us": { "role": { "label": "Contingent liabilities [member]", "terseLabel": "Contingent liabilities [member]" } } }, "localname": "ContingentLiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContractLiabilities": { "auth_ref": [ "r153", "r155" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } }, "en-us": { "role": { "label": "Contract liabilities", "terseLabel": "Contract liabilities" } } }, "localname": "ContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "auth_ref": [ "r278" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]", "terseLabel": "Patents [member]" } } }, "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_CostOfSales": { "auth_ref": [ "r1", "r39" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 2.0, "parentTag": "ifrs-full_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } }, "en-us": { "role": { "label": "Cost of sales", "negatedLabel": "Cost of Sales", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSales", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CostOfSalesMember": { "auth_ref": [ "r331", "r334" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to goods or services sold. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss." } }, "en-us": { "role": { "label": "Cost of sales [member]", "terseLabel": "Cost Of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CreditRiskMember": { "auth_ref": [ "r238", "r239", "r240", "r297" ], "lang": { "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Credit risk [member]", "terseLabel": "Credit risk [member]" } } }, "localname": "CreditRiskMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrencyRiskMember": { "auth_ref": [ "r216", "r238", "r239", "r240", "r241" ], "lang": { "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Currency risk [member]", "terseLabel": "Currency risk [member]" } } }, "localname": "CurrencyRiskMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r23", "r131", "r289" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "terseLabel": "Current Assets", "totalLabel": "Total Current Assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current Assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentContractLiabilities": { "auth_ref": [ "r153" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Contract Liability - thereof short-term" } } }, "localname": "CurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentFinancialAssets": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Current financial assets", "terseLabel": "Current financial assets" } } }, "localname": "CurrentFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentFinancialAssetsAtAmortisedCost": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Current financial assets at amortised cost", "terseLabel": "Financial assets at amortised cost" } } }, "localname": "CurrentFinancialAssetsAtAmortisedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Current financial assets at fair value through profit or loss", "terseLabel": "Financial assets at fair value through profit or loss" } } }, "localname": "CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentFinancialAssetsAvailableforsale": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Current financial assets]" } }, "en-us": { "role": { "label": "Current financial assets available-for-sale", "terseLabel": "Current financial assets available-for-sale" } } }, "localname": "CurrentFinancialAssetsAvailableforsale", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentFinancialLiabilities": { "auth_ref": [ "r199" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Current financial liabilities", "terseLabel": "Current financial liabilities" } } }, "localname": "CurrentFinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost": { "auth_ref": [ "r212", "r257" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current financial liabilities measured at amortised cost. [Refer: Financial liabilities at amortised cost]" } }, "en-us": { "role": { "label": "Current financial liabilities at amortised cost", "negatedTerseLabel": "Financial liabilities at amortised cost" } } }, "localname": "CurrentFinancialLiabilitiesAtAmortisedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentInvestments": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current investments." } }, "en-us": { "role": { "label": "Current investments", "terseLabel": "Current investments" } } }, "localname": "CurrentInvestments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r162" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r24", "r133", "r289" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "terseLabel": "Current Liabilities", "totalLabel": "Total Current Liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentLoansAndReceivables": { "auth_ref": [ "r255" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current loans and receivables. [Refer: Loans and receivables]" } }, "en-us": { "role": { "label": "Current loans and receivables", "terseLabel": "Cost" } } }, "localname": "CurrentLoansAndReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPortionOfLongtermBorrowings": { "auth_ref": [ "r336" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Current portion of non-current borrowings", "terseLabel": "Bonds" } } }, "localname": "CurrentPortionOfLongtermBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Current prepaid expenses" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [ "r336" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } }, "en-us": { "role": { "label": "Current prepayments and other current assets", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentProvisions": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Current provisions", "negatedTerseLabel": "Current provisions" } } }, "localname": "CurrentProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": { "auth_ref": [ "r346" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]" } }, "en-us": { "role": { "label": "Current raw materials and current production supplies", "terseLabel": "Raw materials and supplies" } } }, "localname": "CurrentRawMaterialsAndCurrentProductionSupplies", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentRestrictedCashAndCashEquivalents": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } }, "en-us": { "role": { "label": "Current restricted cash and cash equivalents", "terseLabel": "Restricted Cash (included in Other Assets, Net of Current Portion)" } } }, "localname": "CurrentRestrictedCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncome": { "auth_ref": [ "r266" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } }, "en-us": { "role": { "label": "Current tax expense (income)", "negatedLabel": "Current Tax Benefit / (Expense)" } } }, "localname": "CurrentTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]" } }, "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods", "terseLabel": "Current tax expense (income) and adjustments for current tax of prior periods" } } }, "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTradeReceivables": { "auth_ref": [ "r261", "r262" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Accounts Receivable" } } }, "localname": "CurrentTradeReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsAssets": { "auth_ref": [ "r150" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of decrease in the fair value measurement of assets due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions." } }, "en-us": { "role": { "label": "Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets", "terseLabel": "Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets" } } }, "localname": "DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities": { "auth_ref": [ "r150" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of decrease in the fair value measurement of liabilities due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions." } }, "en-us": { "role": { "label": "Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities", "negatedTerseLabel": "Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities", "terseLabel": "Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities" } } }, "localname": "DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": { "auth_ref": [ "r298", "r300", "r307" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Decrease through derecognition, financial assets", "negatedTerseLabel": "Cash Receipts", "terseLabel": "Decrease through derecognition, financial assets" } } }, "localname": "DecreaseThroughDerecognitionFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInvestmentAdivoGmbHDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxAssets": { "auth_ref": [ "r17", "r19", "r44" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Deferred tax assets", "negatedTerseLabel": "Deferred Tax Asset", "terseLabel": "Deferred Tax Asset" } } }, "localname": "DeferredTaxAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets and liabilities [abstract]", "terseLabel": "Deferred tax assets and liabilities [abstract]" } } }, "localname": "DeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax expense arising from the write-down, or reversal of a previous write-down, of a deferred tax asset. [Refer: Deferred tax assets]" } }, "en-us": { "role": { "label": "Deferred tax expense arising from write-down or reversal of write-down of deferred tax asset", "terseLabel": "Deferred tax expense arising from write-down or reversal of write-down of deferred tax asset" } } }, "localname": "DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncome": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Deferred tax expense (income)", "negatedLabel": "Deferred Tax Benefit / (Expenses)" } } }, "localname": "DeferredTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "auth_ref": [ "r45" ], "lang": { "en": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Deferred tax expense (income) recognised in profit or loss", "terseLabel": "Recognized in Profit or Loss" } } }, "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Deferred tax expense (income) relating to origination and reversal of temporary differences", "negatedTerseLabel": "Deferred tax income from temporary differences" } } }, "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxLiabilities": { "auth_ref": [ "r17", "r19", "r44" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } }, "en-us": { "role": { "label": "Deferred tax liabilities", "negatedTerseLabel": "Deferred Tax Liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Deferred tax relating to items credited (charged) directly to equity", "terseLabel": "Recognized in Equity" } } }, "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationAndAmortisationExpense": { "auth_ref": [ "r2", "r39", "r139", "r220", "r227", "r258" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation and amortisation expense", "negatedTerseLabel": "Depreciation and Amortization", "terseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationExpense": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation expense", "terseLabel": "Depreciation" } } }, "localname": "DepreciationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r53", "r56" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "terseLabel": "Depreciation Charge for the Year" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r163" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedTerseLabel": "Depreciation, right-of-use assets" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r182" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected Volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": { "auth_ref": [ "r86", "r87" ], "lang": { "en": { "role": { "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]" } }, "en-us": { "role": { "label": "Growth rate used to extrapolate cash flow projections", "terseLabel": "Perpetual growth rate" } } }, "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r93" ], "lang": { "en": { "role": { "documentation": "Description of useful life used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description of useful life, intangible assets other than goodwill", "terseLabel": "Useful Life" } } }, "localname": "DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": { "auth_ref": [ "r47" ], "lang": { "en": { "role": { "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description of useful life, property, plant and equipment", "terseLabel": "Useful Life" } } }, "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r77", "r78" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Earnings per Share, Diluted", "verboseLabel": "Diluted" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "perShareItemType" }, "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": { "auth_ref": [ "r349" ], "lang": { "en": { "role": { "documentation": "The number of dilutive potential ordinary shares that relate to the assumed conversion of the entity's convertible instruments." } }, "en-us": { "role": { "label": "Dilutive effect of convertible instruments on number of ordinary shares", "terseLabel": "Dilutive effect of convertible instruments on number of ordinary shares" } } }, "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": { "auth_ref": [ "r349" ], "lang": { "en": { "role": { "documentation": "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options." } }, "en-us": { "role": { "label": "Dilutive effect of share options on number of ordinary shares", "terseLabel": "Dilutive Shares" } } }, "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "sharesItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of contingent liabilities [line items]", "terseLabel": "Disclosure of contingent liabilities [line items]" } } }, "localname": "DisclosureOfContingentLiabilitiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "auth_ref": [ "r91" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } }, "en-us": { "role": { "label": "Disclosure of contingent liabilities [table]", "terseLabel": "Disclosure of contingent liabilities [table]" } } }, "localname": "DisclosureOfContingentLiabilitiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } }, "en-us": { "role": { "label": "Disclosure of general information about financial statements [text block]", "terseLabel": "General Information" } } }, "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/GeneralInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of geographical areas [line items]", "terseLabel": "Disclosure of geographical areas [line items]" } } }, "localname": "DisclosureOfGeographicalAreasLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } }, "en-us": { "role": { "label": "Disclosure of geographical areas [table]", "terseLabel": "Disclosure of geographical areas [table]" } } }, "localname": "DisclosureOfGeographicalAreasTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements." } }, "en-us": { "role": { "label": "Disclosure of notes and other explanatory information [text block]", "terseLabel": "Additional Notes" } } }, "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotes" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of associates [line items]", "terseLabel": "Disclosure of associates [line items]" } } }, "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "auth_ref": [ "r73", "r75", "r145" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to associates." } }, "en-us": { "role": { "label": "Disclosure of associates [table]", "terseLabel": "Disclosure of associates [table]" } } }, "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r249" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disposals, intangible assets other than goodwill", "terseLabel": "Disposals" } } }, "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedTerseLabel": "Disposals, property, plant and equipment" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DividendsReceived": { "auth_ref": [ "r130" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of dividends received." } }, "en-us": { "role": { "label": "Dividends received", "terseLabel": "Dividends received" } } }, "localname": "DividendsReceived", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share [abstract]", "terseLabel": "Earnings per Share (in \u20ac)" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r109", "r110" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Effect of Exchange Rate Differences on Cash" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r2", "r39", "r258" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense", "terseLabel": "Employee benefits expense" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForAssociatesMember": { "auth_ref": [ "r73", "r75", "r145", "r248", "r254" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for associates [member]", "terseLabel": "Entity's total for associates [member]" } } }, "localname": "EntitysTotalForAssociatesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForBusinessCombinationsMember": { "auth_ref": [ "r188", "r192" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for business combinations [member]", "terseLabel": "Entity's total for business combinations [member]" } } }, "localname": "EntitysTotalForBusinessCombinationsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r69" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]", "terseLabel": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "auth_ref": [ "r73", "r75", "r144" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for subsidiaries [member]", "terseLabel": "Entity's total for subsidiaries [member]" } } }, "localname": "EntitysTotalForSubsidiariesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r18", "r27", "r121", "r125", "r146", "r147", "r149" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Stockholders' Equity", "totalLabel": "Total Stockholders' Equity" } } }, "localname": "Equity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Stockholders' Equity" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r18" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "terseLabel": "Total Capital", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "EquityAndLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]", "terseLabel": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "auth_ref": [ "r180" ], "lang": { "en": { "role": { "documentation": "The exercise price of outstanding share options." } }, "en-us": { "role": { "label": "Exercise price of outstanding share options", "terseLabel": "Exercise price of outstanding share options" } } }, "localname": "ExercisePriceOfOutstandingShareOptions2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from cash-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from cash-settled share-based payment transactions", "terseLabel": "Expense from cash-settled share-based payment transactions" } } }, "localname": "ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from equity-settled share-based payment transactions", "terseLabel": "Expense from equity-settled share-based payment transactions" } } }, "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2019RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": { "auth_ref": [ "r166" ], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "order": 2.0, "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets." } }, "en-us": { "role": { "label": "Expense relating to leases of low-value assets for which recognition exemption has been used", "terseLabel": "Expense relating to leases of low-value assets for which recognition exemption has been used" } } }, "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "auth_ref": [ "r165" ], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "order": 4.0, "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease." } }, "en-us": { "role": { "label": "Expense relating to short-term leases for which recognition exemption has been used", "terseLabel": "Expense relating to short-term leases for which recognition exemption has been used" } } }, "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FairValueAsDeemedCostAxis": { "auth_ref": [ "r124" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Fair value as deemed cost [axis]", "terseLabel": "Fair value as deemed cost [axis]" } } }, "localname": "FairValueAsDeemedCostAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r194", "r213" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Investments in equity instruments designated at fair value through other comprehensive income", "terseLabel": "Fair Value of Adivo GmbH" } } }, "localname": "FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r35" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 5.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedLabel": "Finance Expenses", "negatedTerseLabel": "Finance Expenses", "verboseLabel": "Reimbursement costs" } } }, "localname": "FinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r340" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 4.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 }, "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "terseLabel": "Finance Income", "totalLabel": "Finance Income" } } }, "localname": "FinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssets": { "auth_ref": [ "r199", "r203", "r204", "r206", "r302" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } } }, "localname": "FinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "auth_ref": [ "r211" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Financial assets at amortised cost, category [member]", "terseLabel": "Financial assets at amortised cost, category [member]" } } }, "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsAtFairValue": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Fair value of the financial asset" } } }, "localname": "FinancialAssetsAtFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets; Other comprehensive income]" } }, "en-us": { "role": { "label": "Financial assets at fair value through other comprehensive income", "negatedTerseLabel": "Through Other Comprehensive Income" } } }, "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInvestmentAdivoGmbHDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r210" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets at fair value through profit or loss", "terseLabel": "Other Financial Assets" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "auth_ref": [ "r210" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Financial assets at fair value through profit or loss, category [member]", "terseLabel": "Financial assets at fair value through profit or loss, category [member]" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsCategoryMember": { "auth_ref": [ "r214" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, category [member]", "terseLabel": "Financial assets, category [member]" } } }, "localname": "FinancialAssetsCategoryMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r208", "r209", "r234", "r244", "r245", "r246" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, class [member]", "terseLabel": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r199" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial liabilities", "negatedTerseLabel": "Financial liabilities", "terseLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "auth_ref": [ "r215" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } }, "en-us": { "role": { "label": "Financial liabilities at amortised cost, class [member]", "terseLabel": "Financial liabilities at amortised cost [member]" } } }, "localname": "FinancialLiabilitiesAtAmortisedCostMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesMember": { "auth_ref": [ "r208", "r209", "r234", "r245" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, class [member]", "terseLabel": "Financial liabilities, class [member]" } } }, "localname": "FinancialLiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinishedGoods": { "auth_ref": [ "r263", "r346" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current finished goods", "terseLabel": "Current finished goods" } } }, "localname": "FinishedGoods", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FixturesAndFittingsMember": { "auth_ref": [ "r270" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Fixtures and fittings [member]", "terseLabel": "Furniture and fixtures [member]" } } }, "localname": "FixturesAndFittingsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ForeignExchangeLoss": { "auth_ref": [ "r8", "r61" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Foreign exchange loss", "negatedTerseLabel": "Foreign exchange loss" } } }, "localname": "ForeignExchangeLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainLossOnCessationOfConsolidationOfSubsidiariesDueToChangeOfInvestmentEntityStatus": { "auth_ref": [ "r129" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gain (loss) arising on the cessation of the consolidation of subsidiaries due to the change of investment entity status. [Refer: Disclosure of investment entities [text block]; Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Gain (loss) on cessation of consolidation of subsidiaries due to change of investment entity status", "terseLabel": "Gain from Deconsolidation of Lanthio Entities" } } }, "localname": "GainLossOnCessationOfConsolidationOfSubsidiariesDueToChangeOfInvestmentEntityStatus", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Gains (losses) on exchange differences on translation of foreign operations, net of tax", "terseLabel": "Gains (losses) on exchange differences on translation of foreign operations, net of tax" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r8", "r61" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Foreign exchange gain (loss)", "terseLabel": "Foreign exchange gain (loss)" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r195" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Gains (losses) on financial assets at fair value through profit or loss", "terseLabel": "Gains (losses) on financial assets at fair value through profit or loss" } } }, "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInvestmentAdivoGmbHDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "auth_ref": [ "r340" ], "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } }, "en-us": { "role": { "label": "Gains on change in fair value of derivatives", "terseLabel": "Gain on Financial Assets at Fair Value through Profit or Loss" } } }, "localname": "GainsOnChangeInFairValueOfDerivatives", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r334" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 4.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and Administrative", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r231", "r272", "r292", "r311" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]", "terseLabel": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r231", "r272", "r292", "r311" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical areas [member]", "terseLabel": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_Goodwill": { "auth_ref": [ "r11", "r85", "r88", "r191" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GoodwillMember": { "auth_ref": [ "r276" ], "lang": { "en": { "role": { "documentation": "This member stands for goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Goodwill [member]", "terseLabel": "Goodwill [member]" } } }, "localname": "GoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r48", "r94", "r103", "r106", "r191", "r204", "r206", "r302", "r367", "r368" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross carrying amount [member]", "terseLabel": "Gross carrying amount [member]" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossProfit": { "auth_ref": [ "r259" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } }, "en-us": { "role": { "label": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": { "auth_ref": [ "r190" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 2.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]" } }, "en-us": { "role": { "label": "Impairment loss recognised in profit or loss, goodwill", "negatedTerseLabel": "Impairment of Goodwill" } } }, "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementImpairmentofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r52" ], "lang": { "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Impairment loss recognised in profit or loss, property, plant and equipment", "terseLabel": "Impairment" } } }, "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]", "terseLabel": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r36", "r40", "r42", "r43", "r71", "r142", "r221" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 8.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income Tax Benefit / (Expenses)", "negatedTerseLabel": "Actual Income Tax", "terseLabel": "Tax expense (income)" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r360" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 19.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } }, "en-us": { "role": { "label": "Income taxes paid, classified as operating activities", "negatedLabel": "Income Taxes Paid" } } }, "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r118" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Increase / (Decrease) in Cash and Cash Equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": { "auth_ref": [ "r343" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]" } }, "en-us": { "role": { "label": "Increase (decrease) in deferred tax liability (asset)", "terseLabel": "Increase (decrease) in deferred tax liability (asset)" } } }, "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "auth_ref": [ "r334" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) in number of ordinary shares issued", "terseLabel": "Effect of Share Issuance" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "auth_ref": [ "r29" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } }, "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding", "terseLabel": "Increase (decrease) in number of shares outstanding" } } }, "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r116" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through changes in fair values, liabilities arising from financing activities", "terseLabel": "Increase (decrease) through changes in fair values, liabilities arising from financing activities" } } }, "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r115" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities", "terseLabel": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities" } } }, "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities", "terseLabel": "Increase (decrease) through financing cash flows, liabilities arising from financing activities" } } }, "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill", "terseLabel": "Exchange differences" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through other changes, liabilities arising from financing activities", "terseLabel": "Increase (decrease) through other changes, liabilities arising from financing activities" } } }, "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Expenses through Share-based Payment Transactions and Issue of Convertible Instruments" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsAssets": { "auth_ref": [ "r150" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of increase in the fair value measurement of assets due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions." } }, "en-us": { "role": { "label": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets", "terseLabel": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets" } } }, "localname": "IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities": { "auth_ref": [ "r150" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of increase in the fair value measurement of liabilities due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions." } }, "en-us": { "role": { "label": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities", "negatedTerseLabel": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities", "terseLabel": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities" } } }, "localname": "IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsRecognisedInProfitOrLossAfterTaxLiabilities": { "auth_ref": [ "r362" ], "lang": { "en": { "role": { "documentation": "The amount of increase in the fair value measurement of liabilities, recognised in profit or loss after tax, due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions. [Refer: Tax income (expense)]" } }, "en-us": { "role": { "label": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, recognised in profit or loss, after tax, liabilities", "negatedTerseLabel": "Changes from Adjustments to Planning Assumptions" } } }, "localname": "IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsRecognisedInProfitOrLossAfterTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r284", "r287" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase through new leases, liabilities arising from financing activities", "terseLabel": "Increase through new leases, liabilities arising from financing activities" } } }, "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets": { "auth_ref": [ "r298", "r299", "r307" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase in financial assets resulting from origination or purchase. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Increase through origination or purchase, financial assets", "terseLabel": "Additions" } } }, "localname": "IncreaseThroughOriginationOrPurchaseFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInvestmentAdivoGmbHDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwill": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Carrying Amount" } } }, "localname": "IntangibleAssetsAndGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "auth_ref": [ "r351" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill [member]", "terseLabel": "Intangible assets and goodwill [member]" } } }, "localname": "IntangibleAssetsAndGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r11", "r98" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r99", "r276", "r294" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill [member]", "terseLabel": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpense": { "auth_ref": [ "r141", "r219", "r227" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from interest." } }, "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r196" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense for financial liabilities that are not at fair value through profit or loss. [Refer: At fair value [member]; Interest expense; Financial liabilities]" } }, "en-us": { "role": { "label": "Interest expense for financial liabilities not at fair value through profit or loss", "negatedTerseLabel": "Effective interest expense from Financial Liabilities at Amortized Cost" } } }, "localname": "InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnDebtInstrumentsIssued": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on debt instruments issued. [Refer: Interest expense; Debt instruments issued]" } }, "en-us": { "role": { "label": "Interest expense on debt instruments issued", "terseLabel": "Interest expense on debt instruments issued" } } }, "localname": "InterestExpenseOnDebtInstrumentsIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r164" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "negatedTerseLabel": "Interest Expenses on Lease Liabilities", "terseLabel": "Interest Expenses on Lease Liabilities" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnOtherFinancialLiabilities": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on other financial liabilities. [Refer: Interest expense; Other financial liabilities]" } }, "en-us": { "role": { "label": "Interest expense on other financial liabilities", "negatedTerseLabel": "Interest expense on other financial liabilities" } } }, "localname": "InterestExpenseOnOtherFinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from interest for financial assets that are measured at amortised cost. [Refer: Interest income; Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Interest revenue for financial assets measured at amortised cost", "terseLabel": "Interest Income on Other Financial Assets at Amortized Cost" } } }, "localname": "InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } }, "en-us": { "role": { "label": "Interest paid, classified as financing activities", "negatedLabel": "Interest Paid" } } }, "localname": "InterestPaidClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } }, "en-us": { "role": { "label": "Interest received, classified as investing activities", "terseLabel": "Interest Received" } } }, "localname": "InterestReceivedClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InternalCreditGradesAxis": { "auth_ref": [ "r252", "r301", "r308", "r314", "r317" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Internal credit grades [axis]", "terseLabel": "Internal credit grades [axis]" } } }, "localname": "InternalCreditGradesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r12", "r60", "r261" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "Inventories", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod": { "auth_ref": [ "r336" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments in associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Investments in associates accounted for using equity method", "terseLabel": "Investments in associates" } } }, "localname": "InvestmentsInAssociatesAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis": { "auth_ref": [ "r194" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Investments in equity instruments designated at fair value through other comprehensive income [axis]", "terseLabel": "Investments in equity instruments designated at fair value through other comprehensive income [axis]" } } }, "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_IssueOfConvertibleInstruments": { "auth_ref": [ "r332" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } }, "en-us": { "role": { "label": "Issue of convertible instruments", "terseLabel": "Issue of convertible instruments" } } }, "localname": "IssueOfConvertibleInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "verboseLabel": "Capital Increase, Net of Issuance Cost" } } }, "localname": "IssueOfEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r264" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Common Stock" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Common stock [member]" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation", "terseLabel": "Key management personnel compensation", "totalLabel": "Key management personnel compensation" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r64" ], "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "order": 3.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, post-employment benefits", "terseLabel": "Key management personnel compensation, post-employment benefits", "verboseLabel": "Post-employment benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r66" ], "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "order": 2.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Total Share-Based Payment", "verboseLabel": "Long-term incentive compensation" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r63" ], "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "order": 1.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Key management personnel compensation, short-term employee benefits" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": { "auth_ref": [ "r65" ], "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "order": 4.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, termination benefits", "terseLabel": "Key management personnel compensation, termination benefits" } } }, "localname": "KeyManagementPersonnelCompensationTerminationBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LaterThanFiveYearsMember": { "auth_ref": [ "r170", "r171", "r243", "r304", "r305", "r309" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than five years." } }, "en-us": { "role": { "label": "Later than five years [member]", "terseLabel": "Later than five years [member]" } } }, "localname": "LaterThanFiveYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "auth_ref": [ "r303", "r309" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } }, "en-us": { "role": { "label": "Later than one year and not later than five years [member]", "terseLabel": "Later than one year and not later than five years [member]" } } }, "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearMember": { "auth_ref": [ "r21", "r315", "r318" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year." } }, "en-us": { "role": { "label": "Later than one year [member]", "terseLabel": "Later than one year [member]" } } }, "localname": "LaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r162" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilitiesMember": { "auth_ref": [ "r285", "r288" ], "lang": { "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease liabilities" } } }, "localname": "LeaseLiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r58", "r147" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level 1 of fair value hierarchy [member]", "terseLabel": "Level 1 of fair value hierarchy [member]" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level2OfFairValueHierarchyMember": { "auth_ref": [ "r147" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } }, "en-us": { "role": { "label": "Level 2 of fair value hierarchy [member]", "terseLabel": "Level 2 of fair value hierarchy [member]" } } }, "localname": "Level2OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level3OfFairValueHierarchyMember": { "auth_ref": [ "r147" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } }, "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3 of fair value hierarchy [member]" } } }, "localname": "Level3OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r58", "r147" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]", "terseLabel": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r18", "r146", "r147", "r149", "r222", "r226" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "terseLabel": "Total Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } }, "en-us": { "role": { "label": "Liabilities arising from financing activities", "terseLabel": "Liabilities arising from financing activities" } } }, "localname": "LiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011": { "auth_ref": [ "r186" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Liabilities from share-based payment transactions", "terseLabel": "Liabilities from share-based payment transactions" } } }, "localname": "LiabilitiesFromSharebasedPaymentTransactions2011", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2019RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesMember": { "auth_ref": [ "r151" ], "lang": { "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } }, "en-us": { "role": { "label": "Liabilities [member]", "terseLabel": "Liabilities [member]" } } }, "localname": "LiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LicencesMember": { "auth_ref": [ "r352" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Licences [member]", "terseLabel": "Licenses and Licenses for Marketed Products [member]" } } }, "localname": "LicencesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_LongtermBorrowings": { "auth_ref": [ "r336" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Bonds" } } }, "localname": "LongtermBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LossesOnChangeInFairValueOfDerivatives": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } }, "en-us": { "role": { "label": "Losses on change in fair value of derivatives", "negatedLabel": "Loss on Financial Assets at Fair Value through Profit or Loss" } } }, "localname": "LossesOnChangeInFairValueOfDerivatives", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major components of tax expense (income) [abstract]", "terseLabel": "Major components of tax expense (income) [abstract]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r22", "r159", "r170", "r171", "r198", "r207", "r235", "r236", "r237", "r243", "r274", "r304" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]", "terseLabel": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r101", "r105", "r146" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [axis]", "terseLabel": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NetDeferredTaxLiabilities": { "auth_ref": [ "r342" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Net deferred tax liabilities", "terseLabel": "Deferred Tax Liability" } } }, "localname": "NetDeferredTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeGain": { "auth_ref": [ "r335", "r348" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange gain", "terseLabel": "Gain on Foreign Exchange from Operating Activities" } } }, "localname": "NetForeignExchangeGain", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeLoss": { "auth_ref": [ "r335", "r348" ], "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "order": 1.0, "parentTag": "ifrs-full_OtherExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange loss", "negatedLabel": "Loss on Foreign Exchange from Operating Activities" } } }, "localname": "NetForeignExchangeLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NewIFRSsAxis": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "New IFRSs [axis]", "terseLabel": "New IFRSs [axis]" } } }, "localname": "NewIFRSsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_NewIFRSsMember": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "This member stands for IFRSs that have been issued but are not yet effective. It also represents the standard value for the 'New IFRSs' axis if no other member is used. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "New IFRSs [member]", "terseLabel": "New IFRSs [member]" } } }, "localname": "NewIFRSsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r23", "r132", "r289" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "terseLabel": "Non-current Assets", "totalLabel": "Total Non-currentAssets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current Assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentContractLiabilities": { "auth_ref": [ "r153" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Contract Liability - thereof long-term" } } }, "localname": "NoncurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentFinancialAssets": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Non-current financial assets", "terseLabel": "Non-current financial assets" } } }, "localname": "NoncurrentFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost": { "auth_ref": [ "r211" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]" } } }, "localname": "NoncurrentFinancialAssetsAtAmortisedCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentFinancialLiabilities": { "auth_ref": [ "r199" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Non-current financial liabilities", "terseLabel": "Non-current financial liabilities" } } }, "localname": "NoncurrentFinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r162" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease Liabilities" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r24", "r134", "r289" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "terseLabel": "Non-current Liabilities", "totalLabel": "Total Non-current Liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current Liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentProvisions": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Non-current provisions", "negatedLabel": "Non-current provisions" } } }, "localname": "NoncurrentProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentRestrictedCashAndCashEquivalents": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } }, "en-us": { "role": { "label": "Non-current restricted cash and cash equivalents", "terseLabel": "Non-current restricted cash" } } }, "localname": "NoncurrentRestrictedCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPrepaidAssetsandOtherAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r20", "r170", "r171", "r243", "r304", "r309" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Not later than one year [member]" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NotionalAmount": { "auth_ref": [ "r334" ], "lang": { "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } }, "en-us": { "role": { "label": "Notional amount", "terseLabel": "Nominal value of the convertible bond" } } }, "localname": "NotionalAmount", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfEmployees": { "auth_ref": [ "r334" ], "lang": { "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } }, "en-us": { "role": { "label": "Number of employees", "terseLabel": "Number of employees" } } }, "localname": "NumberOfEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r295", "r296" ], "lang": { "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of instruments granted in share-based payment arrangement", "terseLabel": "Exercisable Shares" } } }, "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r184", "r364" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Additions" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "auth_ref": [ "r364" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "terseLabel": "Allocations" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r364" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "terseLabel": "Forfeitures" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "auth_ref": [ "r364" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Number of other equity instruments outstanding in share-based payment arrangement" } } }, "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r172", "r177", "r180" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "terseLabel": "Outstanding" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r178" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "terseLabel": "Exercisable stock options" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "negatedTerseLabel": "Exercises", "terseLabel": "Exercised Stock Options" } } }, "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "auth_ref": [ "r176" ], "lang": { "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options expired in share-based payment arrangement", "terseLabel": "Expired" } } }, "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "negatedTerseLabel": "Forfeitures", "terseLabel": "Forfeitures" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Number of share options granted in share-based payment arrangement" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r28" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Authorized shares" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r332" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Ordinary Shares Issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r29" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "terseLabel": "Ordinary Shares Outstanding" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OfficeEquipmentMember": { "auth_ref": [ "r271" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Office equipment [member]", "terseLabel": "Office equipment [member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r340" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "negatedTotalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r77", "r339" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary shares [member]", "terseLabel": "Ordinary shares [member]" } } }, "localname": "OrdinarySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherAssets": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r5", "r32", "r37", "r137" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income", "totalLabel": "Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets": { "auth_ref": [ "r250", "r251" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to available-for-sale financial assets. [Refer: Financial assets available-for-sale; Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, available-for-sale financial assets", "verboseLabel": "Change in Fair Value of Shares through Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r25", "r37" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 2.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Foreign Currency Translation Differences from Consolidation", "verboseLabel": "Foreign Currency Translation Differences from Consolidation" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments": { "auth_ref": [ "r25", "r37" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) from investments in equity instruments", "terseLabel": "Change in Fair Value of Shares through Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentLiabilities": { "auth_ref": [ "r336" ], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails": { "order": 1.0, "parentTag": "mor_AccountsPayableAndAccruedExpensesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentNonfinancialAssets": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Other current non-financial assets", "terseLabel": "thereof Non-Financial Assets" } } }, "localname": "OtherCurrentNonfinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r262" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other Receivables" } } }, "localname": "OtherCurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherExpenseByNature": { "auth_ref": [ "r39", "r258" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 }, "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Other expenses, by nature", "negatedLabel": "Other Expenses", "negatedTotalLabel": "Other Expenses" } } }, "localname": "OtherExpenseByNature", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinancialLiabilities": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Other financial liabilities", "terseLabel": "Other financial liabilities" } } }, "localname": "OtherFinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherIncome": { "auth_ref": [ "r70", "r258", "r259" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other income", "terseLabel": "Other Income" } } }, "localname": "OtherIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherLongtermProvisions": { "auth_ref": [ "r26" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]" } }, "en-us": { "role": { "label": "Other non-current provisions", "terseLabel": "Provisions" } } }, "localname": "OtherLongtermProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentAssets": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } }, "en-us": { "role": { "label": "Other non-current assets", "terseLabel": "Other Current Assets" } } }, "localname": "OtherNoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNonfinancialLiabilities": { "auth_ref": [ "r336" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]" } }, "en-us": { "role": { "label": "Other non-financial liabilities", "negatedTerseLabel": "Other Non-Financial Liabilities" } } }, "localname": "OtherNonfinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherProvisions": { "auth_ref": [ "r26", "r89" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other provisions", "terseLabel": "Provisions" } } }, "localname": "OtherProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherProvisionsMember": { "auth_ref": [ "r90" ], "lang": { "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other provisions [member]", "terseLabel": "Other provisions [member]" } } }, "localname": "OtherProvisionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherReceivables": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other receivables", "terseLabel": "Other Receivables" } } }, "localname": "OtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)", "negatedLabel": "Other Effects" } } }, "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsForShareIssueCosts": { "auth_ref": [ "r355" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for share issue costs." } }, "en-us": { "role": { "label": "Payments for share issue costs", "negatedTerseLabel": "Cash Payments for Costs from Issuing Shares" } } }, "localname": "PaymentsForShareIssueCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r283" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedTerseLabel": "Cash Payments for Principal Elements of Lease Payments" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsToAndOnBehalfOfEmployees": { "auth_ref": [ "r279" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to, and on behalf of, employees." } }, "en-us": { "role": { "label": "Payments to and on behalf of employees", "terseLabel": "Payments to and on behalf of employees" } } }, "localname": "PaymentsToAndOnBehalfOfEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "auth_ref": [ "r187" ], "lang": { "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Percentage of voting equity interests acquired", "terseLabel": "Percentage of voting equity interests acquired" } } }, "localname": "PercentageOfVotingEquityInterestsAcquired", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PerformanceObligationsAxis": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Performance obligations [axis]", "terseLabel": "Performance obligations [axis]" } } }, "localname": "PerformanceObligationsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_PerformanceObligationsMember": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used." } }, "en-us": { "role": { "label": "Performance obligations [member]", "terseLabel": "Performance obligations [member]" } } }, "localname": "PerformanceObligationsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "This member stands for performance obligations satisfied at a point in time. An entity satisfies a performance obligation at a point in time, if the performance obligation is not satisfied over time. [Refer: Performance obligations [member]]" } }, "en-us": { "role": { "label": "Performance obligations satisfied at point in time [member]", "terseLabel": "Performance obligations satisfied at point in time [member]" } } }, "localname": "PerformanceObligationsSatisfiedAtPointInTimeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PerformanceObligationsSatisfiedOverTimeMember": { "auth_ref": [ "r160" ], "lang": { "en": { "role": { "documentation": "This member stands for performance obligations satisfied over time. An entity satisfies a performance obligation over time, if one of the following criteria is met: (a) the customer simultaneously receives and consumes the benefits provided by the entity\u2019s performance as the entity performs; (b) the entity\u2019s performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced; or (c) the entity\u2019s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. [Refer: Performance obligations [member]]" } }, "en-us": { "role": { "label": "Performance obligations satisfied over time [member]", "terseLabel": "Performance obligations satisfied over time [member]" } } }, "localname": "PerformanceObligationsSatisfiedOverTimeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } }, "en-us": { "role": { "label": "Post-employment benefit expense, defined contribution plans", "terseLabel": "Costs for defined-contribution plans" } } }, "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesAdditionalinformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r366" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Proceeds from disposal or maturity of available-for-sale financial assets", "verboseLabel": "Cash Receipts from Sales of Other Financial Assets" } } }, "localname": "ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": { "auth_ref": [ "r355" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of bonds, notes and debentures." } }, "en-us": { "role": { "label": "Proceeds from issue of bonds, notes and debentures", "terseLabel": "Cash Proceeds from Issuing Convertible Bonds" } } }, "localname": "ProceedsFromIssueOfBondsNotesAndDebentures", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r282" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "verboseLabel": "Cash Proceeds from Issuing Shares" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromNoncurrentBorrowings": { "auth_ref": [ "r355" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Proceeds from non-current borrowings", "terseLabel": "Cash Receipts from Financing from Collaborations" } } }, "localname": "ProceedsFromNoncurrentBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r281" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Proceeds from sales of property, plant and equipment, classified as investing activities", "verboseLabel": "Cash Receipts from Sales of Property, Plant and Equipment" } } }, "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r4", "r31", "r108", "r122", "r126", "r222", "r224", "r289", "r310", "r313" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "negatedLabel": "Consolidated Net Loss", "terseLabel": "Consolidated Net Profit / (Loss)", "totalLabel": "Consolidated Net Profit / (Loss)", "verboseLabel": "Consolidated Net Profit / (Loss)" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome", "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccumulatedDeficitDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss) from continuing operations]" } }, "en-us": { "role": { "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share", "terseLabel": "Profit used in calculating Diluted Earnings per Share" } } }, "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r275", "r340" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "terseLabel": "Operating Profit / (Loss)" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r10", "r54" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r55", "r276", "r294" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment [member]", "terseLabel": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_ProportionOfVotingPowerHeldInSubsidiary": { "auth_ref": [ "r72", "r74", "r127" ], "lang": { "en": { "role": { "documentation": "The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Proportion of voting rights held in subsidiary", "terseLabel": "Proportion of voting rights held in subsidiary" } } }, "localname": "ProportionOfVotingPowerHeldInSubsidiary", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Provisions": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits." } }, "en-us": { "role": { "label": "Provisions", "terseLabel": "Provisions" } } }, "localname": "Provisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r366" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Purchase of available-for-sale financial assets", "negatedTerseLabel": "Cash Payments to Acquire Other Financial Assets" } } }, "localname": "PurchaseOfAvailableforsaleFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r280" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedTerseLabel": "Cash Payments to Acquire Intangible Assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r280" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedTerseLabel": "Cash Payments to Acquire Property, Plant and Equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r152", "r180", "r237", "r290", "r291", "r365" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]", "terseLabel": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r152", "r180", "r237", "r290", "r291", "r365" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]", "terseLabel": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReceivablesDueFromAssociates": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of receivables due from associates. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Receivables due from associates", "terseLabel": "Receivables due from associates" } } }, "localname": "ReceivablesDueFromAssociates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReceivablesFromContractsWithCustomers": { "auth_ref": [ "r153", "r155" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due." } }, "en-us": { "role": { "label": "Receivables from contracts with customers", "terseLabel": "Accounts receivable from customer" } } }, "localname": "ReceivablesFromContractsWithCustomers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]", "terseLabel": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]" } } }, "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r100" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 1.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and Development", "negatedTerseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfChangeInValueOfTimeValueOfOptions": { "auth_ref": [ "r233", "r338" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the accumulated change in the value of the time value of options when separating the intrinsic value and time value of an option contract and designating as the hedging instrument only the changes in the intrinsic value." } }, "en-us": { "role": { "label": "Reserve of change in value of time value of options", "terseLabel": "Reserve of change in value of time value of options" } } }, "localname": "ReserveOfChangeInValueOfTimeValueOfOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherComprehensiveIncomeReserveDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Reserve of exchange differences on translation" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherComprehensiveIncomeReserveDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r264", "r265" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccumulatedDeficitDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r7", "r260" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Accumulated Income/(Deficit) [member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r34", "r136", "r193", "r217", "r223", "r229", "r230", "r232", "r258", "r259", "r289" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 1.0, "parentTag": "ifrs-full_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenues", "totalLabel": "Revenues", "verboseLabel": "Revenue" } } }, "localname": "Revenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromGovernmentGrants": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } }, "en-us": { "role": { "label": "Income from government grants", "terseLabel": "Grant Income" } } }, "localname": "RevenueFromGovernmentGrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromInterest": { "auth_ref": [ "r140", "r218", "r227", "r334" ], "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "order": 4.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from interest." } }, "en-us": { "role": { "label": "Interest income", "negatedTerseLabel": "Interest income", "terseLabel": "Interest income" } } }, "localname": "RevenueFromInterest", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods": { "auth_ref": [ "r157" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Revenue from performance obligations satisfied or partially satisfied in previous periods", "terseLabel": "Performance obligations fulfilled in previous periods" } } }, "localname": "RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromRoyalties": { "auth_ref": [ "r334" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 3.0, "parentTag": "ifrs-full_Revenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from royalties." } }, "en-us": { "role": { "label": "Royalty income", "terseLabel": "Royalties" } } }, "localname": "RevenueFromRoyalties", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromSaleOfGoods": { "auth_ref": [ "r334" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 2.0, "parentTag": "ifrs-full_Revenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Revenue from sale of goods", "terseLabel": "Product sales" } } }, "localname": "RevenueFromSaleOfGoods", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": { "auth_ref": [ "r156" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Revenue that was included in contract liability balance at beginning of period", "negatedTerseLabel": "Revenue that was included in contract liability balance at beginning of period" } } }, "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss": { "auth_ref": [ "r81", "r83" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of reversal of impairment loss recognised in profit or loss. [Refer: Reversal of impairment loss; Profit (loss)]" } }, "en-us": { "role": { "label": "Reversal of impairment loss recognised in profit or loss", "negatedLabel": "(Income) from Reversals of Impairments on Inventories" } } }, "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r168" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Right-of-Use Assets" } } }, "localname": "RightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SaleOrIssueOfTreasuryShares": { "auth_ref": [ "r332" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Sale or issue of treasury shares", "terseLabel": "Transfer of Treasury Stock for Long-Term Incentive Programs" } } }, "localname": "SaleOrIssueOfTreasuryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SegmentsAxis": { "auth_ref": [ "r84", "r154", "r222", "r273", "r312" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Segments [axis]", "terseLabel": "Segments [axis]" } } }, "localname": "SegmentsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_SegmentsMember": { "auth_ref": [ "r84", "r154", "r228", "r273", "r312" ], "lang": { "en": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used." } }, "en-us": { "role": { "label": "Segments [member]", "terseLabel": "Segments [member]" } } }, "localname": "SegmentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SellingExpense": { "auth_ref": [ "r334" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 3.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to selling activities of the entity." } }, "en-us": { "role": { "label": "Selling expense", "negatedLabel": "Selling", "terseLabel": "Selling expenses" } } }, "localname": "SellingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expense [abstract]", "terseLabel": "Selling, general and administrative expense [abstract]" } } }, "localname": "SellingGeneralAndAdministrativeExpenseAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "auth_ref": [ "r340" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 7.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]" } }, "en-us": { "role": { "label": "Share of profit (loss) of associates accounted for using equity method", "terseLabel": "Share of loss of associates accounted for using equity method" } } }, "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareOfProfitLossOfContinuingOperationsOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": { "auth_ref": [ "r143" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 21.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The entity's share of the profit (loss) from continuing operations of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Continuing operations [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss) from continuing operations]" } }, "en-us": { "role": { "label": "Share of profit (loss) from continuing operations of associates and joint ventures accounted for using equity method", "terseLabel": "Share of loss of associates accounted for using equity method" } } }, "localname": "ShareOfProfitLossOfContinuingOperationsOfAssociatesAndJointVenturesAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Share-based payment arrangements [member]", "terseLabel": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2019RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "auth_ref": [ "r73", "r75", "r145", "r248", "r254" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Associates [axis]", "terseLabel": "Associates [axis]" } } }, "localname": "SignificantInvestmentsInAssociatesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "auth_ref": [ "r73", "r75", "r144" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Subsidiaries [axis]", "terseLabel": "Subsidiaries [axis]" } } }, "localname": "SignificantInvestmentsInSubsidiariesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]", "terseLabel": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]", "terseLabel": "Statement of changes in equity [abstract]" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]", "terseLabel": "Statement of comprehensive income [abstract]" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]", "terseLabel": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]", "terseLabel": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxEffectFromChangeInTaxRate": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect from change in tax rate", "terseLabel": "Effect of Tax Rate Changes" } } }, "localname": "TaxEffectFromChangeInTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)", "negatedLabel": "Non-Tax-Deductible Items" } } }, "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfForeignTaxRates": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of foreign tax rates", "negatedLabel": "Tax Rate Differences to Local Tax Rates" } } }, "localname": "TaxEffectOfForeignTaxRates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "negatedLabel": "Expected Income Tax" } } }, "localname": "TaxExpenseIncomeAtApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]", "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "auth_ref": [ "r46" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]", "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r152", "r180", "r237", "r290", "r291", "r365" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Top of range [member]" } } }, "localname": "TopOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "negatedTerseLabel": "Trade and other current payables" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeReceivablesMember": { "auth_ref": [ "r202", "r205", "r302", "r334" ], "lang": { "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Trade receivables [member]", "terseLabel": "Accounts Receivable [member]" } } }, "localname": "TradeReceivablesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TreasuryShares": { "auth_ref": [ "r76", "r264" ], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury shares", "negatedLabel": "Treasury Stock", "terseLabel": "As of" } } }, "localname": "TreasuryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasurySharesMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury shares [member]", "terseLabel": "Treasury shares [member]" } } }, "localname": "TreasurySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfCustomersAxis": { "auth_ref": [ "r293" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of customers [axis]", "terseLabel": "Types of customers [axis]" } } }, "localname": "TypesOfCustomersAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfCustomersMember": { "auth_ref": [ "r293" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of customers. It also represents the standard value for the 'Types of customers' axis if no other member is used." } }, "en-us": { "role": { "label": "Types of customers [member]", "terseLabel": "Types of customers [member]" } } }, "localname": "TypesOfCustomersMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r197", "r200", "r201", "r238", "r239", "r240", "r242" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]", "terseLabel": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r197", "r200", "r201", "r238", "r239", "r240", "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]", "terseLabel": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r181" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]", "terseLabel": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2019RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsAxis": { "auth_ref": [ "r148", "r363" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Unobservable inputs [axis]", "terseLabel": "Unobservable inputs [axis]" } } }, "localname": "UnobservableInputsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsMember": { "auth_ref": [ "r148", "r363" ], "lang": { "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } }, "en-us": { "role": { "label": "Unobservable inputs [member]", "terseLabel": "Unobservable inputs [member]" } } }, "localname": "UnobservableInputsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "auth_ref": [ "r183" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average fair value at measurement date, share options granted", "terseLabel": "Fair Value on" } } }, "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageMember": { "auth_ref": [ "r152", "r237", "r290", "r291", "r365" ], "lang": { "en": { "role": { "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average." } }, "en-us": { "role": { "label": "Weighted average [member]", "terseLabel": "Weighted average [member]" } } }, "localname": "WeightedAverageMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Weighted-average Price" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r182" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price, share options granted", "terseLabel": "Share Price on Grant Date in" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r80" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted-average number of ordinary shares outstanding" } } }, "localname": "WeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "sharesItemType" }, "ifrs-full_WorkInProgress": { "auth_ref": [ "r263", "r346" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]" } }, "en-us": { "role": { "label": "Current work in progress", "terseLabel": "Current unfinished goods" } } }, "localname": "WorkInProgress", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "mor_A2017LongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 Long-term Incentive Plan", "label": "2017 Long-term Incentive Plan [Member]", "terseLabel": "2017 Long-term Incentive Plan [Member]" } } }, "localname": "A2017LongTermIncentivePlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2017StockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen stock option plan.", "label": "2017 Stock Option Plan [Member]", "terseLabel": "2017 Stock Option Plan [Member]" } } }, "localname": "A2017StockOptionPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails" ], "xbrltype": "domainItemType" }, "mor_A2018LongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Long-term Incentive Plan", "label": "2018 Long-term Incentive Plan [Member]", "terseLabel": "2018 Long-term Incentive Plan [Member]" } } }, "localname": "A2018LongTermIncentivePlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2018StockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen stock option plan.", "label": "2018 Stock Option Plan [Member]", "terseLabel": "2018 Stock Option Plan [Member]" } } }, "localname": "A2018StockOptionPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2019AprilStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Nineteen Stock Option Plan.", "label": "2019 April Stock Option Plan [Member]", "terseLabel": "April 2019 Stock Option Plan [Member]" } } }, "localname": "A2019AprilStockOptionPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2019LongTermIncentivePlanMORAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Long-term Incentive Plan MOR AG", "label": "2019 Long-term Incentive Plan MOR AG [Member]", "terseLabel": "2019 Long-term Incentive Plan MOR AG [Member]" } } }, "localname": "A2019LongTermIncentivePlanMORAGMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails" ], "xbrltype": "domainItemType" }, "mor_A2019LongTermIncentivePlanMORUSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Long-term Incentive Plan MOR US", "label": "2019 Long-term Incentive Plan MOR US [Member]", "terseLabel": "2019 Long-term Incentive Plan MOR US [Member]" } } }, "localname": "A2019LongTermIncentivePlanMORUSMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails" ], "xbrltype": "domainItemType" }, "mor_A2019MorphUSRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Morph. US RSU", "label": "2019 Morph. US RSU [Member]", "terseLabel": "2019 Morph. US RSU [Member]" } } }, "localname": "A2019MorphUSRSUMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2019RestrictedStockUnitPlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2019OctoberStockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October Two Thousand Nineteen Stock Option Plan.", "label": "2019 October Stock Option Plan [Member]", "terseLabel": "October 2019 Stock Option Plan [Member]" } } }, "localname": "A2019OctoberStockOptionPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2019StockOptionPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Stock Option Plans", "label": "2019 Stock Option Plans [Member]", "terseLabel": "2019 Stock Option Plans [Member]" } } }, "localname": "A2019StockOptionPlansMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2020AprilPerformanceShareUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 April Performance Share Unit", "label": "2020 April Performance Share Unit [Member]", "terseLabel": "2020 April Performance Share Unit [Member]" } } }, "localname": "A2020AprilPerformanceShareUnitMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails" ], "xbrltype": "domainItemType" }, "mor_A2020AprilRestrictedStockUnitPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 April Restricted Stock Unit Plan", "label": "2020 April Restricted Stock Unit Plan [Member]", "terseLabel": "2020 April Restricted Stock Unit Plan" } } }, "localname": "A2020AprilRestrictedStockUnitPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails" ], "xbrltype": "domainItemType" }, "mor_A2020JunePerformanceShareUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 June Performance Share Unit", "label": "2020 June Performance Share Unit [Member]", "terseLabel": "2020 June Performance Share Unit [Member]" } } }, "localname": "A2020JunePerformanceShareUnitMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails" ], "xbrltype": "domainItemType" }, "mor_A2020OctoberRestrictedStockUnitPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 October Restricted Stock Unit Plan", "label": "2020 October Restricted Stock Unit Plan [Member]", "terseLabel": "2020 October Restricted Stock Unit Plan" } } }, "localname": "A2020OctoberRestrictedStockUnitPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails" ], "xbrltype": "domainItemType" }, "mor_A2020StockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 stock Option Plan", "label": "2020 stock Option Plan [Member]", "terseLabel": "2020 Stock Option Plan [member]" } } }, "localname": "A2020StockOptionPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2021AprilPerformanceShareUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 April Performance Share Unit", "label": "2021 April Performance Share Unit [Member]", "terseLabel": "2021 April Performance Share Unit [Member]" } } }, "localname": "A2021AprilPerformanceShareUnitMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails" ], "xbrltype": "domainItemType" }, "mor_A2021AprilRestrictedStockUnitPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 April Restricted Stock Unit Plan", "label": "2021 April Restricted Stock Unit Plan [Member]", "terseLabel": "2021 April Restricted Stock Unit Plan [Member]" } } }, "localname": "A2021AprilRestrictedStockUnitPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails" ], "xbrltype": "domainItemType" }, "mor_A2021OctoberPerformanceShareUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 October Performance Share Unit", "label": "2021 October Performance Share Unit [Member]", "terseLabel": "2021 October Performance Share Unit [Member]" } } }, "localname": "A2021OctoberPerformanceShareUnitMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails" ], "xbrltype": "domainItemType" }, "mor_A2021OctoberRestrictedStockUnitPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 October Restricted Stock Unit Plan", "label": "2021 October Restricted Stock Unit Plan [Member]", "terseLabel": "2021 October Restricted Stock Unit Plan [Member]" } } }, "localname": "A2021OctoberRestrictedStockUnitPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails" ], "xbrltype": "domainItemType" }, "mor_A2021StockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Stock Option Plan", "label": "2021 Stock Option Plan [Member]", "terseLabel": "2021 Stock Option Plan [Member]" } } }, "localname": "A2021StockOptionPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2022JunePerformanceShareUnitProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 June Performance Share Unit Program", "label": "2022 June Performance Share Unit Program [Member]", "terseLabel": "2022 June Performance Share Unit Program [Member]" } } }, "localname": "A2022JunePerformanceShareUnitProgramMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails" ], "xbrltype": "domainItemType" }, "mor_A2022JuneRestrictedStockUnitPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 June Restricted Stock Unit Plan", "label": "2022 June Restricted Stock Unit Plan [Member]", "terseLabel": "2022 June Restricted Stock Unit Plan [Member]" } } }, "localname": "A2022JuneRestrictedStockUnitPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "xbrltype": "domainItemType" }, "mor_A2022OctoberPerformanceShareUnitProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 October Performance Share Unit Program", "label": "2022 October Performance Share Unit Program [Member]", "terseLabel": "2022 October Performance Share Unit Program [Member]" } } }, "localname": "A2022OctoberPerformanceShareUnitProgramMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails" ], "xbrltype": "domainItemType" }, "mor_A2022OctoberRestrictedStockUnitPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 October Restricted Stock Unit Plan", "label": "2022 October Restricted Stock Unit Plan [Member]", "terseLabel": "2022 October Restricted Stock Unit Plan [Member]" } } }, "localname": "A2022OctoberRestrictedStockUnitPlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "xbrltype": "domainItemType" }, "mor_AccountsPayableAndAccrualsCurrent": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts payable and accruals current.", "label": "Accounts payable and accruals current", "negatedTerseLabel": "Accounts payable and accruals current", "terseLabel": "Accounts Payable and Accruals" } } }, "localname": "AccountsPayableAndAccrualsCurrent", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "mor_AccountsPayableAndAccruedExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accounts payable and accrued expenses current.", "label": "Accounts payable and accrued expenses current", "totalLabel": "Accounts payable and accrued expenses current" } } }, "localname": "AccountsPayableAndAccruedExpensesCurrent", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AccountsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable [Line Items]", "label": "Accounts Payable [Line Items]", "terseLabel": "Accounts Payable [Line Items]" } } }, "localname": "AccountsPayableLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "xbrltype": "stringItemType" }, "mor_AccountsPayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable [Table]", "label": "Accounts Payable [Table]", "terseLabel": "Accounts Payable [Table]" } } }, "localname": "AccountsPayableTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "xbrltype": "stringItemType" }, "mor_AccountsReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable [Line Items]", "label": "Accounts Receivable [Line Items]", "terseLabel": "Accounts Receivable [Line Items]" } } }, "localname": "AccountsReceivableLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "xbrltype": "stringItemType" }, "mor_AccountsReceivableNonInterestBearingPaymentTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts receivables non interest bearing maturity term.", "label": "Accounts receivable non interest bearing payment terms", "terseLabel": "Non-interest bearing payment terms" } } }, "localname": "AccountsReceivableNonInterestBearingPaymentTerms", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "mor_AccountsReceivableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable [Table]", "label": "Accounts Receivable [Table]", "terseLabel": "Accounts Receivable [Table]" } } }, "localname": "AccountsReceivableTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "xbrltype": "stringItemType" }, "mor_AccruedExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Expenses [Line Items]", "label": "Accrued Expenses [Line Items]", "terseLabel": "Accrued Expenses [Line Items]" } } }, "localname": "AccruedExpensesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "mor_AccruedExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued expenses.", "label": "Accrued Expenses [member]", "terseLabel": "Accrued expenses [member]" } } }, "localname": "AccruedExpensesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "domainItemType" }, "mor_AccruedExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Expenses [Table]", "label": "Accrued Expenses [Table]", "terseLabel": "Accrued Expenses [Table]" } } }, "localname": "AccruedExpensesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "mor_AccruedLiabiityCurrent": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued liabiity.", "label": "Accrued Liabiity Current", "totalLabel": "Accrued Liabiity Current" } } }, "localname": "AccruedLiabiityCurrent", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails": { "order": 3.0, "parentTag": "mor_AccountsPayableAndAccruedExpensesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued liabilities.", "label": "Accrued Liabilities", "terseLabel": "Accruals" } } }, "localname": "AccruedLiabilities", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AccruedOutstandingExpense": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "order": 6.0, "parentTag": "mor_AccruedLiabiityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued outstanding expense.", "label": "Accrued Outstanding Expense", "terseLabel": "Accrued Outstanding Expense" } } }, "localname": "AccruedOutstandingExpense", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AccruedPersonnelExpensesForPaymentsToEmployeesAndManagement": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "order": 7.0, "parentTag": "mor_AccruedLiabiityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued personnel expenses for payments to employees and management.", "label": "Accrued personnel expenses for payments to employees and management", "terseLabel": "Accrued personnel expenses for payments to employees and management" } } }, "localname": "AccruedPersonnelExpensesForPaymentsToEmployeesAndManagement", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AccruedRevenueDeductionsFromProductSales": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "order": 4.0, "parentTag": "mor_AccruedLiabiityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued revenue deductions from product sales.", "label": "Accrued Revenue Deductions from Product Sales", "terseLabel": "Accruals for Revenue Deductions from Product Sales" } } }, "localname": "AccruedRevenueDeductionsFromProductSales", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AcquisitionsNetOfCashAcquired": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Acquisitions, Net of Cash Acquired", "label": "Acquisitions, Net of Cash Acquired", "negatedTerseLabel": "Acquisitions, Net of Cash Acquired" } } }, "localname": "AcquisitionsNetOfCashAcquired", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_AdditionForLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Addition for lease liabilities.", "label": "Addition For Lease Liabilities", "terseLabel": "Additions" } } }, "localname": "AdditionForLeaseLiabilities", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AdditionalInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Information [Line Items]", "label": "Additional Information [Line Items]", "terseLabel": "Additional Information [Line Items]" } } }, "localname": "AdditionalInformationLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "mor_AdditionalInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Information [Table]", "label": "Additional Information [Table]", "terseLabel": "Additional Information [Table]" } } }, "localname": "AdditionalInformationTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "mor_AdditionalPaidInCapitalLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Paid-In Capital [Line Items]", "label": "Additional Paid-In Capital [Line Items]", "terseLabel": "Additional Paid-In Capital [Line Items]" } } }, "localname": "AdditionalPaidInCapitalLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "xbrltype": "stringItemType" }, "mor_AdditionalPaidInCapitalTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Paid-In Capital [Table]", "label": "Additional Paid-In Capital [Table]", "terseLabel": "Additional Paid-In Capital [Table]" } } }, "localname": "AdditionalPaidInCapitalTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "xbrltype": "stringItemType" }, "mor_AdditionalPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional Payments", "label": "Additional Payments", "terseLabel": "Additional Payments" } } }, "localname": "AdditionalPayments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "mor_AdditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additions", "label": "Additions [Member]", "terseLabel": "Additions [Member]" } } }, "localname": "AdditionsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "domainItemType" }, "mor_AdditionsPropertyPlantAndEquipmentAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions property plant and equipment and intangible assets.", "label": "Additions property plant and equipment and intangible assets", "terseLabel": "Capital Expenditure" } } }, "localname": "AdditionsPropertyPlantAndEquipmentAndIntangibleAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "mor_AdivoGmbH": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adivo GmbH", "label": "Adivo GmbH", "terseLabel": "Adivo GmbH" } } }, "localname": "AdivoGmbH", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInvestmentAdivoGmbHDetails" ], "xbrltype": "monetaryItemType" }, "mor_AdivoGmbHLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adivo GmbH [Line Items]", "label": "Adivo GmbH [Line Items]", "terseLabel": "Adivo GmbH [Line Items]" } } }, "localname": "AdivoGmbHLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInvestmentAdivoGmbHDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails" ], "xbrltype": "stringItemType" }, "mor_AdivoGmbHTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adivo GmbH [Table]", "label": "Adivo GmbH [Table]", "terseLabel": "Adivo GmbH [Table]" } } }, "localname": "AdivoGmbHTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_AdivoGmbhMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adivo GmbH [Member]", "terseLabel": "Adivo GmbH [Member]" } } }, "localname": "AdivoGmbhMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails" ], "xbrltype": "domainItemType" }, "mor_AdjustmentForMarketInequity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment for Market Inequity", "label": "Adjustment for Market Inequity", "terseLabel": "Adjustment for Market Inequity" } } }, "localname": "AdjustmentForMarketInequity", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails" ], "xbrltype": "monetaryItemType" }, "mor_AdjustmentInImpairmentLossReversalOfImpairmentLossRecognisedOnFinancialAssets": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment in impairment loss reversal of impairment loss recognised on financial assets.", "label": "Adjustment In Impairment Loss Reversal Of Impairment Loss Recognised On Financial Assets", "negatedLabel": "(Income) from Reversals of Impairments / Impairments on Financial Assets" } } }, "localname": "AdjustmentInImpairmentLossReversalOfImpairmentLossRecognisedOnFinancialAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_AdjustmentInNetGainLossOnSalesOfFinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment in net (gain) / loss on sales of financial assets at fair value through profit or loss.", "label": "Adjustment in net (gain) / loss on sales of financial assets at fair value through profit or loss", "terseLabel": "Net (Gain) / Loss of Other Financial Assets" } } }, "localname": "AdjustmentInNetGainLossOnSalesOfFinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_AdjustmentsForDecreaseIncreaseInAccountsPayableAndAccrualsTaxProvisionsAndOtherProvisions": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 17.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease increase in accounts payable and accruals tax provisions and other provisions.", "label": "Adjustments For Decrease Increase In Accounts Payable And Accruals Tax Provisions And Other Provisions", "terseLabel": "Accounts Payable and Accruals, Lease Liabilities, Tax Liabilities and Provisions" } } }, "localname": "AdjustmentsForDecreaseIncreaseInAccountsPayableAndAccrualsTaxProvisionsAndOtherProvisions", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableAndContractAssets": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable and contract assets.", "label": "Adjustments for decrease (increase) in trade accounts receivable and contract assets", "terseLabel": "Accounts Receivable" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableAndContractAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_AdoptedByTheEuropeanUnionStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adopted by the European Union status.", "label": "Adopted by the European Union status", "terseLabel": "Adopted by the European Union" } } }, "localname": "AdoptedByTheEuropeanUnionStatus", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "stringItemType" }, "mor_AgreementsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements", "label": "Agreements [Axis]", "terseLabel": "Agreements [Axis]" } } }, "localname": "AgreementsAxis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "xbrltype": "stringItemType" }, "mor_AgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements", "label": "Agreements [Member]", "terseLabel": "Agreements" } } }, "localname": "AgreementsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "xbrltype": "domainItemType" }, "mor_AgreementsRelatedToClinicalDevelopmentThroughPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements Related to Clinical Development Through Partners", "label": "Agreements Related to Clinical Development Through Partners [Member]", "terseLabel": "Agreements Related to Clinical Development Through Partners [Member]" } } }, "localname": "AgreementsRelatedToClinicalDevelopmentThroughPartnersMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "xbrltype": "domainItemType" }, "mor_AgreementsRelatedToPropertyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements related to Property [Line Items]", "label": "Agreements related to Property [Line Items]", "terseLabel": "Agreements related to Property [Line Items]" } } }, "localname": "AgreementsRelatedToPropertyLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "xbrltype": "stringItemType" }, "mor_AgreementsRelatedToPropertyTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements related to Property [Table]", "label": "Agreements related to Property [Table]", "terseLabel": "Agreements related to Property [Table]" } } }, "localname": "AgreementsRelatedToPropertyTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_AgreementsRelatedToProprietaryClinicalDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements Related to Proprietary Clinical Development", "label": "Agreements Related to Proprietary Clinical Development [Member]", "terseLabel": "Agreements Related to Proprietary Clinical Development [Member]" } } }, "localname": "AgreementsRelatedToProprietaryClinicalDevelopmentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "xbrltype": "domainItemType" }, "mor_AmortisationRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortisation rate", "label": "Amortisation rate", "terseLabel": "Amortisation rate", "verboseLabel": "Depreciation rate" } } }, "localname": "AmortisationRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "textBlockItemType" }, "mor_AmortizationChargeForTheYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization Charge for the Year", "label": "Amortization Charge for the Year", "terseLabel": "Amortization Charge for the Year" } } }, "localname": "AmortizationChargeForTheYear", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_AmortizationExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization Expenses [Line Items]", "label": "Amortization Expenses [Line Items]", "terseLabel": "Amortization Expenses [Line Items]" } } }, "localname": "AmortizationExpensesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_AmortizationExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization Expenses [Table]", "label": "Amortization Expenses [Table]", "terseLabel": "Amortization Expenses [Table]" } } }, "localname": "AmortizationExpensesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_AmortizationFromEffectiveInterestMethod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization from Effective Interest Method", "label": "Amortization from Effective Interest Method", "terseLabel": "Amortization from Effective Interest Method" } } }, "localname": "AmortizationFromEffectiveInterestMethod", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "mor_AmortizationOfIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization of intangible assets.", "label": "Amortization of intangible assets [member]", "terseLabel": "Amortization of intangible assets [member]" } } }, "localname": "AmortizationOfIntangibleAssetsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_AmountWrittenOffDuringPeriodAsUncollectible": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount written off during period as uncollectible.", "label": "Amount Written Off During Period as Uncollectible", "terseLabel": "Amounts written off during the Year as uncollectible" } } }, "localname": "AmountWrittenOffDuringPeriodAsUncollectible", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_AndrewChengMDPhDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Andrew Cheng, M.D., Ph.D.", "label": "Andrew Cheng, M.D., Ph.D. [Member]", "terseLabel": "Andrew Cheng, M.D., Ph.D." } } }, "localname": "AndrewChengMDPhDMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_AnnualImprovementsToInternationalFinancialReportingStandards20182020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Improvements to International Financial Reporting Standards 2018 2020 [Member]", "terseLabel": "Annual improvements to international financial reporting standards 2018 2020 [Member]" } } }, "localname": "AnnualImprovementsToInternationalFinancialReportingStandards20182020Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail" ], "xbrltype": "domainItemType" }, "mor_AntiDilutionRightOtherReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Anti-dilution right (other receivable)", "label": "Anti-dilution right (other receivable)", "terseLabel": "Anti-dilution right (other receivable)" } } }, "localname": "AntiDilutionRightOtherReceivable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AuditFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Audit fees", "label": "Audit fees", "negatedTerseLabel": "Audit fees" } } }, "localname": "AuditFees", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AuditFeesAndOtherAuditrelatedCosts": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "order": 3.0, "parentTag": "mor_AccruedLiabiityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Audit fees and other audit-related costs.", "label": "Audit fees and other audit-related costs", "negatedTerseLabel": "Audit fees and other audit-related costs", "terseLabel": "Audit fees and other audit-related costs" } } }, "localname": "AuditFeesAndOtherAuditrelatedCosts", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "xbrltype": "monetaryItemType" }, "mor_AuditFeesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit fees [Line Items]", "label": "Audit fees [Line Items]", "terseLabel": "Audit fees [Line Items]" } } }, "localname": "AuditFeesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "xbrltype": "stringItemType" }, "mor_AuditFeesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit fees [Table]", "label": "Audit fees [Table]", "terseLabel": "Audit fees [Table]" } } }, "localname": "AuditFeesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "xbrltype": "stringItemType" }, "mor_AuthorizedCapital2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized Capital 2018", "label": "Authorized Capital 2018 [Member]", "terseLabel": "Authorized Capital 2018 [Member]" } } }, "localname": "AuthorizedCapital2018Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_AuthorizedCapital2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized Capital 2020", "label": "Authorized Capital 2020 [Member]", "terseLabel": "Authorized Capital 2020" } } }, "localname": "AuthorizedCapital2020Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_AuthorizedCapitalIIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized Capital III", "label": "Authorized Capital III [Member]", "terseLabel": "Authorized Capital III [Member]" } } }, "localname": "AuthorizedCapitalIIIMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_AuthorizedCapitalIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized Capital II", "label": "Authorized Capital II [Member]", "terseLabel": "Authorized Capital II [Member]" } } }, "localname": "AuthorizedCapitalIIMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_AuthorizedCapitalIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized Capital I", "label": "Authorized Capital I [Member]", "terseLabel": "Authorized Capital I [Member]" } } }, "localname": "AuthorizedCapitalIMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_AuthorizedCapitalLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized Capital [Line Items]", "label": "Authorized Capital [Line Items]", "terseLabel": "Authorized Capital [Line Items]" } } }, "localname": "AuthorizedCapitalLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "stringItemType" }, "mor_AuthorizedCapitalTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized Capital [Table]", "label": "Authorized Capital [Table]", "terseLabel": "Authorized Capital [Table]" } } }, "localname": "AuthorizedCapitalTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "xbrltype": "stringItemType" }, "mor_AvailableForSaleFinancialAssetsCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale financial assets cost.", "label": "Available for sale financial assets cost", "terseLabel": "Cost" } } }, "localname": "AvailableForSaleFinancialAssetsCost", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_AvailableforsaleFinancialAssetsMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available-for-sale financial assets, maturity.", "label": "Available-for-sale financial assets, maturity", "terseLabel": "Maturity" } } }, "localname": "AvailableforsaleFinancialAssetsMaturity", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_AverageNumberOfEmployeesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average Number of Employees", "label": "Average Number of Employees [Table Text Block]", "terseLabel": "Summary of Average Number of Employees" } } }, "localname": "AverageNumberOfEmployeesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_AverageStateTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average State Tax Rate", "label": "Average State Tax Rate", "terseLabel": "Average State Tax Rate" } } }, "localname": "AverageStateTaxRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mor_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Balance sheet location axis.", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "stringItemType" }, "mor_BalanceSheetLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Balance sheet location domain.", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "domainItemType" }, "mor_BasisOfConsolidationBeginningDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of consolidation beginning date.", "label": "Basis of consolidation beginning date", "terseLabel": "Included in Basis of Consolidation since" } } }, "localname": "BasisOfConsolidationBeginningDate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "xbrltype": "stringItemType" }, "mor_BearerOrdinarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bearer Ordinary Shares", "label": "Bearer Ordinary Shares [Member]", "terseLabel": "Bearer Ordinary Shares [Member]" } } }, "localname": "BearerOrdinarySharesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "domainItemType" }, "mor_BetaFactor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beta factor.", "label": "Beta factor", "terseLabel": "Beta factor" } } }, "localname": "BetaFactor", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "percentItemType" }, "mor_BoardAndCommitteeMeetingAttendanceFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Board and committee meeting attendance fee.", "label": "Board and committee meeting attendance fee [member]", "terseLabel": "Attendance fee [member]" } } }, "localname": "BoardAndCommitteeMeetingAttendanceFeeMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_BondsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonds [Line Items]", "label": "Bonds [Line Items]", "terseLabel": "Bonds [Line Items]" } } }, "localname": "BondsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "stringItemType" }, "mor_BondsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonds [Table]", "label": "Bonds [Table]", "terseLabel": "Bonds [Table]" } } }, "localname": "BondsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "stringItemType" }, "mor_CPI0209Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CPI-0209", "label": "CPI-0209 [Member]", "terseLabel": "CPI-0209 [Member]" } } }, "localname": "CPI0209Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "domainItemType" }, "mor_CapitalManagementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Management [Line Items]", "label": "Capital Management [Line Items]", "terseLabel": "Capital Management [Line Items]" } } }, "localname": "CapitalManagementLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails" ], "xbrltype": "stringItemType" }, "mor_CapitalManagementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Management [Table]", "label": "Capital Management [Table]", "terseLabel": "Capital Management [Table]" } } }, "localname": "CapitalManagementTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_CapitalizedRDProgram": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Capitalized R&D Program", "label": "Capitalized R&D Program", "terseLabel": "Capitalized R&D Program" } } }, "localname": "CapitalizedRDProgram", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "monetaryItemType" }, "mor_CarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Car [Member]", "terseLabel": "Car [Member]" } } }, "localname": "CarMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mor_CarryForwardOfTaxLossesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carry Forward of Tax Losses (Axis).", "label": "Carry Forward of Tax Losses [Axis]", "terseLabel": "Carry Forward of Tax Losses [axis]" } } }, "localname": "CarryForwardOfTaxLossesAxis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "stringItemType" }, "mor_CarryForwardOfTaxLossesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Carry Forward of Tax Losses (Domain).", "label": "Carry Forward of Tax Losses [Domain]", "terseLabel": "Carry Forward of Tax Losses [domain]" } } }, "localname": "CarryForwardOfTaxLossesDomain", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "domainItemType" }, "mor_CashAndCashEquivalentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent.", "label": "Cash and Cash Equivalent [member]", "terseLabel": "Cash and cash equivalent [member]" } } }, "localname": "CashAndCashEquivalentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "domainItemType" }, "mor_CashAndCashEquivalentsAccumulatedImpairments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents accumulated impairments.", "label": "Cash and cash equivalents accumulated impairments", "negatedTerseLabel": "Cash and cash equivalents accumulated impairments" } } }, "localname": "CashAndCashEquivalentsAccumulatedImpairments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "mor_CashFlowsFinancialLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flows Financial Liabilities [Line Items]", "label": "Cash Flows Financial Liabilities [Line Items]", "terseLabel": "Cash Flows Financial Liabilities [Line Items]" } } }, "localname": "CashFlowsFinancialLiabilitiesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mor_CashFlowsFinancialLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flows Financial Liabilities [Table]", "label": "Cash Flows Financial Liabilities [Table]", "terseLabel": "Cash Flows Financial Liabilities [Table]" } } }, "localname": "CashFlowsFinancialLiabilitiesTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_CashPaymentsDevelopmentFundingBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Payments Development Funding Bond", "label": "Cash Payments Development Funding Bond", "terseLabel": "Cash Payments Development Funding Bond" } } }, "localname": "CashPaymentsDevelopmentFundingBond", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails" ], "xbrltype": "monetaryItemType" }, "mor_CashPaymentsForCostsInConnectionWithContractsWithRoyaltyPharma": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Payments for Costs in Connection with Contracts with Royalty Pharma", "label": "Cash Payments for Costs in Connection with Contracts with Royalty Pharma", "negatedTerseLabel": "Cash Payments for Costs in Connection with Contracts with Royalty Pharma" } } }, "localname": "CashPaymentsForCostsInConnectionWithContractsWithRoyaltyPharma", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_CashReceiptsFromContractsForFuturePaymentsToRoyaltyPharma": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Receipts from Contracts for Future Payments to Royalty Pharma", "label": "Cash Receipts from Contracts for Future Payments to Royalty Pharma", "negatedTerseLabel": "Cash Receipts from Contracts for Future Payments to Royalty Pharma" } } }, "localname": "CashReceiptsFromContractsForFuturePaymentsToRoyaltyPharma", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_CashReceiptsFromDevelopmentFundingBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Receipts from Development Funding Bond", "label": "Cash Receipts from Development Funding Bond", "terseLabel": "Cash Receipts from Development Funding Bond" } } }, "localname": "CashReceiptsFromDevelopmentFundingBond", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails" ], "xbrltype": "monetaryItemType" }, "mor_ChangeInExpectedSalesRevenues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Expected Sales Revenues", "label": "Change in Expected Sales Revenues", "terseLabel": "Change in Expected Sales Revenues" } } }, "localname": "ChangeInExpectedSalesRevenues", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "mor_ChangeInFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in Fair Value", "label": "Change in Fair Value", "terseLabel": "Change in Fair Value" } } }, "localname": "ChangeInFairValue", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_ChangeInForeignExchangeRateForFutureRoyaltiesAndNetSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Foreign Exchange Rate for future Royalties and Net Sales", "label": "Change in Foreign Exchange Rate for future Royalties and Net Sales [Member]", "terseLabel": "Change in Foreign Exchange Rate for future Royalties and Net Sales [Member]" } } }, "localname": "ChangeInForeignExchangeRateForFutureRoyaltiesAndNetSalesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "domainItemType" }, "mor_ChangeInManufacturingCostsAndCostsRelatedComponentsCostRelatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change In Manufacturing Costs And Costs Related Components Cost Related [Member]", "terseLabel": "Change In Manufacturing Costs And Costs Related Components Cost Related [Member]" } } }, "localname": "ChangeInManufacturingCostsAndCostsRelatedComponentsCostRelatedMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "domainItemType" }, "mor_ChangeInPatientNumbersAndNumberOfDosesAdministeredCostRelatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change In Patient Numbers And Number Of Doses Administered Cost Related [Member]", "terseLabel": "Change In Patient Numbers And Number Of Doses Administered Cost Related [Member]" } } }, "localname": "ChangeInPatientNumbersAndNumberOfDosesAdministeredCostRelatedMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "domainItemType" }, "mor_ChangeInPatientNumbersAndNumberOfDosesAdministeredRevenueRelatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change In Patient Numbers And Number Of Doses Administered Revenue Related [Member]", "terseLabel": "Change In Patient Numbers And Number Of Doses Administered Revenue Related [Member]" } } }, "localname": "ChangeInPatientNumbersAndNumberOfDosesAdministeredRevenueRelatedMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "domainItemType" }, "mor_ChangeInPatientNumbersRevenueRelatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Patient Numbers (revenue related)", "label": "Change in Patient Numbers (revenue related) [Member]", "terseLabel": "Change in Patient Numbers (revenue related) [Member]" } } }, "localname": "ChangeInPatientNumbersRevenueRelatedMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "domainItemType" }, "mor_ChangeInPriceObtainedInTheMarketRevenueRelatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change In Price Obtained In The Market Revenue Related [Member]", "terseLabel": "Change In Price Obtained In The Market Revenue Related [Member]" } } }, "localname": "ChangeInPriceObtainedInTheMarketRevenueRelatedMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "domainItemType" }, "mor_ChangeInVariableFactorsOnRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in variable factors on Revenues", "label": "Change in variable factors on Revenues [Member]", "terseLabel": "Change in variable factors on Revenues [Member]" } } }, "localname": "ChangeInVariableFactorsOnRevenuesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "domainItemType" }, "mor_ChangeInWACCBeforeTaxesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in WACC before Taxes", "label": "Change in WACC before Taxes [Member]", "terseLabel": "Change in WACC before Taxes [Member]" } } }, "localname": "ChangeInWACCBeforeTaxesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "domainItemType" }, "mor_ClinicalAgreementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical Agreements [Line Items]", "label": "Clinical Agreements [Line Items]", "terseLabel": "Clinical Agreements [Line Items]" } } }, "localname": "ClinicalAgreementsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "xbrltype": "stringItemType" }, "mor_ClinicalAgreementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical Agreements [Table]", "label": "Clinical Agreements [Table]", "terseLabel": "Clinical Agreements [Table]" } } }, "localname": "ClinicalAgreementsTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_ClinicalMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical milestone payments", "label": "Clinical milestone payments", "terseLabel": "Clinical milestone payments" } } }, "localname": "ClinicalMilestonePayments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "xbrltype": "monetaryItemType" }, "mor_CollaborationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborations [Member] .", "label": "Collaborations [Member]", "terseLabel": "Collaborations [Member]" } } }, "localname": "CollaborationsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_CommonStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock [Line Items]", "label": "Common Stock [Line Items]", "terseLabel": "Common Stock [Line Items]" } } }, "localname": "CommonStockLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "xbrltype": "stringItemType" }, "mor_CommonStockTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock [Table]", "label": "Common Stock [Table]", "terseLabel": "Common Stock [Table]" } } }, "localname": "CommonStockTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "xbrltype": "stringItemType" }, "mor_CompanyFactor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Company factor", "label": "Company factor", "terseLabel": "Company factor" } } }, "localname": "CompanyFactor", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails" ], "xbrltype": "percentItemType" }, "mor_CompensationOfFormerEmployees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Compensation of former Employees", "label": "Compensation of former Employees", "terseLabel": "Compensation of former Employees" } } }, "localname": "CompensationOfFormerEmployees", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_ComponentsOfDepreciationRightOfUseAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components Of Depreciation Right Of Use Assets[Text Block]", "label": "Components Of Depreciation Right Of Use Assets [Table Text Block]", "terseLabel": "Summary Of Depreciation Right Of Use Assets" } } }, "localname": "ComponentsOfDepreciationRightOfUseAssetsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_ConditionalCapital2016IIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conditional Capital 2016 III", "label": "Conditional Capital 2016 III [Member]", "terseLabel": "Conditional Capital 2016 III [Member]" } } }, "localname": "ConditionalCapital2016IIIMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_ConditionalCapital2016IMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conditional Capital 2016 I", "label": "Conditional Capital 2016 I [Member]", "terseLabel": "Conditional Capital 2016 I [Member]" } } }, "localname": "ConditionalCapital2016IMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_ConditionalCapital2018IIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conditional Capital 2018 III", "label": "Conditional Capital 2018 III [Member]", "terseLabel": "Conditional Capital 2018 III [Member]" } } }, "localname": "ConditionalCapital2018IIIMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_ConditionalCapitalIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conditional Capital I", "label": "Conditional Capital I [Member]", "terseLabel": "Conditional Capital 2021 I [Member]" } } }, "localname": "ConditionalCapitalIMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_ConditionalCapitalLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conditional Capital [Line Items]", "label": "Conditional Capital [Line Items]", "terseLabel": "Conditional Capital [Line Items]" } } }, "localname": "ConditionalCapitalLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "stringItemType" }, "mor_ConditionalCapitalTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conditional Capital [Table]", "label": "Conditional Capital [Table]", "terseLabel": "Conditional Capital [Table]" } } }, "localname": "ConditionalCapitalTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "stringItemType" }, "mor_ConstellationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Constellation", "label": "Constellation [Member]", "terseLabel": "Constellation" } } }, "localname": "ConstellationMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "xbrltype": "domainItemType" }, "mor_ConstellationPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Constellation Pharmaceuticals, Inc.", "label": "Constellation Pharmaceuticals, Inc. [Member]", "terseLabel": "Constellation Pharmaceuticals, Inc." } } }, "localname": "ConstellationPharmaceuticalsIncMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "xbrltype": "domainItemType" }, "mor_ConstellationSecuritiesCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Constellation Securities, Corp.", "label": "Constellation Securities, Corp. [Member]", "terseLabel": "Constellation Securities, Corp." } } }, "localname": "ConstellationSecuritiesCorpMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "xbrltype": "domainItemType" }, "mor_ConsumableSuppliesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consumable supplies.", "label": "Consumable Supplies [member]", "terseLabel": "Consumable supplies [member]" } } }, "localname": "ConsumableSuppliesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_ContingentPurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contingent Purchase Price", "label": "Contingent Purchase Price", "terseLabel": "Contingent Purchase Price" } } }, "localname": "ContingentPurchasePrice", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "mor_ContractLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Liabilities [Line Items]", "label": "Contract Liabilities [Line Items]", "terseLabel": "Contract Liabilities [Line Items]" } } }, "localname": "ContractLiabilitiesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mor_ContractLiabilitiesPrepaymentsReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract liabilities prepayments received.", "label": "Contract Liabilities Prepayments Received", "terseLabel": "Contract Liabilities Prepayments Received" } } }, "localname": "ContractLiabilitiesPrepaymentsReceived", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_ContractLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Liabilities [Table]", "label": "Contract Liabilities [Table]", "terseLabel": "Contract Liabilities [Table]" } } }, "localname": "ContractLiabilitiesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mor_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "contractual obligation.", "label": "contractual obligation", "terseLabel": "contractual obligation" } } }, "localname": "ContractualObligation", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "xbrltype": "monetaryItemType" }, "mor_ConvertibleBondMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Bond [Member]", "terseLabel": "Convertible Bond [Member]" } } }, "localname": "ConvertibleBondMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "domainItemType" }, "mor_ConvertibleBondsDueToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible bonds due to related parties.", "label": "Convertible bonds due to related parties", "terseLabel": "Convertible bonds due to related parties" } } }, "localname": "ConvertibleBondsDueToRelatedParties", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_ConvertibleBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible bonds.", "label": "Convertible bonds [member]", "terseLabel": "Convertible bonds [member]", "verboseLabel": "Convertible Bonds [Member]" } } }, "localname": "ConvertibleBondsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_CorporateTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate tax rate.", "label": "Corporate tax rate", "terseLabel": "Corporate tax rate" } } }, "localname": "CorporateTaxRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mor_CostOfSalesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of sales [abstract]", "label": "Cost of sales [abstract]", "terseLabel": "Cost of sales [abstract]" } } }, "localname": "CostOfSalesAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_CostOfSalesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of sales [line items]", "label": "Cost of sales [line items]", "terseLabel": "Cost of sales [line items]" } } }, "localname": "CostOfSalesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "xbrltype": "stringItemType" }, "mor_CostOfSalesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of sales.", "label": "Cost of sales [table]", "terseLabel": "Cost of sales [table]" } } }, "localname": "CostOfSalesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "xbrltype": "stringItemType" }, "mor_CostSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost Sales", "label": "Cost Sales [Member]", "terseLabel": "Cost of Sales [Member]" } } }, "localname": "CostSalesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails" ], "xbrltype": "domainItemType" }, "mor_CreditRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Risk [Line Items]", "label": "Credit Risk [Line Items]", "terseLabel": "Credit Risk [Line Items]" } } }, "localname": "CreditRiskLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "mor_CreditRiskTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Risk [Table]", "label": "Credit Risk [Table]", "terseLabel": "Credit Risk [Table]" } } }, "localname": "CreditRiskTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_Currency": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency", "label": "Currency", "terseLabel": "Currency" } } }, "localname": "Currency", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails" ], "xbrltype": "textBlockItemType" }, "mor_CurrentAndFormerEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current and Former Employees", "label": "Current and Former Employees [Member]", "terseLabel": "Current and Former Employees" } } }, "localname": "CurrentAndFormerEmployeesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_CurrentConvertibleBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current Convertible Bond.", "label": "Current Convertible Bond", "terseLabel": "Current Portion of Convertible Bond" } } }, "localname": "CurrentConvertibleBond", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_CurrentFinancialAssetsFromCollaboration": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current Financial Assets from Collaboration.", "label": "Current Financial Assets from Collaboration", "terseLabel": "Financial Assets from Collaborations" } } }, "localname": "CurrentFinancialAssetsFromCollaboration", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "mor_CurrentFinancialLiabilitiesFromCollaboration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current Financial Liabilities from Collaboration.", "label": "Current Financial Liabilities from Collaboration", "terseLabel": "Current Portion of Financial Liabilities from Collaborations" } } }, "localname": "CurrentFinancialLiabilitiesFromCollaboration", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_CurrentIncomeTaxReceivables": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current income tax receivables.", "label": "Current Income Tax Receivables", "terseLabel": "Income Tax Receivables" } } }, "localname": "CurrentIncomeTaxReceivables", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIncomeTaxReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "mor_CurrentPortionOfFinancialLiabilitiesFromCollaborations": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current portion of financial liabilities from collaborations.", "label": "Current Portion Of Financial Liabilities From Collaborations", "terseLabel": "Financial Liabilities from Collaborations" } } }, "localname": "CurrentPortionOfFinancialLiabilitiesFromCollaborations", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "mor_CurrentPortionOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current Portion of Financial Liabilities from Future Payments to Royalty Pharma", "label": "Current Portion of Financial Liabilities from Future Payments to Royalty Pharma", "terseLabel": "Financial Liabilities from Future Payments to Royalty Pharma", "verboseLabel": "Current Portion of Financial Liabilities from Future Payments to Royalty Pharma" } } }, "localname": "CurrentPortionOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails" ], "xbrltype": "monetaryItemType" }, "mor_CurrentTaxProvisions": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of current tax provisions other than provisions.", "label": "Current Tax Provisions", "terseLabel": "Tax Liabilities" } } }, "localname": "CurrentTaxProvisions", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "mor_CurrentYearTaxLossesCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current Year Tax Losses Carryforwards.", "label": "Current Year Tax Losses Carryforwards", "verboseLabel": "Tax Losses from Current Year" } } }, "localname": "CurrentYearTaxLossesCarryforwards", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "monetaryItemType" }, "mor_Customer1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 1", "label": "Customer 1 [Member]", "terseLabel": "Customer 1 [Member]" } } }, "localname": "Customer1Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "mor_Customer2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 2", "label": "Customer 2 [Member]", "terseLabel": "Customer 2 [Member]" } } }, "localname": "Customer2Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "mor_Customer3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 3", "label": "Customer 3 [Member]", "terseLabel": "Customer 3 [Member]" } } }, "localname": "Customer3Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "mor_DFBInitialMeasurementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DFB, initial measurement", "label": "DFB, initial measurement [Member]", "terseLabel": "DFB, initial measurement [Member]" } } }, "localname": "DFBInitialMeasurementMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails" ], "xbrltype": "domainItemType" }, "mor_DebtConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Conversion Price", "label": "Debt Conversion Price", "terseLabel": "Debt Conversion Price" } } }, "localname": "DebtConversionPrice", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "decimalItemType" }, "mor_DebtCouponRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Coupon Rate", "label": "Debt Coupon Rate", "terseLabel": "Debt Coupon Rate" } } }, "localname": "DebtCouponRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "mor_DebtInstrumentConvertibleNumberOfEquityInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Convertible Number of Equity Instruments", "label": "Intial Conversion of Coveritible Bonds to Ordinary Shares", "terseLabel": "Intial Conversion of Coveritible Bonds to Ordinary Shares" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "sharesItemType" }, "mor_DecreaseEuro10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decrease Euro 10%", "label": "Decrease Euro 10% [Member]", "terseLabel": "Decrease Euro 10% [Member]" } } }, "localname": "DecreaseEuro10Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails" ], "xbrltype": "domainItemType" }, "mor_DecreaseInBusinessValuationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decrease in business valuation", "label": "Decrease in business valuation [Member]", "terseLabel": "Decrease in business valuation [Member]" } } }, "localname": "DecreaseInBusinessValuationMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "mor_DecreaseVariableInterestRate10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decrease Variable Interest Rate 10%", "label": "Decrease Variable Interest Rate 10% [Member]", "terseLabel": "Decrease Variable Interest Rate 10% [Member]" } } }, "localname": "DecreaseVariableInterestRate10Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "xbrltype": "domainItemType" }, "mor_DeferredIncomeFromObligationsToRoyaltyPharma": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred income from Obligations to Royalty Pharma", "label": "Deferred income from Obligations to Royalty Pharma", "terseLabel": "Deferred income from Obligations to Royalty Pharma" } } }, "localname": "DeferredIncomeFromObligationsToRoyaltyPharma", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_DeferredTaxAssetLiabilityOtherProvisionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax asset liability other provisions.", "label": "Deferred Tax Asset Liability Other Provisions [member]", "terseLabel": "Other provisions [member]" } } }, "localname": "DeferredTaxAssetLiabilityOtherProvisionsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_DeferredTaxAssetsOnTemporaryDifferencesNotCapitalized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax assets on temporary differences not capitalized", "label": "Deferred Tax assets on temporary differences not capitalized", "terseLabel": "Deferred Tax assets on temporary differences not capitalized" } } }, "localname": "DeferredTaxAssetsOnTemporaryDifferencesNotCapitalized", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "mor_DeferredTaxExpenseFromReversalAndNonRecognitionOfImpairmentAndTemporaryDifferences": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax expense from reversal and non-recognition of impairment and temporary differences", "label": "Deferred tax expense from reversal and non-recognition of impairment and temporary differences", "terseLabel": "Deferred tax expense from reversal and non-recognition of impairment and temporary differences" } } }, "localname": "DeferredTaxExpenseFromReversalAndNonRecognitionOfImpairmentAndTemporaryDifferences", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "mor_DeferredTaxItemsRecognizedAgainstEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax items recognized against equity", "label": "Deferred tax items recognized against equity", "terseLabel": "Deferred tax items recognized against equity" } } }, "localname": "DeferredTaxItemsRecognizedAgainstEquity", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "xbrltype": "monetaryItemType" }, "mor_DeferredTaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Tax [member]", "label": "Deferred Tax [member]", "terseLabel": "Deferred Tax [member]" } } }, "localname": "DeferredTaxMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "xbrltype": "domainItemType" }, "mor_DepreciationAndOtherCostsForInfrastructureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation and other costs for infrastructure.", "label": "Depreciation and Other Costs for Infrastructure[member]", "terseLabel": "Depreciation and other costs for infrastructure [member]" } } }, "localname": "DepreciationAndOtherCostsForInfrastructureMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_DepreciationExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation Expense [Line Items]", "label": "Depreciation Expense [Line Items]", "terseLabel": "Depreciation Expense [Line Items]" } } }, "localname": "DepreciationExpenseLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_DepreciationExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation Expense [Table]", "label": "Depreciation Expense [Table]", "terseLabel": "Depreciation Expense [Table]" } } }, "localname": "DepreciationExpenseTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_DepreciationRightOfUseAssetsAfterCurrencyTranslation": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "order": 1.0, "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation Right-of-use Assets after Currency Translation", "label": "Depreciation Right-of-use Assets after Currency Translation", "terseLabel": "Depreciation, right-of-use assets" } } }, "localname": "DepreciationRightOfUseAssetsAfterCurrencyTranslation", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mor_DepreciationRightOfUseAssetsLl": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation, right-of-use assets, ll", "label": "Depreciation, right-of-use assets, ll", "negatedTerseLabel": "Depreciation, right-of-use assets, ll" } } }, "localname": "DepreciationRightOfUseAssetsLl", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_DescriptionOfACCOUNTINGPOLICIESAPPLIEDTOLINEITEMSOFTHEINCOMESTATEMENTExplanatoryPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of ACCOUNTING POLICIES APPLIED TO LINE ITEMS OF THE INCOME STATEMENT Explanatory", "label": "Description of ACCOUNTING POLICIES APPLIED TO LINE ITEMS OF THE INCOME STATEMENT Explanatory [Policy Text Block]", "terseLabel": "Accounting policies applied to line items of profit or loss" } } }, "localname": "DescriptionOfACCOUNTINGPOLICIESAPPLIEDTOLINEITEMSOFTHEINCOMESTATEMENTExplanatoryPolicyTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mor_DescriptionOfAccountingPoliciesAppliedToTheLineItemsOfTheBalanceSheetPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of accounting policies applied to the assets of the balance sheet.", "label": "Description of accounting policies applied to the line items of the balance sheet [Policy Text Block]", "terseLabel": "Accounting policies applied to the line items of the balance sheet" } } }, "localname": "DescriptionOfAccountingPoliciesAppliedToTheLineItemsOfTheBalanceSheetPolicyTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mor_DescriptionOfAccountingPolicyForBASISOFANDCHANGESINACCOUNTINGSTANDARDSPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for BASIS OF AND CHANGES IN ACCOUNTING STANDARDS.", "label": "Description of accounting policy for BASIS OF AND CHANGES IN ACCOUNTING STANDARDS [Policy Text Block]", "terseLabel": "Basis of Application and Changes in Accounting Standards" } } }, "localname": "DescriptionOfAccountingPolicyForBASISOFANDCHANGESINACCOUNTINGSTANDARDSPolicyTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mor_DescriptionOfConsolidationPrinciplesExplanatoryPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of consolidation principles explanatory.", "label": "Description of consolidation principles explanatory [Policy Text Block]", "terseLabel": "Consolidation Principles" } } }, "localname": "DescriptionOfConsolidationPrinciplesExplanatoryPolicyTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mor_DescriptionOfRecognitionOfExpectedCreditLossProvision": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of recognition of expected credit loss provision.", "label": "Description of recognition of expected credit loss provision", "terseLabel": "Basis for Recognition of Expected Credit Loss Provision" } } }, "localname": "DescriptionOfRecognitionOfExpectedCreditLossProvision", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "stringItemType" }, "mor_DevelopmentFundingBondMeasurementLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development Funding Bond, measurement loss", "label": "Development Funding Bond, measurement loss", "terseLabel": "Development Funding Bond, measurement loss" } } }, "localname": "DevelopmentFundingBondMeasurementLoss", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails" ], "xbrltype": "monetaryItemType" }, "mor_DevelopmentFundingBondMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development Funding Bond", "label": "Development Funding Bond [Member]", "terseLabel": "Development Funding Bond [Member]" } } }, "localname": "DevelopmentFundingBondMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails" ], "xbrltype": "domainItemType" }, "mor_DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Details Of Remuneration To Key Managerial Personnel [Text Block]", "label": "Disclosure Details Of Remuneration To Key Managerial Personnel [Table Text Block]", "terseLabel": "Summary Of Remuneration of Key Management Personnel" } } }, "localname": "DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Line Items]", "terseLabel": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Line Items]" } } }, "localname": "DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Table]", "terseLabel": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Table]" } } }, "localname": "DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Text Block]", "label": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Table Text Block]", "terseLabel": "Summary Of Useful Lives Of Intangible Assets Including Goodwill" } } }, "localname": "DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfAccountingPoliciesForKeyEstimatesAndAssumptionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policies for key estimates and assumptions", "label": "Disclosure of accounting policies for key estimates and assumptions [Policy Text Block]", "terseLabel": "Key Estimates and Assumptions" } } }, "localname": "DisclosureOfAccountingPoliciesForKeyEstimatesAndAssumptionsPolicyTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfAnalysisOfIncomeStatementExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of analysis of Income Statement [text block]", "label": "Disclosure of analysis of Income Statement [text block]", "terseLabel": "Notes to the Income Statement" } } }, "localname": "DisclosureOfAnalysisOfIncomeStatementExplanatory", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatement" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfAnalysisOfRevenuelineItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Analysis Of Revenue [Line Item]", "label": "Disclosure Of Analysis Of Revenue Line Item [Line Items]", "terseLabel": "Disclosure Of Analysis Of Revenue Line Item [Line Items]" } } }, "localname": "DisclosureOfAnalysisOfRevenuelineItemLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfAnalysisOfRevenuetableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Analysis Of Revenue [Table] .", "label": "Disclosure Of Analysis Of Revenue Table [Table]", "terseLabel": "Disclosure Of Analysis Of Revenue [Table]" } } }, "localname": "DisclosureOfAnalysisOfRevenuetableTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfDeferredTaxAssetsAndDeferredTaxLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of deferred tax assets and deferred tax liabilities.", "label": "Disclosure of deferred tax assets and deferred tax liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Deferred Tax Liabilities" } } }, "localname": "DisclosureOfDeferredTaxAssetsAndDeferredTaxLiabilitiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfDetailedInformationAboutCostOfSalesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about cost of sales.", "label": "Disclosure Of Detailed Information About Cost Of Sales [Table Text Block]", "terseLabel": "Summary of Cost of Sales" } } }, "localname": "DisclosureOfDetailedInformationAboutCostOfSalesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About General And Administrative Expense Explanatory", "label": "Disclosure Of Detailed Information About General And Administrative Expense Explanatory [Table Text Block]", "terseLabel": "Summary of General and Administrative Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfDetailedInformationAboutInLimitedAndUnlimitedCarryForwardOfTaxLossesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Detailed InformationAbout In Limited And Unlimited Carry Forward Of Tax Losses Explanatory.", "label": "Disclosure of Detailed InformationAbout In Limited And Unlimited Carry Forward Of Tax Losses Explanatory [Table Text Block]", "terseLabel": "Summary Of Detailed Information About In Limited Unlimited Carry Forward Tax Losses" } } }, "localname": "DisclosureOfDetailedInformationAboutInLimitedAndUnlimitedCarryForwardOfTaxLossesExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfDetailedInformationAboutInSignificantInvestmentsInSubsidiariesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Detailed Information About In Significant Investments In Subsidiaries Explanatory.", "label": "Disclosure of Detailed Information About In Significant Investments In Subsidiaries Explanatory [Table Text Block]", "terseLabel": "Summary of Consolidation Methods" } } }, "localname": "DisclosureOfDetailedInformationAboutInSignificantInvestmentsInSubsidiariesExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about other income and expenses.", "label": "Disclosure of detailed information about other income and expenses [Table Text Block]", "terseLabel": "Summary of Other Income and Expenses, Finance Income and Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Detailed Information about Personnel Expenses Explanatory [text block]", "label": "Disclosure of Detailed Information about Personnel Expenses Explanatory [Table Text Block]", "terseLabel": "Summary of Personnel Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Research and Development Expense Explanatory", "label": "Disclosure Of Detailed Information About Research and Development Expense Explanatory [Table Text Block]", "terseLabel": "Summary of Research and Development Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of estimated useful lives of property plant and equipment.", "label": "Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory [Table Text Block]", "terseLabel": "Summary of Estimated Useful Life of Property Plant and Equipment" } } }, "localname": "DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfFairValueOfPerformanceSharesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of share options assumptions related to savings related schemes explanatory.", "label": "Disclosure Of Fair Value of Performance Shares [Table Text Block]", "terseLabel": "Summary of Fair Value of LTI Plans" } } }, "localname": "DisclosureOfFairValueOfPerformanceSharesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfGeneralAndAdministrativeExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represents information about general and administrative expense.", "label": "Disclosure of general and administrative expense [Line items]", "terseLabel": "Disclosure of general and administrative expense [Line items]" } } }, "localname": "DisclosureOfGeneralAndAdministrativeExpenseLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfGeneralAndAdministrativeExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information about general and administrative expense.", "label": "Disclosure of General and Administrative Expense [table]", "terseLabel": "Disclosure of General and Administrative Expense [table]" } } }, "localname": "DisclosureOfGeneralAndAdministrativeExpenseTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfLeasesByLesseeExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Leases By Lessee Explanatory.", "label": "Disclosure Of Leases By Lessee Explanatory [Table Text Block]", "terseLabel": "Summary of Future Minimum Payments for Leases" } } }, "localname": "DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfLimitedAndUnlimitedCarryForwardOfTaxLossesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Line items].", "label": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Line Items]", "terseLabel": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Line Items]" } } }, "localname": "DisclosureOfLimitedAndUnlimitedCarryForwardOfTaxLossesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfLimitedAndUnlimitedCarryForwardOfTaxLossesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Table].", "label": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Table]", "terseLabel": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [table]" } } }, "localname": "DisclosureOfLimitedAndUnlimitedCarryForwardOfTaxLossesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfMajorComponentsOfIncomeTaxTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of major components of income tax.", "label": "Disclosure of Major Components of Income Tax [Table Text Block]", "terseLabel": "Summary of Income Taxes and Benefits" } } }, "localname": "DisclosureOfMajorComponentsOfIncomeTaxTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfMaturityAnalysisOfLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Maturity Analysis Of Lease Liabilities Explanatory.", "label": "Disclosure Of Maturity Analysis Of Lease Liabilities [Table Text Block]", "terseLabel": "Summary Of Maturity Analysis Of Lease Liabilities" } } }, "localname": "DisclosureOfMaturityAnalysisOfLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of new and revised standards and interpretations.", "label": "Disclosure of new and revised standards and interpretations [Table Text Block]", "terseLabel": "Summary of New and Revised Standards and Interpretations" } } }, "localname": "DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfNewAndRevisedStandardsAndInterpretationsWhichWereNotYetMandatoryForFinancialYearOrWereNotYetAdoptedByEuropeanUnionWereNotAppliedExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of new and revised standards and interpretations, which were not yet mandatory for financial year or were not yet adopted by European Union, were not applied.", "label": "Disclosure of new and revised standards and interpretations, which were not yet mandatory for financial year or were not yet adopted by European Union, were not applied explanatory [Table Text Block]", "terseLabel": "Summary of New and Revised Standards and Interpretations not yet Mandatorily Applicable" } } }, "localname": "DisclosureOfNewAndRevisedStandardsAndInterpretationsWhichWereNotYetMandatoryForFinancialYearOrWereNotYetAdoptedByEuropeanUnionWereNotAppliedExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfOperatingLeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of operating lease.", "label": "Disclosure of operating lease [abstract]", "terseLabel": "Disclosure of operating lease [abstract]" } } }, "localname": "DisclosureOfOperatingLeaseAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_DisclosureOfOperatingLeaseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of operating lease [Line Items]", "label": "Disclosure of operating lease [Line Items]", "terseLabel": "Disclosure of operating lease [Line Items]" } } }, "localname": "DisclosureOfOperatingLeaseLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfOperatingLeaseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of operating lease [table].", "label": "Disclosure of operating lease [table]", "terseLabel": "Disclosure of operating lease [table]" } } }, "localname": "DisclosureOfOperatingLeaseTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfPersonnelExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of personnel expense [abstract]", "label": "Disclosure of personnel expense [abstract]", "terseLabel": "Disclosure of personnel expense [abstract]" } } }, "localname": "DisclosureOfPersonnelExpenseAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_DisclosureOfPersonnelExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represents information about personnel expense.", "label": "Disclosure of personnel expense [line items]", "terseLabel": "Disclosure of personnel expense [line items]" } } }, "localname": "DisclosureOfPersonnelExpenseLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfPersonnelExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information about personnel expense.", "label": "Disclosure of personnel expense [table]", "terseLabel": "Disclosure of personnel expense [table]" } } }, "localname": "DisclosureOfPersonnelExpenseTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of reconciliation of changes in deferred tax liability asset.", "label": "Disclosure Of Reconciliation Of Changes In Deferred Tax Liability Asset Explanatory [Table Text Block]", "terseLabel": "Schedule of Changes in Deferred Taxes" } } }, "localname": "DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of reconciliation of changes in deferred tax liability asset line items.", "label": "Disclosure of Reconciliation of Changes in Deferred Tax Liability Asset [line items]", "terseLabel": "Disclosure of Reconciliation of Changes in Deferred Tax Liability Asset [line items]" } } }, "localname": "DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of reconciliation of changes in deferred tax liability asset [table]", "label": "Disclosure of Reconciliation of Changes in Deferred Tax Liability Asset [table]", "terseLabel": "Disclosure of Reconciliation of Changes in Deferred Tax Liability Asset [table]" } } }, "localname": "DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfReconciliationOfExpectedIncomeTaxExpenseWithActualIncomeTaxExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of reconciliation of expected income tax expense with actual income tax expense [text block]", "label": "Disclosure of reconciliation of expected income tax expense with actual income tax expense [Table Text Block]", "terseLabel": "Summary of Reconciliation of Expected Income Tax Expense with Actual Income Tax Expense" } } }, "localname": "DisclosureOfReconciliationOfExpectedIncomeTaxExpenseWithActualIncomeTaxExpenseTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfRemunerationSystemForManagementBoardAndEmployeesOfGroupExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of remuneration system for management board and employees of group.", "label": "Disclosure of remuneration system for management board and employees of group [Text block]", "terseLabel": "Remuneration System for the Management Board and Employees of the Group" } } }, "localname": "DisclosureOfRemunerationSystemForManagementBoardAndEmployeesOfGroupExplanatory", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroup" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfSellingExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of selling expense .", "label": "Disclosure of selling expense [Table Text Block]", "terseLabel": "Summary of Selling Expenses" } } }, "localname": "DisclosureOfSellingExpenseTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfSellingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Abstract represents disclosure of selling expenses.", "label": "Disclosure Of Selling Expenses [abstract]", "terseLabel": "Disclosure Of Selling Expenses [abstract]" } } }, "localname": "DisclosureOfSellingExpensesAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_DisclosureOfSellingExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of selling expenses.", "label": "Disclosure of selling expenses [line items]", "terseLabel": "Disclosure of selling expenses [line items]" } } }, "localname": "DisclosureOfSellingExpensesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfSellingExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of selling and expenses.", "label": "Disclosure of selling expenses [table]", "terseLabel": "Disclosure of selling expenses [table]" } } }, "localname": "DisclosureOfSellingExpensesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfSensitivityAnalysisOfFairValueMeasurementDueToChangesInMulipleUnobervableInputsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Sensitivity Analysis Of Fair Value Measurement Due To Changes In Muliple Unobervable Inputs [Table Text Block]", "label": "Disclosure Of Sensitivity Analysis Of Fair Value Measurement Due To Changes In Muliple Unobervable Inputs [Table Text Block]", "terseLabel": "Summary Of Sensitivity Analysis Of Financial Liabilities from Collaborations" } } }, "localname": "DisclosureOfSensitivityAnalysisOfFairValueMeasurementDueToChangesInMulipleUnobervableInputsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_DisclosureOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of significant accounting policies.", "label": "Disclosure of significant accounting policies [abstract]", "terseLabel": "Disclosure of significant accounting policies [abstract]" } } }, "localname": "DisclosureOfSignificantAccountingPoliciesAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_DisclosureOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of significant accounting policies [line items]", "label": "Disclosure of significant accounting policies [line items]", "terseLabel": "Disclosure of significant accounting policies [line items]" } } }, "localname": "DisclosureOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of significant accounting policies [table]", "label": "Disclosure of significant accounting policies [table]", "terseLabel": "Disclosure of significant accounting policies [table]" } } }, "localname": "DisclosureOfSignificantAccountingPoliciesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "stringItemType" }, "mor_DisclosureofrevenueexplanatoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DisclosureOfRevenueExplanatory .", "label": "DisclosureOfRevenueExplanatory [Abstract]", "terseLabel": "DisclosureOfRevenueExplanatory [Abstract]" } } }, "localname": "DisclosureofrevenueexplanatoryAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_DiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount rate", "label": "Discount rate", "terseLabel": "Discount rate" } } }, "localname": "DiscountRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "xbrltype": "percentItemType" }, "mor_DisposalOfCashAndCashEquivalentsDueToDeconsolidationOfSubsidaries": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Of Cash And Cash Equivalents Due To Deconsolidation Of Subsidaries", "label": "Disposal Of Cash And Cash Equivalents Due To Deconsolidation Of Subsidaries", "negatedTerseLabel": "Disposal of Cash and Cash Equivalents due to Deconsolidation of Subsidiaries" } } }, "localname": "DisposalOfCashAndCashEquivalentsDueToDeconsolidationOfSubsidaries", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_DisposalOfLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal of Leases", "label": "Disposal of Leases", "terseLabel": "Disposal of Leases" } } }, "localname": "DisposalOfLeases", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_DisposalOfRightOfUseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal of Right of use Assets.", "label": "Disposal of Right of use Assets", "terseLabel": "Disposals" } } }, "localname": "DisposalOfRightOfUseAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_DisposalsForLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposals For Lease Liabilities.", "label": "Disposals For Lease Liabilities", "terseLabel": "Disposals" } } }, "localname": "DisposalsForLeaseLiabilities", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_DrGeorgeGolumbeskiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "George Golumbeski.", "label": "Dr George Golumbeski [member]", "terseLabel": "Dr George Golumbeski [member]" } } }, "localname": "DrGeorgeGolumbeskiMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_DrGeraldMollerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gerald Moller.", "label": "DrGeraldMoller [member]", "terseLabel": "Krisja Vermeylen [member]" } } }, "localname": "DrGeraldMollerMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "mor_DrMarcCluzelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr Marc Cluzel.", "label": "Dr Marc Cluzel [member]", "terseLabel": "Dr. Marc Cluzel [member]" } } }, "localname": "DrMarcCluzelMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_EarningPerShareReconciliationabstractAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earning Per Share Reconciliation [Abstract] .", "label": "Earning Per Share Reconciliation Abstract [Abstract]", "terseLabel": "Earning Per Share Reconciliation Abstract [Abstract]" } } }, "localname": "EarningPerShareReconciliationabstractAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_EarningsPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]", "label": "Earnings per Share, Basic and Diluted", "terseLabel": "Earnings per Share, Basic and Diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "perShareItemType" }, "mor_EffectiveTradeTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective trade tax rate.", "label": "Effective trade tax rate", "terseLabel": "Effective trade tax rate" } } }, "localname": "EffectiveTradeTaxRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mor_EndBalanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End Balance", "label": "End Balance [Member]", "terseLabel": "End Balance [Member]" } } }, "localname": "EndBalanceMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "domainItemType" }, "mor_EquityBeginningBalanceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity beginning balance shares.", "label": "Equity beginning balance shares", "terseLabel": "Beginning balance, shares" } } }, "localname": "EquityBeginningBalanceShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mor_EquityCapitalPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity capital percentage.", "label": "Equity capital percentage", "terseLabel": "In % of Total Capital" } } }, "localname": "EquityCapitalPercentage", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails" ], "xbrltype": "percentItemType" }, "mor_EquityComponentOfTheConvertibleBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity component of the convertible debt value", "label": "Equity component of the convertible bond", "terseLabel": "Equity component of the convertible bond" } } }, "localname": "EquityComponentOfTheConvertibleBond", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mor_EquityComponentOfTheConvertibleBondShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Component of the Convertible Bond, shares", "label": "Equity Component of the Convertible Bond, shares", "terseLabel": "Equity Component of the Convertible Bond, shares" } } }, "localname": "EquityComponentOfTheConvertibleBondShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mor_EquityEndingBalanceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity ending balance shares.", "label": "Equity ending balance shares", "totalLabel": "Ending balance, shares" } } }, "localname": "EquityEndingBalanceShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mor_EquityInAssociate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity in associate", "label": "Equity in associate", "terseLabel": "Proportion of ownership interest in associate" } } }, "localname": "EquityInAssociate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "mor_EquityMethodInvestmentAccountedInDomesticCurrency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment Accounted In Domestic Currency.", "label": "Equity Method Investment Accounted In Domestic Currency", "terseLabel": "Equity method investment accounted in domestic currency" } } }, "localname": "EquityMethodInvestmentAccountedInDomesticCurrency", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInvestmentadivoGmbHDetails" ], "xbrltype": "monetaryItemType" }, "mor_EuropeAndAsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Europe and Asia.", "label": "Europe and Asia [member]", "terseLabel": "Europe and Asia [member]" } } }, "localname": "EuropeAndAsiaMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_ExecutiveCommitteeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive Committee", "label": "Executive Committee [Member]", "terseLabel": "Executive Committee [Member]" } } }, "localname": "ExecutiveCommitteeMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_ExerciseOfConvertibleBondsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercise Of Convertible Bonds Issued .", "label": "Exercise Of Convertible Bonds Issued", "terseLabel": "Exercise of Stock Options Issued" } } }, "localname": "ExerciseOfConvertibleBondsIssued", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mor_ExerciseOfConvertibleBondsIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Of Convertible Bonds Issued Shares .", "label": "Exercise Of Convertible Bonds Issued Shares", "terseLabel": "Exercise of Stock Options Issued, shares" } } }, "localname": "ExerciseOfConvertibleBondsIssuedShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mor_ExerciseOfConvertibleBondsIssuedToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercise of convertible bonds issued to related parties.", "label": "Exercise of convertible bonds issued to related parties", "terseLabel": "Exercise of Convertible Bonds Issued to Related Parties" } } }, "localname": "ExerciseOfConvertibleBondsIssuedToRelatedParties", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mor_ExerciseOfConvertibleBondsIssuedToRelatedPartiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of convertible bonds issued to related parties, shares.", "label": "Exercise of convertible bonds issued to related parties, shares", "terseLabel": "Exercise of Convertible Bonds Issued to Related Parties, shares" } } }, "localname": "ExerciseOfConvertibleBondsIssuedToRelatedPartiesShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mor_ExpectedLicensingPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expected Licensing Payments", "label": "Expected Licensing Payments", "terseLabel": "Expected Licensing Payments" } } }, "localname": "ExpectedLicensingPayments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "mor_ExpenseCategoriesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expense Categories [axis]", "label": "Expense Categories [axis]", "terseLabel": "Expense Categories [axis]" } } }, "localname": "ExpenseCategoriesAxis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_ExpenseCategoriesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expense Categories [domain]", "label": "Expense Categories [domain]", "terseLabel": "Expense Categories [domain]" } } }, "localname": "ExpenseCategoriesDomain", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_ExpensedAcquisitionOrProductionCostOfInventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expensed Acquisition or Production Cost of Inventories .", "label": "Expensed Acquisition or Production Cost of Inventories [Member]", "terseLabel": "Expensed Acquisition or Production Cost of Inventories [member]" } } }, "localname": "ExpensedAcquisitionOrProductionCostOfInventoriesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "xbrltype": "domainItemType" }, "mor_ExpensesForLegalAdvice": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "order": 1.0, "parentTag": "mor_AccruedLiabiityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Expenses for legal advice.", "label": "Expenses for legal advice", "terseLabel": "Expenses for legal advice" } } }, "localname": "ExpensesForLegalAdvice", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_ExpiryOrDeconsolidation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expiry Or Deconsolidation .", "label": "Expiry Or Deconsolidation", "terseLabel": "Expiry / Deconsolidation" } } }, "localname": "ExpiryOrDeconsolidation", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "monetaryItemType" }, "mor_ExternalLaboratoryServices": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "order": 2.0, "parentTag": "mor_AccruedLiabiityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "External laboratory services.", "label": "External laboratory services", "terseLabel": "External laboratory services" } } }, "localname": "ExternalLaboratoryServices", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_ExternalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "External services.", "label": "External Services [member]", "terseLabel": "External services [member]" } } }, "localname": "ExternalServicesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_FairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value", "label": "Fair Value", "terseLabel": "Fair Value" } } }, "localname": "FairValue", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "monetaryItemType" }, "mor_FairValueLevelLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Level [Line Items]", "label": "Fair Value Level [Line Items]", "terseLabel": "Fair Value Level [Line Items]" } } }, "localname": "FairValueLevelLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mor_FairValueLevelTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Level [Table]", "label": "Fair Value Level [Table]", "terseLabel": "Fair Value Level [Table]" } } }, "localname": "FairValueLevelTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_FederalCorporateIncomeTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal corporate income tax rate.", "label": "Federal corporate income tax rate", "terseLabel": "Federal corporate income tax rate" } } }, "localname": "FederalCorporateIncomeTaxRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mor_FinancialAssetsFromCollaboration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial Assets from Collaboration.", "label": "Financial Assets from Collaboration", "terseLabel": "Financial Assets from Collaborations" } } }, "localname": "FinancialAssetsFromCollaboration", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_FinancialAssetsFromCollaborationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Assets from Collaborations [Line Items]", "label": "Financial Assets from Collaborations [Line Items]", "terseLabel": "Financial Assets from Collaborations [Line Items]" } } }, "localname": "FinancialAssetsFromCollaborationsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "stringItemType" }, "mor_FinancialAssetsFromCollaborationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Assets from Collaborations", "label": "Financial Assets from Collaborations [Member]", "terseLabel": "Financial Assets from Collaborations [Member]" } } }, "localname": "FinancialAssetsFromCollaborationsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "mor_FinancialAssetsFromCollaborationsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Assets from Collaborations [Table]", "label": "Financial Assets from Collaborations [Table]", "terseLabel": "Financial Assets from Collaborations [Table]" } } }, "localname": "FinancialAssetsFromCollaborationsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "stringItemType" }, "mor_FinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instruments [Line Items]", "label": "Financial instruments [Line Items]", "terseLabel": "Financial instruments [Line Items]" } } }, "localname": "FinancialInstrumentsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "mor_FinancialInstrumentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instruments [Table]", "label": "Financial instruments [Table]", "terseLabel": "Financial instruments [Table]" } } }, "localname": "FinancialInstrumentsTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_FinancialLiabilitiesFromCollaboration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial Liabilities from Collaboration.", "label": "Financial Liabilities from Collaboration", "terseLabel": "Financial Liabilities from Collaboration" } } }, "localname": "FinancialLiabilitiesFromCollaboration", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_FinancialLiabilitiesFromCollaborationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial liabilities from collaborations member.", "label": "Financial Liabilities From Collaborations [Member]", "terseLabel": "Financial Liabilities From Collaborations [Member]" } } }, "localname": "FinancialLiabilitiesFromCollaborationsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "xbrltype": "domainItemType" }, "mor_FinancialLiabilitiesFromCollaborationsNetOfCurrentPortion": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial liabilities from collaborations net of current portion.", "label": "Financial Liabilities From Collaborations Net Of Current Portion", "terseLabel": "Financial Liabilities from Collaborations" } } }, "localname": "FinancialLiabilitiesFromCollaborationsNetOfCurrentPortion", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "mor_FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial Liabilities from Future Payments to Royalty Pharma, long and short-term", "label": "Financial Liabilities from Future Payments to Royalty Pharma, long and short-term", "terseLabel": "Financial Liabilities from Future Payments to Royalty Pharma, long and short-term" } } }, "localname": "FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "mor_FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongTerm": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial Liabilities from Future Payments to Royalty Pharma, Long-term", "label": "Financial Liabilities from Future Payments to Royalty Pharma, Long-term", "terseLabel": "Financial Liabilities from Future Payments to Royalty Pharma", "verboseLabel": "Non-current Portion of Financial Liabilities from Future Payments to Royalty Pharma" } } }, "localname": "FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongTerm", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails" ], "xbrltype": "monetaryItemType" }, "mor_FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Liabilities from Future Payments to Royalty Pharma", "label": "Financial Liabilities from Future Payments to Royalty Pharma [Member]", "terseLabel": "Financial Liabilities from Future Payments to Royalty Pharma [Member]" } } }, "localname": "FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_FinancialLiabilitiesRoyaltyPharmaLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Liabilities Royalty Pharma [Line Items]", "label": "Financial Liabilities Royalty Pharma [Line Items]", "terseLabel": "Financial Liabilities Royalty Pharma [Line Items]" } } }, "localname": "FinancialLiabilitiesRoyaltyPharmaLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "stringItemType" }, "mor_FinancialLiabilitiesRoyaltyPharmaTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Liabilities Royalty Pharma [Table]", "label": "Financial Liabilities Royalty Pharma [Table]", "terseLabel": "Financial Liabilities from Future Payments [Table]" } } }, "localname": "FinancialLiabilitiesRoyaltyPharmaTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "stringItemType" }, "mor_FixedCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed compensation.", "label": "Fixed Compensation [member]", "terseLabel": "Fixed compensation [member]" } } }, "localname": "FixedCompensationMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_ForeignCurrencyGainsFromFinancialAssetsFromCollaborations": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign Currency Gains from Financial Assets from Collaborations.", "label": "Foreign Currency Gains from Financial Assets from Collaborations", "verboseLabel": "Foreign Currency Gains from Financial Assets from Collaborations" } } }, "localname": "ForeignCurrencyGainsFromFinancialAssetsFromCollaborations", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "mor_ForeignCurrencyLossesFromFinancialLiabilitiesFromCollaborations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Foreign Currency Losses From Financial Liabilities From Collaborations .", "label": "Foreign Currency Losses From Financial Liabilities From Collaborations", "negatedTerseLabel": "Foreign Currency Losses from Financial Assets from Collaborations" } } }, "localname": "ForeignCurrencyLossesFromFinancialLiabilitiesFromCollaborations", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "mor_ForeignCurrencyRiskExposureNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Foreign currency risk exposure, net.", "label": "Foreign currency risk exposure, net", "terseLabel": "Foreign currency risk exposure, net" } } }, "localname": "ForeignCurrencyRiskExposureNet", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_ForeignCurrencyRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Currency Risk [Line Items]", "label": "Foreign Currency Risk [Line Items]", "terseLabel": "Foreign Currency Risk [Line Items]" } } }, "localname": "ForeignCurrencyRiskLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "stringItemType" }, "mor_ForeignCurrencyRiskTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Currency Risk [Table]", "label": "Foreign Currency Risk [Table]", "terseLabel": "Foreign Currency Risk [Table]" } } }, "localname": "ForeignCurrencyRiskTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_ForeignCurrencyTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign Currency Translation", "label": "Foreign Currency Translation", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTranslation", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "monetaryItemType" }, "mor_ForeignCurrencyTranslationDifferencesMembersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Currency Translation Differences Members", "label": "Foreign Currency Translation Differences Members [Member]", "terseLabel": "Foreign Currency Translation Differences [Members]" } } }, "localname": "ForeignCurrencyTranslationDifferencesMembersMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "xbrltype": "domainItemType" }, "mor_ForeignExchangeGainLossLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign Exchange gain (loss) - Lease Liabilities", "label": "Foreign Exchange gain (loss) - Lease Liabilities", "terseLabel": "Foreign Exchange gain (loss) - Lease Liabilities" } } }, "localname": "ForeignExchangeGainLossLeaseLiabilities", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_ForeignExchangeGainLossRightOfUseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign Exchange gain (loss) - Right of use Assets", "label": "Foreign Exchange gain (loss) - Right of use Assets", "terseLabel": "Foreign exchange gain (loss)" } } }, "localname": "ForeignExchangeGainLossRightOfUseAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_ForeignExchangeRatesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Rates [Line Items]", "label": "Foreign Exchange Rates [Line Items]", "terseLabel": "Foreign Exchange Rates [Line Items]" } } }, "localname": "ForeignExchangeRatesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails" ], "xbrltype": "stringItemType" }, "mor_ForeignExchangeRatesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign Exchange Rates [Table]", "label": "Foreign Exchange Rates [Table]", "terseLabel": "Foreign Exchange Rates [Table]" } } }, "localname": "ForeignExchangeRatesTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_ForeignExchangeSensitivityAnalysis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Foreign Exchange, Sensitivity Analysis", "label": "Foreign Exchange, Sensitivity Analysis", "terseLabel": "Foreign Exchange, Sensitivity Analysis" } } }, "localname": "ForeignExchangeSensitivityAnalysis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "xbrltype": "monetaryItemType" }, "mor_FutureMinimumLeasesPaymentsOfLowValueAssetsAndOtherShortTermLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum lease payments of low value assets and other short term leases.", "label": "Future Minimum Leases Payments Of Low Value Assets And Other Short Term Leases", "terseLabel": "Future Minimum Leases Payments Of Low Value Assets And Other Short Term Leases" } } }, "localname": "FutureMinimumLeasesPaymentsOfLowValueAssetsAndOtherShortTermLeases", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "xbrltype": "monetaryItemType" }, "mor_FutureMinimumPaymentsPerformanceShareAndUnitPrograms": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future minimum payments performance share and unit programs.", "label": "Future Minimum Payments Performance Share And Unit Programs", "terseLabel": "Future Minimum Payments Performance Share And Unit Programs" } } }, "localname": "FutureMinimumPaymentsPerformanceShareAndUnitPrograms", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "xbrltype": "monetaryItemType" }, "mor_FuturePaymentCommitmentsForClinicalStudies": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future payment commitments for clinical studies.", "label": "Future payment commitments for clinical studies", "terseLabel": "Future payment commitments for clinical studies" } } }, "localname": "FuturePaymentCommitmentsForClinicalStudies", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "xbrltype": "monetaryItemType" }, "mor_GainLossOnFinancialInstruments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain loss on financial instruments.", "label": "Gain Loss On Financial Instruments", "terseLabel": "Net Gains or Losses from Financial Instruments" } } }, "localname": "GainLossOnFinancialInstruments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "mor_GeneralAndAdministrativeExpense1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General and administrative expense1.", "label": "General And Administrative Expense1 [member]", "terseLabel": "General and administrative [member]" } } }, "localname": "GeneralAndAdministrativeExpense1Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "xbrltype": "domainItemType" }, "mor_GeneralAndAdministrativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General and administrative.", "label": "General and administrative [Member]", "terseLabel": "General and administrative [member]" } } }, "localname": "GeneralAndAdministrativeMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "domainItemType" }, "mor_GeneralImpairmentModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General impairment model.", "label": "General impairment model [member]", "terseLabel": "General impairment model [member]" } } }, "localname": "GeneralImpairmentModelMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "domainItemType" }, "mor_GoodwillAcquiredLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Acquired [Line Items]", "label": "Goodwill Acquired [Line Items]", "terseLabel": "Goodwill Acquired [Line Items]" } } }, "localname": "GoodwillAcquiredLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "xbrltype": "stringItemType" }, "mor_GoodwillAcquiredTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Acquired [Table]", "label": "Goodwill Acquired [Table]", "terseLabel": "Goodwill Acquired [Table]" } } }, "localname": "GoodwillAcquiredTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "xbrltype": "stringItemType" }, "mor_GoodwillOfConstellationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill of Constellation", "label": "Goodwill of Constellation [Member]", "terseLabel": "Goodwill of Constellation [Member]" } } }, "localname": "GoodwillOfConstellationMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "domainItemType" }, "mor_Granted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Granted", "label": "Granted", "terseLabel": "Granted" } } }, "localname": "Granted", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails" ], "xbrltype": "monetaryItemType" }, "mor_GrossCarryingAmountByCreditRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Carrying Amount by Credit Risk [Line Items]", "label": "Gross Carrying Amount by Credit Risk [Line Items]", "terseLabel": "Gross Carrying Amount by Credit Risk [Line Items]" } } }, "localname": "GrossCarryingAmountByCreditRiskLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "stringItemType" }, "mor_GrossCarryingAmountByCreditRiskTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Carrying Amount by Credit Risk [Table]", "label": "Gross Carrying Amount by Credit Risk [Table]", "terseLabel": "Gross Carrying Amount by Credit Risk [Table]" } } }, "localname": "GrossCarryingAmountByCreditRiskTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_GrossCarryingAmountOfFinancialAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount of financial assets.", "label": "Gross carrying amount of financial assets", "terseLabel": "Gross Carrying Amount" } } }, "localname": "GrossCarryingAmountOfFinancialAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_GrossGainsLossesOnFinancialInstruments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross Gains (Losses) on Financial Instruments", "label": "Gross Gains (Losses) on Financial Instruments", "terseLabel": "Gross Gains (Losses) on Financial Instruments" } } }, "localname": "GrossGainsLossesOnFinancialInstruments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "mor_GrossUnrealizedGainsOnFinancialAssetsAvailableforsale": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross unrealized gains on financial assets available-for-sale.", "label": "Gross unrealized gains on financial assets available-for-sale", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "GrossUnrealizedGainsOnFinancialAssetsAvailableforsale", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_GrossUnrealizedGainsOnLoansAndReceivables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross unrealized gains on loans and receivables.", "label": "Gross unrealized gains on loans and receivables", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "GrossUnrealizedGainsOnLoansAndReceivables", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "monetaryItemType" }, "mor_GrossUnrealizedLossesOnFinancialAssetsAvailableforsale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross unrealized losses on financial assets available-for-sale.", "label": "Gross unrealized losses on financial assets available-for-sale", "negatedTerseLabel": "Gross unrealized losses on financial assets available-for-sale" } } }, "localname": "GrossUnrealizedLossesOnFinancialAssetsAvailableforsale", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_GrossUnrealizedLossesOnLoansAndReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross unrealized losses on loans and receivables.", "label": "Gross unrealized losses on loans and receivables", "negatedTerseLabel": "Impairment" } } }, "localname": "GrossUnrealizedLossesOnLoansAndReceivables", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "monetaryItemType" }, "mor_HIBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HI-Bio", "label": "HI-Bio [Member]", "terseLabel": "HI-Bio [Member]" } } }, "localname": "HIBioMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "mor_IAS12ADeferredTaxRelatedToAssetsAndLiabilitiesArisingFromASingleTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IAS 12 (a) Deferred Tax related to Assets and Liabilities arising from a Single Transaction", "label": "IAS 12 (a) Deferred Tax related to Assets and Liabilities arising from a Single Transaction [Member]", "terseLabel": "IAS 12 (a) Deferred Tax related to Assets and Liabilities arising from a Single Transaction" } } }, "localname": "IAS12ADeferredTaxRelatedToAssetsAndLiabilitiesArisingFromASingleTransactionMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "domainItemType" }, "mor_IFRS16ALeaseLiabilityInASaleAndLeasebackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IFRS 16 A Lease Liability in a Sale and Leaseback", "label": "IFRS 16 A Lease Liability in a Sale and Leaseback [Member]", "terseLabel": "IFRS 16 A Lease Liability in a Sale and Leaseback" } } }, "localname": "IFRS16ALeaseLiabilityInASaleAndLeasebackMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "domainItemType" }, "mor_IFRS17AInitialApplicationOfIFRS17AndIFRS9ComparativeInformationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IFRS 17 A Initial application of IFRS 17 and IFRS 9 - Comparative information", "label": "IFRS 17 A Initial application of IFRS 17 and IFRS 9 - Comparative information [Member]", "terseLabel": "IFRS 17 A Initial application of IFRS 17 and IFRS 9 - Comparative information" } } }, "localname": "IFRS17AInitialApplicationOfIFRS17AndIFRS9ComparativeInformationMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "domainItemType" }, "mor_Ias16APropertyPlantAndEquipmentProceedsBeforeIntendedUseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IAS 16 A Property Plant and Equipment Proceeds before Intended Use [Member]", "terseLabel": "IAS 16A property plant and equipment proceeds before intended use [Member]" } } }, "localname": "Ias16APropertyPlantAndEquipmentProceedsBeforeIntendedUseMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail" ], "xbrltype": "domainItemType" }, "mor_Ias1AClassificationOfLiabilitiesAsCurrentOrNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IAS 1 A Classification of Liabilities as Current or Noncurrent [Member]", "terseLabel": "IAS 1A classification of liabilities as current or noncurrent [Member]" } } }, "localname": "Ias1AClassificationOfLiabilitiesAsCurrentOrNoncurrentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "domainItemType" }, "mor_Ias1ADisclosureOfAccountingPoliciesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IAS 1 A Disclosure of Accounting policies [Member]", "terseLabel": "IAS 1A disclosure of accounting policies [Member]" } } }, "localname": "Ias1ADisclosureOfAccountingPoliciesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "domainItemType" }, "mor_Ias37AAmendedByOnerousContractsCostOfFulfillingAContractMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IAS 37 A Amended by Onerous Contracts Cost of Fulfilling a Contract [Member]", "terseLabel": "IAS 37A amended by onerous contracts cost of fulfilling a contract [Member]" } } }, "localname": "Ias37AAmendedByOnerousContractsCostOfFulfillingAContractMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail" ], "xbrltype": "domainItemType" }, "mor_Ias8ADefinitionOfAccountingEstimatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IAS 8 A Definition of Accounting Estimates [Member]", "terseLabel": "IAS 8A definition of accounting estimates [Member]" } } }, "localname": "Ias8ADefinitionOfAccountingEstimatesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "domainItemType" }, "mor_Ifrs17AndIfrs17AInsuranceContractsAndAmendmentsToIfrs17Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IFRS 17 and IFRS 17 A Insurance Contracts and Amendments to IFRS 17 [Member]", "terseLabel": "IFRS 17 and IFRS 17A insurance contracts and amendments to IFRS 17 [Member]" } } }, "localname": "Ifrs17AndIfrs17AInsuranceContractsAndAmendmentsToIfrs17Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "domainItemType" }, "mor_Ifrs3AReferenceToTheConceptualFrameworkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IFRS 3 A Reference to the Conceptual Framework [Member]", "terseLabel": "IFRS 3A reference to the conceptual framework [Member]" } } }, "localname": "Ifrs3AReferenceToTheConceptualFrameworkMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail" ], "xbrltype": "domainItemType" }, "mor_ImpactOfLeasesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impact of Leases [Line Items]", "label": "Impact of Leases [Line Items]", "terseLabel": "Impact of Leases [Line Items]" } } }, "localname": "ImpactOfLeasesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "xbrltype": "stringItemType" }, "mor_ImpactOfLeasesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impact of Leases [Table]", "label": "Impact of Leases [Table]", "terseLabel": "Impact of Leases [Table]" } } }, "localname": "ImpactOfLeasesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "xbrltype": "stringItemType" }, "mor_ImpactOnMorphosysStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impact on MorphoSys status.", "label": "Impact on MorphoSys status", "terseLabel": "Possible Impact on MorphoSys" } } }, "localname": "ImpactOnMorphosysStatus", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail" ], "xbrltype": "stringItemType" }, "mor_ImpactOnProfitOrLossDueToAdoptionOfLease": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impact On Profit Or Loss Due To Adoption Of Lease.", "label": "Impact On Profit Or Loss Due To Adoption Of Lease", "totalLabel": "Impact On Profit Or Loss Due To Adoption Of Lease" } } }, "localname": "ImpactOnProfitOrLossDueToAdoptionOfLease", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mor_ImpairmentAmortizationAndOtherCostsOfIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment, amortization and other costs of intangible assets.", "label": "Impairment, amortization and other costs of intangible assets [member]", "terseLabel": "Impairment, Amortization and Other Costs of Intangible Assets [member]" } } }, "localname": "ImpairmentAmortizationAndOtherCostsOfIntangibleAssetsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_ImpairmentAndReversalsOfImpairmentOnInventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment And Reversals Of Impairment On Inventories [Member] .", "label": "Impairment And Reversals Of Impairment On Inventories [Member]", "terseLabel": "Impairment And Reversals Of Impairment On Inventories [Member]" } } }, "localname": "ImpairmentAndReversalsOfImpairmentOnInventoriesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_ImpairmentGoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment Goodwill [Line Items]", "label": "Impairment Goodwill [Line Items]", "terseLabel": "Impairment Goodwill [Line Items]" } } }, "localname": "ImpairmentGoodwillLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementImpairmentofGoodwillDetails" ], "xbrltype": "stringItemType" }, "mor_ImpairmentGoodwillTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment Goodwill [Table]", "label": "Impairment Goodwill [Table]", "terseLabel": "Impairment Goodwill [Table]" } } }, "localname": "ImpairmentGoodwillTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementImpairmentofGoodwillDetails" ], "xbrltype": "stringItemType" }, "mor_ImpairmentLossOfIntangibleAssetsAndGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment Loss of Intangible Assets and Goodwill", "label": "Impairment Loss of Intangible Assets and Goodwill", "terseLabel": "Impairment Loss of Intangible Assets and Goodwill" } } }, "localname": "ImpairmentLossOfIntangibleAssetsAndGoodwill", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_ImpairmentLossOnFinancialAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment loss on financial asset.", "label": "Impairment loss on financial asset", "terseLabel": "Impairment loss on financial asset" } } }, "localname": "ImpairmentLossOnFinancialAsset", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_ImpairmentLossReversalOfImpairmentLossRecognisedOnFinancialAssets": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 6.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Impairment loss reversal of impairment loss recognised on financial assets.", "label": "Impairment Loss Reversal Of Impairment Loss Recognised On Financial Assets", "terseLabel": "Income from Reversals of\u00a0Impairment Losses\u00a0/ (Impairment Losses)\u00a0on Financial Assets" } } }, "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedOnFinancialAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "monetaryItemType" }, "mor_ImpairmentLossesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment losses [Line Items]", "label": "Impairment losses [Line Items]", "terseLabel": "Impairment losses [Line Items]" } } }, "localname": "ImpairmentLossesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "stringItemType" }, "mor_ImpairmentLossesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment losses [Table]", "label": "Impairment losses [Table]", "terseLabel": "Impairment losses [Table]" } } }, "localname": "ImpairmentLossesTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_ImpairmentOnCombinationCompounds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment on combination compounds.", "label": "Impairment on combination compounds", "terseLabel": "Impairment on combination compounds" } } }, "localname": "ImpairmentOnCombinationCompounds", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPrepaidAssetsandOtherAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_ImpairmentOnResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impairment On Research And Development [Member].", "label": "Impairment On Research And Development [Member]", "terseLabel": "Impairment On Research And Development [Member]" } } }, "localname": "ImpairmentOnResearchAndDevelopmentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails" ], "xbrltype": "domainItemType" }, "mor_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In Process Research And Development [Member]", "terseLabel": "In-process R&D Programs and Internally Generated Intangible Assets [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryOfUsefulLivesOfIntangibleAssetsIncludingGoodwillDetail" ], "xbrltype": "domainItemType" }, "mor_IncomeStatementLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income statement location.", "label": "Income Statement Location [axis]", "terseLabel": "Income Statement Location [axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "stringItemType" }, "mor_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Statement Location Domain", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_IncomeTaxReceivablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax Receivables [Line Items]", "label": "Income tax Receivables [Line Items]", "terseLabel": "Income tax Receivables [Line Items]" } } }, "localname": "IncomeTaxReceivablesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIncomeTaxReceivablesDetails" ], "xbrltype": "stringItemType" }, "mor_IncomeTaxReceivablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax Receivables [Table]", "label": "Income tax Receivables [Table]", "terseLabel": "Income tax Receivables [Table]" } } }, "localname": "IncomeTaxReceivablesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIncomeTaxReceivablesDetails" ], "xbrltype": "stringItemType" }, "mor_IncomestatementlocationaxisAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IncomeStatementLocationAxis .", "label": "IncomeStatementLocationAxis [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomestatementlocationaxisAxis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "stringItemType" }, "mor_IncreaseDecreaseInImpairmentLossForCreditRiskRecognizedInProfitOrLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in impairment loss for credit risk recognized in profit or loss.", "label": "Increase (decrease) in impairment loss for credit risk recognized in profit or loss", "terseLabel": "Increase in Impairment Losses for Credit Risks recognized in Profit or Loss during the Year" } } }, "localname": "IncreaseDecreaseInImpairmentLossForCreditRiskRecognizedInProfitOrLoss", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_IncreaseDecreaseInImpairmentStages": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in impairment stages.", "label": "Increase (Decrease) in impairment stages", "terseLabel": "Increase (Decrease) in impairment stages" } } }, "localname": "IncreaseDecreaseInImpairmentStages", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_IncreaseDecreaseInNumberThroughTransferOfTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in number through transfer of treasury shares.", "label": "Increase (decrease) in number through transfer of treasury shares", "terseLabel": "Transfer in" } } }, "localname": "IncreaseDecreaseInNumberThroughTransferOfTreasuryShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "mor_IncreaseDecreaseInTrasuryStockAmountDueToTransfer": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in treasury stock amount due to transfer.", "label": "Increase (decrease) in trasury stock amount due to transfer", "negatedTerseLabel": "Increase (decrease) in trasury stock amount due to transfer" } } }, "localname": "IncreaseDecreaseInTrasuryStockAmountDueToTransfer", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "mor_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through share based payment transactions shares.", "label": "Increase (decrease) through share based payment transactions shares", "terseLabel": "Expenses through Share-based Payment Transactions and Issue of Convertible Instruments, shares" } } }, "localname": "IncreaseDecreaseThroughShareBasedPaymentTransactionsShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mor_IncreaseInBusinessValuationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in business valuation", "label": "Increase in business valuation [Member]", "terseLabel": "Increase in business valuation [Member]" } } }, "localname": "IncreaseInBusinessValuationMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "mor_IncreaseInCapitalReserve": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in Capital Reserve", "label": "Increase in Capital Reserve", "terseLabel": "Increase in Capital Reserve" } } }, "localname": "IncreaseInCapitalReserve", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "xbrltype": "monetaryItemType" }, "mor_IncreaseOfEuro10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase of Euro 10%", "label": "Increase of Euro 10% [Member]", "terseLabel": "Increase of Euro 10% [Member]" } } }, "localname": "IncreaseOfEuro10Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails" ], "xbrltype": "domainItemType" }, "mor_IncreaseVariableInterestRate10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase Variable Interest Rate 10%", "label": "Increase Variable Interest Rate 10% [Member]", "terseLabel": "Increase Variable Interest Rate 10% [Member]" } } }, "localname": "IncreaseVariableInterestRate10Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "xbrltype": "domainItemType" }, "mor_IncyteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incyte [member].", "label": "Incyte [Member]", "terseLabel": "Incyte [member]" } } }, "localname": "IncyteMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "mor_InprocessResearchAndDevelopmentProjectsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In-process research and development projects.", "label": "In-process research and development projects [member]", "terseLabel": "In-process R&D programs [member]" } } }, "localname": "InprocessResearchAndDevelopmentProjectsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails" ], "xbrltype": "domainItemType" }, "mor_IntangibleAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible asset.", "label": "Intangible asset [member]", "terseLabel": "Intangible asset [member]" } } }, "localname": "IntangibleAssetMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_IntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets [Line Items]", "label": "Intangible Assets [Line Items]", "terseLabel": "Intangible Assets [Line Items]" } } }, "localname": "IntangibleAssetsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "mor_IntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets [Table]", "label": "Intangible Assets [Table]", "terseLabel": "Intangible Assets [Table]" } } }, "localname": "IntangibleAssetsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "mor_InterestExpensesOnFinancialAssetsAtAmortisedCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Expenses on Financial Assets at Amortised Cost", "label": "Interest Expenses on Financial Assets at Amortised Cost", "terseLabel": "Interest Expenses on Financial Assets at Amortised Cost" } } }, "localname": "InterestExpensesOnFinancialAssetsAtAmortisedCost", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "mor_InterestInConnectionWithDilutiveShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest In Connection With Dilutive Shares .", "label": "Interest In Connection With Dilutive Shares", "verboseLabel": "Interest in connection with Dilutive Shares" } } }, "localname": "InterestInConnectionWithDilutiveShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "monetaryItemType" }, "mor_InterestRevenueForFinancialLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Revenue for Financial Liabilities", "label": "Interest Revenue for Financial Liabilities", "terseLabel": "Interest Revenue for Financial Liabilities" } } }, "localname": "InterestRevenueForFinancialLiabilities", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "mor_InternalCreditRating": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internal credit rating.", "label": "Internal Credit Rating", "terseLabel": "Internal Credit Rating" } } }, "localname": "InternalCreditRating", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "stringItemType" }, "mor_InternallyGeneratedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally Generated Intangible Assets", "label": "Internally Generated Intangible Assets [Member]", "terseLabel": "Internally Generated Intangible Assets [Member]" } } }, "localname": "InternallyGeneratedIntangibleAssetsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "mor_InventoriesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventories [Line Items]", "label": "Inventories [Line Items]", "terseLabel": "Inventories [Line Items]" } } }, "localname": "InventoriesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "xbrltype": "stringItemType" }, "mor_InventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventories [Member] .", "label": "Inventories [Member]", "verboseLabel": "Inventories [Member]" } } }, "localname": "InventoriesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_InventoriesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventories [Table]", "label": "Inventories [Table]", "terseLabel": "Inventories [Table]" } } }, "localname": "InventoriesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "xbrltype": "stringItemType" }, "mor_InvestmentsFixedTermDeposits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investments, fixed term deposits", "label": "Investments, fixed term deposits", "terseLabel": "Investments, fixed term deposits" } } }, "localname": "InvestmentsFixedTermDeposits", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_InvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments [Line Items]", "label": "Investments [Line Items]", "terseLabel": "Investments [Line Items]" } } }, "localname": "InvestmentsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_InvestmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments [Table]", "label": "Investments [Table]", "terseLabel": "Investments [Table]" } } }, "localname": "InvestmentsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_IssueOfEquityShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issue of equity shares.", "label": "Issue of equity shares", "terseLabel": "Capital Increase, Net of Issuance Cost, shares" } } }, "localname": "IssueOfEquityShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "xbrltype": "sharesItemType" }, "mor_JeanpaulKressMDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jean-Paul Kress, M.D.", "label": "JeanPaul Kress M D [Member]", "terseLabel": "JeanPaul Kress M D [Member]" } } }, "localname": "JeanpaulKressMDMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "mor_KrisjaVermeylenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Krisja Vermeylen.", "label": "Krisja Vermeylen [member]", "terseLabel": "Krisja Vermeylen [member]" } } }, "localname": "KrisjaVermeylenMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_LaboratoryAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory and office equipment.", "label": "Laboratory and Office Equipment [member]", "terseLabel": "Low-value Office and Laboratory Equipment [member]" } } }, "localname": "LaboratoryAndOfficeEquipmentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "mor_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [member]", "terseLabel": "Laboratory Equipment [member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "mor_LaboratoryServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory services.", "label": "Laboratory services [member]", "terseLabel": "Laboratory services [member]" } } }, "localname": "LaboratoryServicesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "domainItemType" }, "mor_LeaseLiabilitiesMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Liabilities M", "label": "Lease Liabilities M [Member]", "terseLabel": "Lease Liabilities [Member]" } } }, "localname": "LeaseLiabilitiesMMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mor_LeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Payments", "label": "Lease Payments", "negatedTerseLabel": "Lease Payments" } } }, "localname": "LeasePayments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_LeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases.", "label": "Leases [Member]", "terseLabel": "Leases [Member]" } } }, "localname": "LeasesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_LiabilitiesCapitalPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities capital percentage.", "label": "Liabilities capital percentage", "terseLabel": "In % of Total Capital" } } }, "localname": "LiabilitiesCapitalPercentage", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails" ], "xbrltype": "percentItemType" }, "mor_LiabilityComponentOfConvertibleBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability Component of Convertible Bond", "label": "Liability Component of Convertible Bond", "terseLabel": "Liability Component of Convertible Bond" } } }, "localname": "LiabilityComponentOfConvertibleBond", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "monetaryItemType" }, "mor_LicenseFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License fees.", "label": "License Fees [member]", "terseLabel": "License Fees [Member]" } } }, "localname": "LicenseFeesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_LicenseMilestonesAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License, Milestones and Other", "label": "License, Milestones and Other [Member]", "terseLabel": "License, Milestones and Other [Member]" } } }, "localname": "LicenseMilestonesAndOtherMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_LicensePayments": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "order": 5.0, "parentTag": "mor_AccruedLiabiityCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License payments.", "label": "License payments", "terseLabel": "License payments" } } }, "localname": "LicensePayments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_LicensesForMarketedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licenses\u00a0for Marketed Products Member.", "label": "Licenses for Marketed Products [Member]", "terseLabel": "Licenses for Marketed Products [Member]" } } }, "localname": "LicensesForMarketedProductsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "mor_LicensesMilestonesAndOther": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "order": 1.0, "parentTag": "ifrs-full_Revenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Licenses, Milestones and Other", "label": "Licenses, Milestones and Other", "terseLabel": "Licenses, Milestones and Other" } } }, "localname": "LicensesMilestonesAndOther", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "monetaryItemType" }, "mor_LicensingPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Licensing Payments", "label": "Licensing Payments", "terseLabel": "Licensing Payments" } } }, "localname": "LicensingPayments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "mor_LoansAndReceivablesMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans and receivables, maturity.", "label": "Loans and receivables, maturity", "terseLabel": "Maturity" } } }, "localname": "LoansAndReceivablesMaturity", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "stringItemType" }, "mor_LongTermCashIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Term Cash Incentive Plan", "label": "Long-Term Cash Incentive Plan [Member]", "terseLabel": "Long-Term Cash Incentive Plan [Member]" } } }, "localname": "LongTermCashIncentivePlanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails" ], "xbrltype": "domainItemType" }, "mor_LongTermDebt1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt.", "label": "Long Term Debt 1 [member]", "terseLabel": "Term deposits, net of current portion [member]" } } }, "localname": "LongTermDebt1Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "domainItemType" }, "mor_LongTermIncentivePlansLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term Incentive Plans [Line Items]", "label": "Long-term Incentive Plans [Line Items]", "terseLabel": "Long-term Incentive Plans [Line Items]" } } }, "localname": "LongTermIncentivePlansLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails" ], "xbrltype": "stringItemType" }, "mor_LongTermIncentivePlansTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term Incentive Plans [Table]", "label": "Long-term Incentive Plans [Table]", "terseLabel": "Long-term Incentive Plans [Table]" } } }, "localname": "LongTermIncentivePlansTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_LongTermRestrictedCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long term restricted cash.", "label": "Long term restricted cash", "terseLabel": "Long-term restricted cash" } } }, "localname": "LongTermRestrictedCash", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_LowMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Low [member]", "label": "Low [member]", "terseLabel": "Low [member]" } } }, "localname": "LowMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "domainItemType" }, "mor_MOR210Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MOR210", "label": "MOR210 [Member]", "terseLabel": "MOR210 [Member]" } } }, "localname": "MOR210Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "xbrltype": "domainItemType" }, "mor_MaltePetersMDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Malte Peters, M.D.", "label": "Malte Peters M D [Member]", "terseLabel": "Malte Peters M D [Member]" } } }, "localname": "MaltePetersMDMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "mor_ManagementBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management board.", "label": "Management Board [member]", "terseLabel": "Management board [member]" } } }, "localname": "ManagementBoardMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "xbrltype": "domainItemType" }, "mor_MandatoryApplicationForFinancialYearsStartingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mandatory application for financial years starting date.", "label": "Mandatory application for financial years starting date", "terseLabel": "Mandatory application for financial years starting on" } } }, "localname": "MandatoryApplicationForFinancialYearsStartingDate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsDetail", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "stringItemType" }, "mor_MarketInequity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Market Inequity", "label": "Market Inequity", "terseLabel": "Market Inequity" } } }, "localname": "MarketInequity", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails" ], "xbrltype": "monetaryItemType" }, "mor_MaturityOfLeaseLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity of Lease Liabilities [Line Items]", "label": "Maturity of Lease Liabilities [Line Items]", "terseLabel": "Maturity of Lease Liabilities [Line Items]" } } }, "localname": "MaturityOfLeaseLiabilitiesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mor_MaturityOfLeaseLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity of Lease Liabilities [Table]", "label": "Maturity of Lease Liabilities [Table]", "terseLabel": "Maturity of Lease Liabilities [Table]" } } }, "localname": "MaturityOfLeaseLiabilitiesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mor_MaturityTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity, total", "label": "Maturity, total [Member]", "terseLabel": "Maturity, total [Member]" } } }, "localname": "MaturityTotalMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mor_MaximumExposureToCreditRiskOnDebtInstruments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum exposure to credit risk on debt instruments.", "label": "Maximum exposure to credit risk on debt instruments", "terseLabel": "Maximum credit risk corresponded to carrying amounts of debt instruments" } } }, "localname": "MaximumExposureToCreditRiskOnDebtInstruments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_MaximumExposureToCreditRiskOnFinancialGuarantees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum exposure to credit risk on financial guarantees.", "label": "Maximum exposure to credit risk on financial guarantees", "terseLabel": "Maximum credit risk of financial guarantees" } } }, "localname": "MaximumExposureToCreditRiskOnFinancialGuarantees", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_MichaelBrosnanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Michael Brosnan.", "label": "Michael Brosnan [member]", "terseLabel": "Michael Brosnan [member]" } } }, "localname": "MichaelBrosnanMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_MilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment", "label": "Milestone payment", "terseLabel": "Milestone payment" } } }, "localname": "MilestonePayment", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_MilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments", "label": "Milestone Payments", "terseLabel": "Milestone Payments" } } }, "localname": "MilestonePayments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "mor_MilestonePaymentsWereCapitalized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments were Capitalized", "label": "Milestone payments were Capitalized", "terseLabel": "Milestone payments were Capitalized" } } }, "localname": "MilestonePaymentsWereCapitalized", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "monetaryItemType" }, "mor_MilestoneShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone shares", "label": "Milestone shares", "terseLabel": "Milestone shares" } } }, "localname": "MilestoneShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociateHIBIODetails" ], "xbrltype": "monetaryItemType" }, "mor_MilestonesPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones Payments [Member] .", "label": "Milestones Payments [Member]", "terseLabel": "Milestones Payments [Member]" } } }, "localname": "MilestonesPaymentsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_MiscellaneousExpenses": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "order": 2.0, "parentTag": "ifrs-full_OtherExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Miscellaneous expenses.", "label": "Miscellaneous Expenses", "negatedTerseLabel": "Expenses from Other Items" } } }, "localname": "MiscellaneousExpenses", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "mor_MiscellaneousOperatingIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Miscellaneous operating income.", "label": "Miscellaneous operating income", "verboseLabel": "Income from Other Items" } } }, "localname": "MiscellaneousOperatingIncome", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "xbrltype": "monetaryItemType" }, "mor_MoneyMarketFunds1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Money market funds.", "label": "Money Market Funds 1 [member]", "terseLabel": "Money market funds 1 [member]" } } }, "localname": "MoneyMarketFunds1Member", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "mor_MorphosysAgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morphosys AG", "label": "Morphosys AG [Member]", "terseLabel": "Morphosys AG [Member]" } } }, "localname": "MorphosysAgMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_MorphosysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morphosys [Member].", "label": "Morphosys [Member]", "terseLabel": "Morphosys [member]" } } }, "localname": "MorphosysMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "mor_MorphosysShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morphosys Share", "label": "Morphosys Share [Member]", "terseLabel": "Morphosys Share [Member]" } } }, "localname": "MorphosysShareMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "mor_MorphosysUsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MorphoSys US inc.", "label": "MorphoSys US Inc. [member]", "terseLabel": "MorphoSys US Inc. [member]", "verboseLabel": "MorphoSys US Inc., Boston, Massachusetts, USA [member]" } } }, "localname": "MorphosysUsIncMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails", "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "xbrltype": "domainItemType" }, "mor_NASDAQBiotechIndexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NASDAQ Biotech index.", "label": "NASDAQ Biotech Index [member]", "terseLabel": "NASDAQ Biotech index [member]" } } }, "localname": "NASDAQBiotechIndexMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "mor_NetGainFromDisposalOfAvailableforsaleFinancialAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net gain from disposal of available-for-sale financial assets.", "label": "Net gain from disposal of availableforsale financial assets", "terseLabel": "Net gain from disposal of available-for-sale financial assets" } } }, "localname": "NetGainFromDisposalOfAvailableforsaleFinancialAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_NetGainFromDisposalOfFinancialAssetsAtFairValueThroughProfitAndLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net gain from disposal of financial assets at fair value through profit and loss.", "label": "Net gain from disposal of financial assets at fair value through profit and loss", "terseLabel": "Interest expense/ income from financial assets at amortized cost" } } }, "localname": "NetGainFromDisposalOfFinancialAssetsAtFairValueThroughProfitAndLoss", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "monetaryItemType" }, "mor_NetLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net lease liabilities.", "label": "Net Lease Liabilities", "terseLabel": "Carrying Amount Liabilities" } } }, "localname": "NetLeaseLiabilities", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_NetLiabilitiesAndOtherChangesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Liabilities and other Changes [Line Items]", "label": "Net Liabilities and other Changes [Line Items]", "terseLabel": "Net Liabilities and other Changes [Line Items]" } } }, "localname": "NetLiabilitiesAndOtherChangesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "stringItemType" }, "mor_NetLiabilitiesAndOtherChangesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Liabilities and other Changes [Table]", "label": "Net Liabilities and other Changes [Table]", "terseLabel": "Net Liabilities and other Changes [Table]" } } }, "localname": "NetLiabilitiesAndOtherChangesTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_NoParValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No-par value per share", "label": "No-par value per share", "terseLabel": "No-par value per share" } } }, "localname": "NoParValuePerShare", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "xbrltype": "perShareItemType" }, "mor_NominalAmountBond": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nominal amount bond", "label": "Nominal amount bond", "terseLabel": "Nominal amount bond" } } }, "localname": "NominalAmountBond", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "mor_NonCashEffectiveChangeOfFinanicalLiabilitiesAytAmortizedCost": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non Cash Effective Change Of Finanical Liabilities Ayt Amortized Cost .", "label": "Non Cash Effective Change Of Finanical Liabilities Ayt Amortized Cost", "terseLabel": "Non Cash Effective Change of Bonds" } } }, "localname": "NonCashEffectiveChangeOfFinanicalLiabilitiesAytAmortizedCost", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_NonCashEffectiveNetChangeInFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non Cash Effective Net Change in Financial Liabilities from Future Payments to Royalty Pharma", "label": "Non Cash Effective Net Change in Financial Liabilities from Future Payments to Royalty Pharma", "negatedTerseLabel": "Non Cash Effective Net Change in Financial Liabilities from Future Payments to Royalty Pharma" } } }, "localname": "NonCashEffectiveNetChangeInFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_NonCashEffectiveNetChangesInFinancialAssetsOrFinancialLiabilitiesFromCollaborations": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non Cash Effective Net Changes In Financial Assets Or Financial Liabilities From Collaborations .", "label": "Non Cash Effective Net Changes In Financial Assets Or Financial Liabilities From Collaborations", "negatedLabel": "Non Cash Effective Net Change in Financial Assets / Liabilities from Collaborations" } } }, "localname": "NonCashEffectiveNetChangesInFinancialAssetsOrFinancialLiabilitiesFromCollaborations", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_NonCashIncomeFromCapitalizationOfInvestmentInAssociates": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 20.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non Cash Income from Capitalization of Investment in Associates", "label": "Non Cash Income from Capitalization of Investment in Associates", "terseLabel": "Non Cash Income from Capitalization of Investment in Associates" } } }, "localname": "NonCashIncomeFromCapitalizationOfInvestmentInAssociates", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_NonCurrentInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-current Investments", "label": "Non-current Investments", "terseLabel": "Non-current Investments" } } }, "localname": "NonCurrentInvestments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_NonCurrentPrepaidExpensesAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non current prepaid expenses and other assets.", "label": "Non current Prepaid Expenses and Other Assets", "terseLabel": "Prepaid Expenses and Other Assets, Net of Current Portion", "verboseLabel": "Prepaid Expenses and Other Assets" } } }, "localname": "NonCurrentPrepaidExpensesAndOtherAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_NonCurrentPrepaidExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Current Prepaid Expenses [Line Items]", "label": "Non-Current Prepaid Expenses [Line Items]", "terseLabel": "Non-Current Prepaid Expenses [Line Items]" } } }, "localname": "NonCurrentPrepaidExpensesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails" ], "xbrltype": "stringItemType" }, "mor_NonCurrentPrepaidExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Current Prepaid Expenses [Table]", "label": "Non-Current Prepaid Expenses [Table]", "terseLabel": "Non-Current Prepaid Expenses [Table]" } } }, "localname": "NonCurrentPrepaidExpensesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails" ], "xbrltype": "stringItemType" }, "mor_NoncurrentAssetsExcludingDeferredTaxAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-current assets, excluding deferred tax assets.", "label": "Non-current assets, excluding deferred tax assets", "terseLabel": "Non-current assets, excluding deferred tax assets" } } }, "localname": "NoncurrentAssetsExcludingDeferredTaxAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "mor_NoncurrentConvertibleBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent Convertible Bond.", "label": "Noncurrent Convertible Bond", "terseLabel": "Noncurrent Convertible Bond" } } }, "localname": "NoncurrentConvertibleBond", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_NoncurrentFinancialLiabilitiesFromCollaboration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent Financial Liabilities from Collaboration.", "label": "Noncurrent Financial Liabilities from Collaboration", "terseLabel": "Noncurrent Financial Liabilities from Collaboration" } } }, "localname": "NoncurrentFinancialLiabilitiesFromCollaboration", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_NoncurrentPrepaidExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-current prepaid expenses", "label": "Non-current prepaid expenses", "terseLabel": "Non-current prepaid expenses" } } }, "localname": "NoncurrentPrepaidExpenses", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mor_NotesToTheBalanceSheetTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes to the Balance Sheet", "label": "Notes to the Balance Sheet [Text Block]", "terseLabel": "Notes to the Balance Sheet" } } }, "localname": "NotesToTheBalanceSheetTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheet" ], "xbrltype": "textBlockItemType" }, "mor_NotionalAmountPerCent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Notional amount, per cent", "label": "Notional amount, per cent", "negatedTerseLabel": "Notional amount, per cent" } } }, "localname": "NotionalAmountPerCent", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "monetaryItemType" }, "mor_NumberOfEmployeesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Employees [Line Item] .", "label": "Number Of Employees [Line Items]", "terseLabel": "Number Of Employees [Line Items]" } } }, "localname": "NumberOfEmployeesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "stringItemType" }, "mor_NumberOfEmployeesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Employees [Table] .", "label": "Number Of Employees [Table]", "terseLabel": "Number Of Employees [Table]" } } }, "localname": "NumberOfEmployeesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "stringItemType" }, "mor_NumberOfInstrumentsExercisableOnReportingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of instruments exercisable on reporting date", "label": "Number of instruments exercisable on reporting date", "terseLabel": "Number of instruments exercisable on reporting date" } } }, "localname": "NumberOfInstrumentsExercisableOnReportingDate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails" ], "xbrltype": "decimalItemType" }, "mor_NumberOfPerformanceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Performance Shares", "label": "Number of Performance Shares", "terseLabel": "Number of Performance Shares" } } }, "localname": "NumberOfPerformanceShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "mor_NumberOfRestrictedSharesExercisableInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Restricted Shares Exercisable in Share Based Payment Arrangement", "label": "Number of Restricted Shares Exercisable in Share Based Payment Arrangement", "terseLabel": "Number of Restricted Shares Exercisable in Share Based Payment Arrangement" } } }, "localname": "NumberOfRestrictedSharesExercisableInShareBasedPaymentArrangement", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "mor_NumberOfRestrictedStockUnitsUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of restricted stock units unvested", "label": "Number of restricted stock units unvested", "terseLabel": "Number of restricted stock units unvested" } } }, "localname": "NumberOfRestrictedStockUnitsUnvested", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail" ], "xbrltype": "decimalItemType" }, "mor_NumberOfSharesIssuedToRelatedParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued to related parties.", "label": "Number Of Shares Issued To Related Parties", "terseLabel": "Number Of Shares Issued To Related Parties" } } }, "localname": "NumberOfSharesIssuedToRelatedParties", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "sharesItemType" }, "mor_NumberOfSharesIssuedToRelatedPartiesDuringPeriodAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement.", "label": "Number Of Shares Issued To Related Parties During Period Additions", "terseLabel": "Additions" } } }, "localname": "NumberOfSharesIssuedToRelatedPartiesDuringPeriodAdditions", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_NumberOfSharesIssuedToRelatedPartiesSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Number of shares issued to related parties sales.", "label": "Number Of Shares Issued To Related Parties Sales", "terseLabel": "Sales" } } }, "localname": "NumberOfSharesIssuedToRelatedPartiesSales", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_NumberOfSharesOfConditionalCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of Conditional Capital", "label": "Number of shares of Conditional Capital", "terseLabel": "Number of shares of Conditional Capital" } } }, "localname": "NumberOfSharesOfConditionalCapital", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "sharesItemType" }, "mor_NumberOfStockOptionsExcercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock options excercised", "label": "Number of stock options excercised", "terseLabel": "Number of stock options excercised" } } }, "localname": "NumberOfStockOptionsExcercised", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "sharesItemType" }, "mor_NumberOfStockOptionsUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock options unvested", "label": "Number of stock options unvested", "terseLabel": "Number of stock options unvested" } } }, "localname": "NumberOfStockOptionsUnvested", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail" ], "xbrltype": "decimalItemType" }, "mor_NumberOfTreasuryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares.", "label": "Number Of Treasury Shares", "terseLabel": "Treasury Stock shares" } } }, "localname": "NumberOfTreasuryShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "mor_NumeratorAbstractAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Numerator [Abstract] .", "label": "Numerator Abstract [Abstract]", "terseLabel": "Numerator (in \u20ac)" } } }, "localname": "NumeratorAbstractAbstract", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "xbrltype": "stringItemType" }, "mor_OffsettingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offsetting Member.", "label": "Offsetting [Member]", "terseLabel": "Offsetting [member]" } } }, "localname": "OffsettingMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_OperatingExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating expense.", "label": "Operating Expense [abstract]", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingExpenseAbstract", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "stringItemType" }, "mor_OtherAuditRelatedCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other audit-related costs", "label": "Other audit-related costs", "negatedTerseLabel": "Other audit-related costs" } } }, "localname": "OtherAuditRelatedCosts", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "xbrltype": "monetaryItemType" }, "mor_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "other commitment.", "label": "other commitment", "terseLabel": "Other" } } }, "localname": "OtherCommitment", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "xbrltype": "monetaryItemType" }, "mor_OtherCurrencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Currency [member]", "label": "Other Currency [member]", "terseLabel": "Other Currency [member]" } } }, "localname": "OtherCurrencyMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "domainItemType" }, "mor_OtherCurrentPrepayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other current prepayments.", "label": "Other Prepayments", "terseLabel": "Other Prepayments" } } }, "localname": "OtherCurrentPrepayments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_OtherFeesAndOtherServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other fees and other services", "label": "Other fees and other services", "negatedTerseLabel": "Other fees and other services" } } }, "localname": "OtherFeesAndOtherServices", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "xbrltype": "monetaryItemType" }, "mor_OtherFinancialAssetsAtAmortisedCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other financial assets at amortised cost.", "label": "Other financial assets at amortised cost [member]", "terseLabel": "Other financial assets at amortised cost [member]" } } }, "localname": "OtherFinancialAssetsAtAmortisedCostMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "xbrltype": "domainItemType" }, "mor_OtherFinancialAssetsAtAmortizedCostLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Financial Assets at Amortized Cost [Line Items]", "label": "Other Financial Assets at Amortized Cost [Line Items]", "terseLabel": "Other Financial Assets at Amortized Cost [Line Items]" } } }, "localname": "OtherFinancialAssetsAtAmortizedCostLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "stringItemType" }, "mor_OtherFinancialAssetsAtAmortizedCostTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Financial Assets at Amortized Cost [Table]", "label": "Other Financial Assets at Amortized Cost [Table]", "terseLabel": "Other Financial Assets at Amortized Cost [Table]" } } }, "localname": "OtherFinancialAssetsAtAmortizedCostTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "stringItemType" }, "mor_OtherFinancialAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other financial assets", "label": "Other financial assets [Member]", "terseLabel": "Other financial assets [Member]" } } }, "localname": "OtherFinancialAssetsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mor_OtherInterestExpenseLeaseLiability": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "order": 3.0, "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Interest Expense (Lease Liability)", "label": "Other Interest Expense (Lease Liability)", "terseLabel": "Interest Expenses on Lease Liabilities" } } }, "localname": "OtherInterestExpenseLeaseLiability", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mor_OtherLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other liabilities .", "label": "Other Liabilities [member]", "terseLabel": "Other liabilities [member]" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other", "label": "Other [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_OtherOperatingExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other operating expenses.", "label": "Other operating expenses [member]", "terseLabel": "Other Operating expenses [member]" } } }, "localname": "OtherOperatingExpensesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_OtherReceivablesFinancialAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "OtherReceivables, financial assets", "label": "OtherReceivables, financial assets", "terseLabel": "Other Receivables" } } }, "localname": "OtherReceivablesFinancialAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_OtherReceivablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Receivables [Line Items]", "label": "Other Receivables [Line Items]", "terseLabel": "Other Receivables [Line Items]" } } }, "localname": "OtherReceivablesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "stringItemType" }, "mor_OtherReceivablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Receivables [Table]", "label": "Other Receivables [Table]", "terseLabel": "Other Receivables [Table]" } } }, "localname": "OtherReceivablesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "stringItemType" }, "mor_OtherReceivablesThereofNonFinancialAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other receivables, thereof non-financial assets", "label": "Other receivables, thereof non-financial assets", "terseLabel": "Other receivables, thereof non-financial assets" } } }, "localname": "OtherReceivablesThereofNonFinancialAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_PatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patents Member.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "mor_PaymentsFromDerivativeFinancialInstruments": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments from derivative financial instruments", "label": "Payments from derivative financial instruments", "negatedTerseLabel": "Cash Payments from Derivative Financial Instruments" } } }, "localname": "PaymentsFromDerivativeFinancialInstruments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_PaymentsFromHIBio": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments from HI-Bio", "label": "Payments from HI-Bio", "terseLabel": "Payments from HI-Bio" } } }, "localname": "PaymentsFromHIBio", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "xbrltype": "monetaryItemType" }, "mor_PelabresibMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pelabresib", "label": "Pelabresib [Member]", "terseLabel": "Pelabresib [Member]" } } }, "localname": "PelabresibMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "domainItemType" }, "mor_PercentageOfAccountsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of accounts receivable.", "label": "Percentage of accounts receivable", "terseLabel": "Percentage of accounts receivable" } } }, "localname": "PercentageOfAccountsReceivable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "mor_PercentageOfFutureDevelopmentCostsForClinicalTrials": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of future development costs for clinical trials.", "label": "Percentage Of Future Development Costs For Clinical Trials", "terseLabel": "Percentage of future development costs for clinical trials" } } }, "localname": "PercentageOfFutureDevelopmentCostsForClinicalTrials", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "mor_PercentageOfIncomeTaxable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Income Taxable.", "label": "Percentage Of Income Taxable", "terseLabel": "Percentage Of Income Taxable" } } }, "localname": "PercentageOfIncomeTaxable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mor_PercentageOfSharesInDevelopmentCost": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares in development cost.", "label": "Percentage Of Shares In Development Cost", "terseLabel": "Percentage of shares in development cost" } } }, "localname": "PercentageOfSharesInDevelopmentCost", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "mor_PercentageOfSharesVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares vested", "label": "Percentage of shares vested", "terseLabel": "Percentage of shares vested" } } }, "localname": "PercentageOfSharesVested", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails" ], "xbrltype": "percentItemType" }, "mor_PercentageOnShareOfProfitLossOfAssociatesAndJointVentures": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage on share of profit loss of associates and joint ventures.", "label": "Percentage On Share Of Profit Loss Of Associates And Joint Ventures", "terseLabel": "Percentage on share of profit loss of associates and joint ventures" } } }, "localname": "PercentageOnShareOfProfitLossOfAssociatesAndJointVentures", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "mor_PerformanceCriteria": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance criteria", "label": "Performance criteria", "terseLabel": "Performance criteria" } } }, "localname": "PerformanceCriteria", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2019RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018LongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "percentItemType" }, "mor_PerformanceRelatedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Performance-related compensation", "label": "Performance-related compensation", "terseLabel": "Performance-related compensation" } } }, "localname": "PerformanceRelatedCompensation", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_PerformanceShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance share.", "label": "Performance Share [Member]", "terseLabel": "Performance Share [Member]" } } }, "localname": "PerformanceShareMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "mor_PerformanceShareUnitProgramsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Share Unit Programs [Line Items]", "label": "Performance Share Unit Programs [Line Items]", "terseLabel": "Performance Share Unit Programs [Line Items]" } } }, "localname": "PerformanceShareUnitProgramsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledPerformanceShareUnitProgramDetails" ], "xbrltype": "stringItemType" }, "mor_PerformanceShareUnitProgramsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Share Unit Programs [Table]", "label": "Performance Share Unit Programs [Table]", "terseLabel": "Performance Share Unit Programs [Table]" } } }, "localname": "PerformanceShareUnitProgramsTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_PerformanceShareUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance share units", "label": "Performance share units", "terseLabel": "Performance share units" } } }, "localname": "PerformanceShareUnits", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "mor_PerformanceShareUnitsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Share Units granted", "label": "Performance Share Units granted", "terseLabel": "Performance Share Units granted" } } }, "localname": "PerformanceShareUnitsGranted", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails" ], "xbrltype": "sharesItemType" }, "mor_PerformanceSharesOfRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Shares of Related Parties [Line Items]", "label": "Performance Shares of Related Parties [Line Items]", "terseLabel": "Performance Shares of Related Parties [Line Items]" } } }, "localname": "PerformanceSharesOfRelatedPartiesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "mor_PerformanceSharesOfRelatedPartiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Shares of Related Parties [Table]", "label": "Performance Shares of Related Parties [Table]", "terseLabel": "Performance Shares of Related Parties [Table]" } } }, "localname": "PerformanceSharesOfRelatedPartiesTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_PerformanceTermOfShareBasedProgramYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Term of Share Based Program, Years", "label": "Performance Term of Share Based Program, Years", "terseLabel": "Performance Term of Share Based Program, Years" } } }, "localname": "PerformanceTermOfShareBasedProgramYears", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails" ], "xbrltype": "decimalItemType" }, "mor_PerformanceUnrelatedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Performance-unrelated compensation", "label": "Performance-unrelated compensation", "terseLabel": "Performance-unrelated compensation" } } }, "localname": "PerformanceUnrelatedCompensation", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_PermanentImprovementsToPropertyOrBuildingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Permanent improvements to property or buildings.", "label": "Permanent Improvements to Property or Buildings [member]", "terseLabel": "Permanent Improvements to Property/Buildings [member]" } } }, "localname": "PermanentImprovementsToPropertyOrBuildingsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "xbrltype": "domainItemType" }, "mor_PersonnelExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personnel expenses.", "label": "Personnel Expenses [member]", "terseLabel": "Personnel expenses [member]" } } }, "localname": "PersonnelExpensesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_PlanningHorizon": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Planning horizon", "label": "Planning horizon", "terseLabel": "Planning horizon" } } }, "localname": "PlanningHorizon", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "gYearItemType" }, "mor_PossibleImpactOnMorphosysStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Possible Impact on MorphoSys status.", "label": "Possible Impact on MorphoSys status", "terseLabel": "Possible Impact on MorphoSys" } } }, "localname": "PossibleImpactOnMorphosysStatus", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofNewandRevisedStandardsandInterpretationsnotyetMandatorilyApplicableDetail" ], "xbrltype": "stringItemType" }, "mor_PremiumFromCapitalIncreaseByIncyte": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Premium From Capital Increase By Incyte", "label": "Premium From Capital Increase By Incyte", "terseLabel": "Premium From Capital Increase By Incyte" } } }, "localname": "PremiumFromCapitalIncreaseByIncyte", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "mor_PrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other current assets", "label": "Total", "terseLabel": "Total" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_PrepaidExpensesAndOtherCurrentAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses and Other Current Assets [Line Items]", "label": "Prepaid Expenses and Other Current Assets [Line Items]", "terseLabel": "Prepaid Expenses and Other Current Assets [Line Items]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_PrepaidExpensesAndOtherCurrentAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses and Other Current Assets [Table]", "label": "Prepaid Expenses and Other Current Assets [Table]", "terseLabel": "Prepaid Expenses and Other Current Assets [Table]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "stringItemType" }, "mor_Prepaidexpensesandothercurrentassetsconsistedofcombinationcompounds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "PrepaidExpensesAndOtherCurrentAssetsConsistedOfCombinationCompounds", "label": "Combination Compounds", "terseLabel": "Combination Drugs" } } }, "localname": "Prepaidexpensesandothercurrentassetsconsistedofcombinationcompounds", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_PrinciplesOfForeignCurrencyTranslationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principles of Foreign Currency Translation", "label": "Principles of Foreign Currency Translation [Policy Text Block]", "terseLabel": "Principles of Foreign Currency Translation" } } }, "localname": "PrinciplesOfForeignCurrencyTranslationPolicyTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mor_PriorYearTaxLossesCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prior Year Tax Losses Carryforwards.", "label": "Prior Year Tax Losses Carryforwards", "verboseLabel": "Tax Losses from Prior Years" } } }, "localname": "PriorYearTaxLossesCarryforwards", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "monetaryItemType" }, "mor_ProceedsFromDerivativeFinancialInstruments": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from derivative financial instruments.", "label": "Proceeds from derivative financial instruments", "verboseLabel": "Cash Receipts from Derivative Financial Instruments" } } }, "localname": "ProceedsFromDerivativeFinancialInstruments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_ProceedsInConnectionWithConvertibleBondsGrantedToRelatedParties": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds in connection with convertible bonds granted to related parties.", "label": "Convertible Bonds", "verboseLabel": "Cash Proceeds in Connection with Stock Options (2021) and Convertible Bonds (2020, 2019)" } } }, "localname": "ProceedsInConnectionWithConvertibleBondsGrantedToRelatedParties", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_ProductSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Sales [Member].", "label": "Product Sales [Member]", "terseLabel": "Product Sales [Member]" } } }, "localname": "ProductSalesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_ProductionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Production", "label": "Production [Member]", "terseLabel": "Production" } } }, "localname": "ProductionMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "domainItemType" }, "mor_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "mor_PropertyPlantAndEquipmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "PropertyPlantAndEquipmentTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "mor_PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase of financial assets at fair value through other comprehensive income.", "label": "Purchase of financial assets at fair value through other comprehensive income", "negatedTerseLabel": "Cash Receipts from Sales of Shares at Fair Value through Other Comprehensive Income" } } }, "localname": "PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveLoss": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase of financial assets at fair value through other comprehensive loss.", "label": "Purchase Of Financial Assets At Fair Value Through Other Comprehensive Loss", "terseLabel": "Cash Payments for Acquisitions of Shares" } } }, "localname": "PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveLoss", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mor_PurchaseOfSharesEstablishment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase of Shares / Establishment", "label": "Purchase of Shares / Establishment", "terseLabel": "Purchase of Shares / Establishment" } } }, "localname": "PurchaseOfSharesEstablishment", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/SummaryofSignificantAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "xbrltype": "textBlockItemType" }, "mor_RDProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R&D Program", "label": "R&D Program [Member]", "terseLabel": "R&D Program" } } }, "localname": "RDProgramMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "domainItemType" }, "mor_RDProgramsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R&D Programs", "label": "R&D Programs [Line Items]", "terseLabel": "R&D Programs [Line Items]" } } }, "localname": "RDProgramsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "stringItemType" }, "mor_RDProgramsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "R&D Programs", "label": "R&D Programs [Table]", "terseLabel": "R&D Programs [Table]" } } }, "localname": "RDProgramsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "stringItemType" }, "mor_ReceivablesAndOtherAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Receivables and other assets.", "label": "Receivables and other assets [member]", "terseLabel": "Receivables and other assets [member]" } } }, "localname": "ReceivablesAndOtherAssetsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_ReceivablesFromInputTaxSurplus": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables from input tax surplus.", "label": "Receivables due from Tax Authorities from Input Tax Surplus", "terseLabel": "Receivables due from Tax Authorities from Input Tax Surplus" } } }, "localname": "ReceivablesFromInputTaxSurplus", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mor_ReclassificationFromInvestmentsInAssociatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassification from Investments in Associates", "label": "Reclassification from Investments in Associates [Member]", "terseLabel": "Reclassification from Investments in Associates [Member]" } } }, "localname": "ReclassificationFromInvestmentsInAssociatesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "mor_ReclassificationToTemporaryDifference": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reclassification To Temporary Difference .", "label": "Reclassification To Temporary Difference", "terseLabel": "Reclassification to Temporary Differences" } } }, "localname": "ReclassificationToTemporaryDifference", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "monetaryItemType" }, "mor_RedemptionPercentageBasedOnOutstandingNominalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption Percentage, Based on Outstanding Nominal Amount", "label": "Redemption Percentage Based on Outstanding Nominal Amount", "terseLabel": "Redemption Percentage Based on Outstanding Nominal Amount" } } }, "localname": "RedemptionPercentageBasedOnOutstandingNominalAmount", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "mor_RedemptionPercentageOfDebtInstrumentWhenMarketPriceOfSharesFallDown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption Percentage of Debt Instrument When Market Price of Shares Fall Down", "label": "Redemption Percentage of Debt Instrument When Market Price of Shares Fall Down", "terseLabel": "Redemption Percentage of Debt Instrument When Market Price of Shares Fall Down" } } }, "localname": "RedemptionPercentageOfDebtInstrumentWhenMarketPriceOfSharesFallDown", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "mor_RelatedPartiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Parties [Line Items]", "label": "Related Parties [Line Items]", "terseLabel": "Related Parties [Line Items]" } } }, "localname": "RelatedPartiesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "mor_RelatedPartiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Parties [Table]", "label": "Related Parties [Table]", "terseLabel": "Related Parties [Table]" } } }, "localname": "RelatedPartiesTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_ReleaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Release", "label": "Release [Member]", "terseLabel": "Release [Member]" } } }, "localname": "ReleaseMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "domainItemType" }, "mor_RemunerationOfKeyManagementPersonnelLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remuneration of Key Management Personnel [Line Items]", "label": "Remuneration of Key Management Personnel [Line Items]", "terseLabel": "Remuneration of Key Management Personnel [Line Items]" } } }, "localname": "RemunerationOfKeyManagementPersonnelLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "xbrltype": "stringItemType" }, "mor_RemunerationOfKeyManagementPersonnelTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remuneration of Key Management Personnel [Table]", "label": "Remuneration of Key Management Personnel [Table]", "terseLabel": "Remuneration of Key Management Personnel [Table]" } } }, "localname": "RemunerationOfKeyManagementPersonnelTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_RemunerationOfSupervisoryBoard": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Remuneration of Supervisory Board", "label": "Remuneration of Supervisory Board", "terseLabel": "Remuneration of Supervisory Board" } } }, "localname": "RemunerationOfSupervisoryBoard", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "monetaryItemType" }, "mor_RemunerationOfSupervisoryBoardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remuneration of Supervisory Board [Line Items]", "label": "Remuneration of Supervisory Board [Line Items]", "terseLabel": "Remuneration of Supervisory Board [Line Items]" } } }, "localname": "RemunerationOfSupervisoryBoardLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "stringItemType" }, "mor_RemunerationOfSupervisoryBoardTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remuneration of Supervisory Board [Table]", "label": "Remuneration of Supervisory Board [Table]", "terseLabel": "Remuneration of Supervisory Board [Table]" } } }, "localname": "RemunerationOfSupervisoryBoardTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_RentDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rent deposits.", "label": "rent deposits[member]", "terseLabel": "Rent deposits [member]" } } }, "localname": "RentDepositsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "mor_ResearchAndDevelopmentExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development expenses.", "label": "Research and Development Expenses [abstract]", "terseLabel": "Research and Development Expenses [abstract]" } } }, "localname": "ResearchAndDevelopmentExpensesAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_ResearchAndDevelopmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development [line items]", "label": "Research And Development [line items]", "terseLabel": "Research And Development [line items]" } } }, "localname": "ResearchAndDevelopmentLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_ResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development member.", "label": "Research and development [member]", "terseLabel": "Research and development [member]" } } }, "localname": "ResearchAndDevelopmentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "domainItemType" }, "mor_ResearchAndDevelopmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of research and development.", "label": "Research And Development [table]", "terseLabel": "Research And Development [table]" } } }, "localname": "ResearchAndDevelopmentTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "xbrltype": "stringItemType" }, "mor_ReserveOfMiscellaneousOtherComprehensiveIncome": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reserve of miscellaneous other comprehensive income.", "label": "Reserve Of Miscellaneous Other Comprehensive Income", "terseLabel": "Other Comprehensive Income Reserve" } } }, "localname": "ReserveOfMiscellaneousOtherComprehensiveIncome", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "mor_RestrictedCashAsCollateralForCreditCards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted Cash as Collateral for Credit Cards", "label": "Restricted Cash as Collateral for Credit Cards", "terseLabel": "Restricted Cash as Collateral for Credit Cards" } } }, "localname": "RestrictedCashAsCollateralForCreditCards", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPrepaidAssetsandOtherAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_RestrictedStockUnitPlansLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock -Unit Plans [Line Items]", "label": "Restricted Stock Unit Plans [Line Items]", "terseLabel": "Restricted Stock Unit Plans [Line Items]" } } }, "localname": "RestrictedStockUnitPlansLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2019RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "xbrltype": "stringItemType" }, "mor_RestrictedStockUnitPlansTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock -Unit Plans [Table]", "label": "Restricted Stock Unit Plans [Table]", "terseLabel": "Restricted Stock -Unit Plans [Table]" } } }, "localname": "RestrictedStockUnitPlansTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_RevenueRecognitionMilestoneMethodRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue recognition milestone method revenue recognized.", "label": "Revenue Recognition Milestone Method Revenue Recognized", "terseLabel": "Revenue Recognition Milestone Method Revenue Recognized" } } }, "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "mor_RevenueRecognizedForReceivedPrepaymentsAndServicesPerformed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue Recognized for Received Prepayments and Services Performed.", "label": "Revenue Recognized for Received Prepayments and Services Performed", "terseLabel": "Revenue Recognized for Received Prepayments and Services Performed" } } }, "localname": "RevenueRecognizedForReceivedPrepaymentsAndServicesPerformed", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_RightOfUseAssetsAndLeaseLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right of use Assets and Lease Liabilities [Line Items]", "label": "Right of use Assets and Lease Liabilities [Line Items]", "terseLabel": "Right of use Assets and Lease Liabilities [Line Items]" } } }, "localname": "RightOfUseAssetsAndLeaseLiabilitiesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mor_RightOfUseAssetsAndLeaseLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right of use Assets and Lease Liabilities [Table]", "label": "Right of use Assets and Lease Liabilities [Table]", "terseLabel": "Right of use Assets and Lease Liabilities [Table]" } } }, "localname": "RightOfUseAssetsAndLeaseLiabilitiesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mor_RiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk-free Interest Rate", "label": "Risk-free Interest Rate", "terseLabel": "Risk-free Interest Rate" } } }, "localname": "RiskFreeInterestRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "xbrltype": "textBlockItemType" }, "mor_RoyaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties [Member] .", "label": "Royalties [Member]", "terseLabel": "Royalties [Member]" } } }, "localname": "RoyaltiesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_RoyaltyPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma", "label": "Royalty Pharma [Member]", "terseLabel": "Royalty Pharma" } } }, "localname": "RoyaltyPharmaMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "domainItemType" }, "mor_RoyaltyPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement", "label": "Royalty Purchase Agreement [Member]", "terseLabel": "Royalty Purchase Agreement [Member]" } } }, "localname": "RoyaltyPurchaseAgreementMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails" ], "xbrltype": "domainItemType" }, "mor_SaleOrIssueOfTreasurySharesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale or issue of treasury shares, shares.", "label": "Sale or issue of treasury shares, shares", "terseLabel": "Transfer of Treasury Stock for Long-Term Incentive Programs, shares" } } }, "localname": "SaleOrIssueOfTreasurySharesShares", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mor_SatisfactionOfPerformanceObligationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Satisfaction of Performance Obligations [Line Items]", "label": "Satisfaction of Performance Obligations [Line Items]", "terseLabel": "Satisfaction of Performance Obligations [Line Items]" } } }, "localname": "SatisfactionOfPerformanceObligationsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "mor_SatisfactionOfPerformanceObligationsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Satisfaction of Performance Obligations [Table]", "label": "Satisfaction of Performance Obligations [Table]", "terseLabel": "Satisfaction of Performance Obligations [Table]" } } }, "localname": "SatisfactionOfPerformanceObligationsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "mor_SatisfactionOfPerformanceObligationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Satisfaction of performance obligations", "label": "Satisfaction of performance obligations [Table Text Block]", "terseLabel": "Summary of Satisfaction of Performance Obligations" } } }, "localname": "SatisfactionOfPerformanceObligationsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_ScheduleOfTreasuryStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about composition and development of treasury stock.", "label": "Schedule of Treasury Stock [Table Text Block]", "terseLabel": "Summary of Composition and Development of Treasury Stock" } } }, "localname": "ScheduleOfTreasuryStockTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SellingExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Selling expenses.", "label": "Selling Expenses [member]", "terseLabel": "Selling [member]" } } }, "localname": "SellingExpensesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "xbrltype": "domainItemType" }, "mor_SellingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Selling [ Member] .", "label": "Selling [Member]", "terseLabel": "Selling [Member]" } } }, "localname": "SellingMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "xbrltype": "domainItemType" }, "mor_SensitivityAnalysisAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis axis.", "label": "Sensitivity Analysis [axis]", "terseLabel": "Sensitivity Analysis [axis]" } } }, "localname": "SensitivityAnalysisAxis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "stringItemType" }, "mor_SensitivityAnalysisDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity analysis domain.", "label": "Sensitivity Analysis [domain]", "terseLabel": "Sensitivity Analysis [domain]" } } }, "localname": "SensitivityAnalysisDomain", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "mor_SensitivityAnalysisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis [Line Items]", "label": "Sensitivity Analysis [Line Items]", "terseLabel": "Sensitivity Analysis [Line Items]" } } }, "localname": "SensitivityAnalysisLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "stringItemType" }, "mor_SensitivityAnalysisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis [Table]", "label": "Sensitivity Analysis [Table]", "terseLabel": "Sensitivity Analysis [Table]" } } }, "localname": "SensitivityAnalysisTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisofGoodwillDetails" ], "xbrltype": "stringItemType" }, "mor_SensitivityAnalysisVariableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis Variable [Line Items]", "label": "Sensitivity Analysis Variable [Line Items]", "terseLabel": "Sensitivity Analysis Variable [Line Items]" } } }, "localname": "SensitivityAnalysisVariableLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "xbrltype": "stringItemType" }, "mor_SensitivityAnalysisVariableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis Variable [Table]", "label": "Sensitivity Analysis Variable [Table]", "terseLabel": "Sensitivity Analysis Variable [Table]" } } }, "localname": "SensitivityAnalysisVariableTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_ServiceFeesRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service Fees Revenues [Member] .", "label": "Service Fees Revenues [Member]", "terseLabel": "Service Fees Revenues [Member]" } } }, "localname": "ServiceFeesRevenuesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_ShareBasedCompensationByShareBasedPaymentArrangementAdjustmentDueToPerformanceCriteria": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation By Share Based Payment Arrangement Adjustment Due To Performance Criteria", "label": "Share Based Compensation By Share Based Payment Arrangement Adjustment Due To Performance Criteria", "terseLabel": "Adjustment due to Performance Criteria" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentArrangementAdjustmentDueToPerformanceCriteria", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "mor_ShareBasedPaymentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Payment Expense", "label": "Share-based Payment Expense [Member]", "terseLabel": "Share-based Payment Expense" } } }, "localname": "ShareBasedPaymentExpenseMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_SharonCurranMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharon Curran.", "label": "Sharon Curran [Member]", "terseLabel": "Sharon Curran [Member]" } } }, "localname": "SharonCurranMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_ShortTermDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short term deposits [member]", "label": "Short term deposits [member]", "terseLabel": "Term deposits, current portion [member]" } } }, "localname": "ShortTermDepositsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "xbrltype": "domainItemType" }, "mor_SimplifiedImpairmentModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Simplified impairment model.", "label": "Simplified Impairment Model [member]", "terseLabel": "Simplified impairment model [member]" } } }, "localname": "SimplifiedImpairmentModelMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "domainItemType" }, "mor_SingleMostImportantCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Single most important customer.", "label": "Single most important customer [member]", "terseLabel": "Single most important customer [member]" } } }, "localname": "SingleMostImportantCustomerMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "mor_SlonomicsTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Slonomics Technology", "label": "Slonomics Technology [Member]", "terseLabel": "Slonomics Technology [Member]" } } }, "localname": "SlonomicsTechnologyMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "xbrltype": "domainItemType" }, "mor_SocialSecurityContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Social Security Contributions", "label": "Social Security Contributions [Member]", "terseLabel": "Social Security Contributions" } } }, "localname": "SocialSecurityContributionsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_SolidaritySurchargeRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Solidarity surcharge rate.", "label": "Solidarity surcharge rate", "terseLabel": "Solidarity surcharge" } } }, "localname": "SolidaritySurchargeRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mor_StageOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stage one.", "label": "Stage One [member]", "terseLabel": "Stage 1 [member]" } } }, "localname": "StageOneMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "domainItemType" }, "mor_StageThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stage three.", "label": "Stage three [member]", "terseLabel": "Stage 3 [member]" } } }, "localname": "StageThreeMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "domainItemType" }, "mor_StageTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stage two.", "label": "Stage Two [member]", "terseLabel": "Stage 2 [member]" } } }, "localname": "StageTwoMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "domainItemType" }, "mor_StartBalanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Start Balance", "label": "Start Balance [Member]", "terseLabel": "Start Balance [Member]" } } }, "localname": "StartBalanceMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "domainItemType" }, "mor_StateincomeTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "StateIncome tax rate.", "label": "StateIncome Tax Rate", "terseLabel": "State income tax rate" } } }, "localname": "StateincomeTaxRate", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "mor_Statement1Table": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Statement Table.", "label": "Statement 1 [Table]", "terseLabel": "Statement 1 [Table]" } } }, "localname": "Statement1Table", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "stringItemType" }, "mor_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [line items]", "terseLabel": "Statement [LineItems]" } } }, "localname": "StatementLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "xbrltype": "stringItemType" }, "mor_StockOptionsOfRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options of Related Parties [Line Items]", "label": "Stock Options of Related Parties [Line Items]", "terseLabel": "Stock Options of Related Parties [Line Items]" } } }, "localname": "StockOptionsOfRelatedPartiesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "mor_StockOptionsOfRelatedPartiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options of Related Parties [Table]", "label": "Stock Options of Related Parties [Table]", "terseLabel": "Stock Options of Related Parties [Table]" } } }, "localname": "StockOptionsOfRelatedPartiesTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_StockOptionsPlansLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options Plans [Line Items]", "label": "Stock Options Plans [Line Items]", "terseLabel": "Stock Options Plans [Line Items]" } } }, "localname": "StockOptionsPlansLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "stringItemType" }, "mor_StockOptionsPlansTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options Plans [Table]", "label": "Stock Options Plans [Table]", "terseLabel": "Stock Options Plans [Table]" } } }, "localname": "StockOptionsPlansTable", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_StrikePriceShareOptionsGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Strike price, share options granted", "label": "Strike price, share options granted", "terseLabel": "Exercise\u00a0Price in \u20ac" } } }, "localname": "StrikePriceShareOptionsGranted", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "xbrltype": "monetaryItemType" }, "mor_SubLicensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sub licenses.", "label": "Sub licenses [member]", "terseLabel": "Sub licenses [member]" } } }, "localname": "SubLicensesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "domainItemType" }, "mor_SubTotalOfLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sub Total of Liabilities.", "label": "Sub Total of Liabilities [Member]", "terseLabel": "Sub Total of Liabilities" } } }, "localname": "SubTotalOfLiabilitiesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "xbrltype": "domainItemType" }, "mor_SubscriptionRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription right", "label": "Subscription right", "terseLabel": "Subscription right" } } }, "localname": "SubscriptionRight", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "xbrltype": "percentItemType" }, "mor_SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounts payable and accrued liabilities.", "label": "Summary of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accounts Payable and Accrued Liabilities" } } }, "localname": "SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfAccountsReceivableByRegionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Accounts Receivable by Region", "label": "Summary of Accounts Receivable by Region [Table Text Block]", "terseLabel": "Summary of Accounts Receivable by Region" } } }, "localname": "SummaryOfAccountsReceivableByRegionTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfAccruedExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detailed information of accrued expenses explanatory.", "label": "Summary of Accrued Expenses [Table Text Block]", "terseLabel": "Summary of Accrued Expenses" } } }, "localname": "SummaryOfAccruedExpensesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfAmortizationOfIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Amortization of Intangible Assets", "label": "Summary of Amortization of Intangible Assets [Table Text Block]", "terseLabel": "Summary of Amortization of Intangible Assets" } } }, "localname": "SummaryOfAmortizationOfIntangibleAssetsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfAntiDilutionRightOtherReceivableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Anti-dilution Right (Other Receivable)", "label": "Summary of Anti-dilution Right (Other Receivable) [Table Text Block]", "terseLabel": "Summary of Anti-dilution Right (Other Receivable)" } } }, "localname": "SummaryOfAntiDilutionRightOtherReceivableTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfAuditFeesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Audit fees", "label": "Summary of Audit fees [Table Text Block]", "terseLabel": "Summary of Audit fees" } } }, "localname": "SummaryOfAuditFeesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfCapitalManagementTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of capital management information.", "label": "Summary of Capital Management [Table Text Block]", "terseLabel": "Summary of Capital Management" } } }, "localname": "SummaryOfCapitalManagementTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfCarryingAmountOfFinancialInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Carrying Amount of Financial Instruments", "label": "Summary of Carrying Amount of Financial Instruments [Table Text Block]", "terseLabel": "Summary of Carrying Amount of Financial Instruments" } } }, "localname": "SummaryOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfCashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Cash and Cash Equivalents [Line Items]", "label": "Summary of Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "SummaryOfCashAndCashEquivalentsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "mor_SummaryOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Cash and Cash Equivalents [Table]", "label": "Summary of Cash and Cash Equivalents [Table]", "terseLabel": "Cash and Cash Equivalents [Table]" } } }, "localname": "SummaryOfCashAndCashEquivalentsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "mor_SummaryOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Cash and Cash Equivalents", "label": "Summary of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Summary of Cash and Cash Equivalents" } } }, "localname": "SummaryOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfChangeInInvestmentInAdivoGmbHTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Change in investment in Adivo GmbH", "label": "Summary of Change in investment in Adivo GmbH [Table Text Block]", "terseLabel": "Summary of Change in investment in Adivo GmbH" } } }, "localname": "SummaryOfChangeInInvestmentInAdivoGmbHTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfContractLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Contract Liabilities", "label": "Summary of Contract Liabilities [Table Text Block]", "terseLabel": "Summary of Contract Liabilities" } } }, "localname": "SummaryOfContractLiabilitiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfContractualCashFlowsOfFinancialLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of license payments.", "label": "Summary of Contractual Cash Flows of Financial Liabilities [Table Text Block]", "terseLabel": "Summary of Contractual Cash Flows of Financial Liabilities" } } }, "localname": "SummaryOfContractualCashFlowsOfFinancialLiabilitiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfDepreciationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Depreciation", "label": "Summary of Depreciation [Table Text Block]", "terseLabel": "Summary of Depreciation" } } }, "localname": "SummaryOfDepreciationTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfDetailedInformationOfLiabilitiesArisingFromFinancialActivitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information Of Liabilities Arising From Financial Activities Explanatory.", "label": "Summary of Detailed Information Of Liabilities Arising From Financial Activities [Table Text Block]", "terseLabel": "Summary of Net Liabilities and Other Changes which are presented in Operating Activities" } } }, "localname": "SummaryOfDetailedInformationOfLiabilitiesArisingFromFinancialActivitiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfDevelopmentFundingBondTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Development Funding Bond", "label": "Summary of Development Funding Bond [Table Text Block]", "terseLabel": "Summary of Development Funding Bond" } } }, "localname": "SummaryOfDevelopmentFundingBondTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfDevelopmentOfCashSettledProgramsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Development of Cash-settled Programs", "label": "Summary of Development of Cash-settled Programs [Table Text Block]", "terseLabel": "Summary of Development of Cash-settled Programs" } } }, "localname": "SummaryOfDevelopmentOfCashSettledProgramsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Development of Performance Shares under Morphosys US Inc., RSU Plans", "label": "Summary of Development of Performance Shares under Morphosys US Inc., RSU Plans [Table Text Block]", "terseLabel": "Summary of Development of RSU Plans" } } }, "localname": "SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfDevelopmentOfStockOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Parameters Of Share Based Compensation.", "label": "Summary Of Development of Stock Options [Table Text Block]", "terseLabel": "Summary Of Development of Stock Options" } } }, "localname": "SummaryOfDevelopmentOfStockOptionsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfDevelopmentOfTheLTIPlansTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Development of the LTI plans", "label": "Summary of Development of the LTI plans [Table Text Block]", "terseLabel": "Summary of Development of the LTI plans" } } }, "localname": "SummaryOfDevelopmentOfTheLTIPlansTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfEarningsPerShareTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Earnings per Share", "label": "Summary of Earnings per Share [Table Text Block]", "terseLabel": "Summary of Earnings per Share" } } }, "localname": "SummaryOfEarningsPerShareTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of expected impact of initial application of new standards or interpretations", "label": "Summary of expected impact of initial application of new standards or interpretations [Table Text Block]", "terseLabel": "Summary of Impact of Lease Agreements" } } }, "localname": "SummaryOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfFairValueOfCashSettledProgramsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Fair Value of Cash-settled Programs", "label": "Summary of Fair Value of Cash-settled Programs [Table Text Block]", "terseLabel": "Summary of Fair Value of Cash-settled Programs" } } }, "localname": "SummaryOfFairValueOfCashSettledProgramsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfFairValueOfFinancialAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Fair Value of Financial Assets and Liabilities", "label": "Summary of Fair Value of Financial Assets and Liabilities [Table Text Block]", "terseLabel": "Summary of Fair Value of Financial Assets and Liabilities" } } }, "localname": "SummaryOfFairValueOfFinancialAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfFairValueOfStockOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Fair Value of Stock Options", "label": "Summary of Fair Value of Stock Options [Table Text Block]", "terseLabel": "Summary of Fair Value of Stock Options" } } }, "localname": "SummaryOfFairValueOfStockOptionsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfFinancialAssetsAtAmortizedCostTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Financial Assets at Amortized Cost", "label": "Summary of Financial Assets at Amortized Cost [Table Text Block]", "terseLabel": "Summary of Other Financial Assets at Amortized Cost" } } }, "localname": "SummaryOfFinancialAssetsAtAmortizedCostTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfFinancialAssetsFromCollaborationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Financial Assets from Collaborations", "label": "Summary of Financial Assets from Collaborations [Table Text Block]", "terseLabel": "Summary of Financial Assets from Collaborations" } } }, "localname": "SummaryOfFinancialAssetsFromCollaborationsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfFinancialInformationInvestmentInAssociatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Financial Information Investment in Associates", "label": "Summary of Financial Information Investment in Associates [Table Text Block]", "terseLabel": "Summary of Financial Information Investment in Associates" } } }, "localname": "SummaryOfFinancialInformationInvestmentInAssociatesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Financial Liabilities from Future Payments to Royalty Pharma", "label": "Summary of Financial Liabilities from Future Payments to Royalty Pharma [Table Text Block]", "terseLabel": "Summary of Financial Liabilities from Future Payments to Royalty Pharma" } } }, "localname": "SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfForeignCurrencyRiskTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of foreign currency risk.", "label": "Summary of Foreign Currency Risk [Table Text Block]", "terseLabel": "Summary of Exposure to Foreign Currency Risk" } } }, "localname": "SummaryOfForeignCurrencyRiskTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfGrossCarryingAmountsOfFinancialAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Gross Carrying Amounts of Financial Assets", "label": "Summary of Gross Carrying Amounts of Financial Assets [Table Text Block]", "terseLabel": "Summary of Gross Carrying Amounts of Financial Assets by Credit Risk" } } }, "localname": "SummaryOfGrossCarryingAmountsOfFinancialAssetsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfGrossGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Gross Gains or Losses resulted from Financial Instruments", "label": "Summary of Gross Gains or Losses resulted from Financial Instruments [Table Text Block]", "terseLabel": "Summary of Gross Gains or Losses resulted from Financial Instruments" } } }, "localname": "SummaryOfGrossGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfImpairmentLossesOnFinancialAssetsAndProvisionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Impairment Losses on Financial Assets and Provisions", "label": "Summary of Impairment Losses on Financial Assets and Provisions [Table Text Block]", "terseLabel": "Summary of Changes in Impairment Losses for Credit Risk" } } }, "localname": "SummaryOfImpairmentLossesOnFinancialAssetsAndProvisionsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfInitialMeasurementDevelopmentFundingBondTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Initial Measurement - Development Funding Bond", "label": "Summary of Initial Measurement - Development Funding Bond [Table Text Block]", "terseLabel": "Summary of Initial Measurement - Development Funding Bond" } } }, "localname": "SummaryOfInitialMeasurementDevelopmentFundingBondTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Intangible Assets", "label": "Summary of Intangible Assets [Table Text Block]", "terseLabel": "Summary of Intangible Assets" } } }, "localname": "SummaryOfIntangibleAssetsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfInventoriesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Inventories", "label": "Summary of Inventories [Table Text Block]", "terseLabel": "Summary of Inventories" } } }, "localname": "SummaryOfInventoriesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfInvestmentAtFairValueAdivoGmbHTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Investment At FairValue Change In Through Other Comprehensive Income [Text Block].", "label": "Summary of Investment At FairValue (adivo GmbH) [Table Text Block]", "terseLabel": "Summary of Investment At Fair Value (adivo GmbH)" } } }, "localname": "SummaryOfInvestmentAtFairValueAdivoGmbHTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfInvestmentsInAssociatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Investments in Associates", "label": "Summary of Investments in Associates [Table Text Block]", "terseLabel": "Summary of Investments in Associates" } } }, "localname": "SummaryOfInvestmentsInAssociatesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Investments", "label": "Summary of Investments [Table Text Block]", "terseLabel": "Summary of Other Financial Assets" } } }, "localname": "SummaryOfInvestmentsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfNetGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Net Gains or Losses resulted from Financial Instruments", "label": "Summary of Net Gains or Losses resulted from Financial Instruments [Table Text Block]", "terseLabel": "Summary of Net Gains or Losses resulted from Financial Instruments" } } }, "localname": "SummaryOfNetGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfNonCurrentPrepaidExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Non-current Prepaid Expenses", "label": "Summary of Non-current Prepaid Expenses [Table Text Block]", "terseLabel": "Summary of Non-current Prepaid Expenses" } } }, "localname": "SummaryOfNonCurrentPrepaidExpensesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfNumberOfEmployeesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Number Of Employees .", "label": "Summary Of Number Of Employees [Abstract]", "terseLabel": "Summary Of Number Of Employees [Abstract]" } } }, "localname": "SummaryOfNumberOfEmployeesAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_SummaryOfPerformanceSharesOfRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Performance Shares of Related Parties", "label": "Summary of Performance Shares of Related Parties [Table Text Block]", "terseLabel": "Summary of Performance Shares of Related Parties" } } }, "localname": "SummaryOfPerformanceSharesOfRelatedPartiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfPrepaidExpensesAndOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Prepaid Expenses and Other Assets", "label": "Summary of Prepaid Expenses and Other Assets [Table Text Block]", "terseLabel": "Summary of Current Prepaid Expenses and Other Assets" } } }, "localname": "SummaryOfPrepaidExpensesAndOtherAssetsTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfPropertyPlantAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Property, Plant and Equipment", "label": "Summary of Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property, Plant and Equipment" } } }, "localname": "SummaryOfPropertyPlantAndEquipmentTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfQuantitativeInformationAboutRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Quantitative Information About Right of use Assets and Lease Liabilities", "label": "Summary Of Quantitative Information About Right of use Assets and Lease Liabilities [Table Text Block]", "terseLabel": "Summary Of Right of use Assets and Lease Liabilities" } } }, "localname": "SummaryOfQuantitativeInformationAboutRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfRegionalDistributionOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Regional Distribution of Revenue [Line Items]", "label": "Summary of Regional Distribution of Revenue [Line Items]", "terseLabel": "Summary of Regional Distribution of Revenue [Line Items]" } } }, "localname": "SummaryOfRegionalDistributionOfRevenueLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "xbrltype": "stringItemType" }, "mor_SummaryOfRegionalDistributionOfRevenueTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Regional Distribution of Revenue [Table]", "label": "Summary of Regional Distribution of Revenue [Table]", "terseLabel": "Summary of Regional Distribution of Revenue [Table]" } } }, "localname": "SummaryOfRegionalDistributionOfRevenueTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "xbrltype": "stringItemType" }, "mor_SummaryOfRegionalDistributionOfRevenueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Regional Distribution of Revenue", "label": "Summary of Regional Distribution of Revenue [Table Text Block]", "terseLabel": "Summary of Regional Distribution of Revenue" } } }, "localname": "SummaryOfRegionalDistributionOfRevenueTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfRemunerationOfSupervisoryBoardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of supervisory board personnel compensation.", "label": "Summary of Remuneration of Supervisory Board [Table Text Block]", "terseLabel": "Summary of Remuneration of Supervisory Board" } } }, "localname": "SummaryOfRemunerationOfSupervisoryBoardTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfRevenuesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Revenues", "label": "Summary of Revenues [Table Text Block]", "terseLabel": "Summary of Revenue" } } }, "localname": "SummaryOfRevenuesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfRoyaltyPharmaFinancialLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Royalty Pharma - Financial Liability", "label": "Summary of Royalty Pharma - Financial Liability [Table Text Block]", "terseLabel": "Summary of Royalty Pharma - Financial Liability" } } }, "localname": "SummaryOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfSensitivityAnalysisOfForeignExchangeRatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Sensitivity Analysis of Foreign Exchange Rates", "label": "Summary of Sensitivity Analysis of Foreign Exchange Rates [Table Text Block]", "terseLabel": "Summary of Sensitivity Analysis of Foreign Exchange Rates" } } }, "localname": "SummaryOfSensitivityAnalysisOfForeignExchangeRatesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfSensitivityAnalysisOfInterestRateRiskTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Sensitivity Analysis of Interest Rate Risk", "label": "Summary of Sensitivity Analysis of Interest Rate Risk [Table Text Block]", "terseLabel": "Summary of Sensitivity Analysis of Variable Interest Rate Risk" } } }, "localname": "SummaryOfSensitivityAnalysisOfInterestRateRiskTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfSensitivityAnalysisOfRoyaltyPharmaFinancialLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Sensitivity Analysis of Royalty Pharma - Financial Liability", "label": "Summary of Sensitivity Analysis of Royalty Pharma - Financial Liability [Table Text Block]", "terseLabel": "Summary of Sensitivity Analysis of Royalty Pharma - Financial Liability" } } }, "localname": "SummaryOfSensitivityAnalysisOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfSharesOfRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Shares of Related Parties", "label": "Summary of Shares of Related Parties [Table Text Block]", "terseLabel": "Summary of Shares of Related Parties" } } }, "localname": "SummaryOfSharesOfRelatedPartiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfStockOptionsOfRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Stock Options of Related Parties", "label": "Summary of Stock Options of Related Parties [Table Text Block]", "terseLabel": "Summary of Stock Options of Related Parties" } } }, "localname": "SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "xbrltype": "textBlockItemType" }, "mor_SummaryOfTaxLiabilitiesCurrentAndNonCurrentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Tax Liabilities Current and Non-current", "label": "Summary of Tax Liabilities Current and Non-current [Table Text Block]", "terseLabel": "Summary of Tax Liabilities and Other Provisions" } } }, "localname": "SummaryOfTaxLiabilitiesCurrentAndNonCurrentTableTextBlock", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "xbrltype": "textBlockItemType" }, "mor_SungLeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sung Lee", "label": "Sung Lee [Member]", "terseLabel": "Sung Lee [Member]" } } }, "localname": "SungLeeMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "mor_SupervisoryBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supervisory board.", "label": "Supervisory Board [member]", "terseLabel": "Supervisory board [member]" } } }, "localname": "SupervisoryBoardMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "mor_TafasitamabMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tafasitamab", "label": "Tafasitamab [Member]", "terseLabel": "Tafasitamab [Member]" } } }, "localname": "TafasitamabMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "domainItemType" }, "mor_TargetAchievement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Target Achievement", "label": "Target Achievement", "terseLabel": "Target Achievement" } } }, "localname": "TargetAchievement", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORUSDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020RestrictedStockUnitPlansDetails" ], "xbrltype": "percentItemType" }, "mor_TaxEffectAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax effect.", "label": "Tax effect [abstract]", "terseLabel": "Tax Effects Resulting from:" } } }, "localname": "TaxEffectAbstract", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "stringItemType" }, "mor_TaxEffectFromNonRecognitionOfDeferredTaxAssetsOnCurrentYearTaxLosses1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect from non recognition of deferred tax assets on current year tax losses1.", "label": "Tax effect from non recognition of deferred tax assets on current year tax losses1", "negatedLabel": "Non-Recognition of Deferred Tax Assets on Current Year Tax Losses" } } }, "localname": "TaxEffectFromNonRecognitionOfDeferredTaxAssetsOnCurrentYearTaxLosses1", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxEffectFromNonRecognitionOfDeferredTaxAssetsOnTemporaryDifferences1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect from non recognition of deferred tax assets on temporary differences1.", "label": "Tax effect from non recognition of deferred tax assets on temporary differences1", "negatedLabel": "Non-Recognition of Deferred Tax Assets on Temporary Differences" } } }, "localname": "TaxEffectFromNonRecognitionOfDeferredTaxAssetsOnTemporaryDifferences1", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxEffectFromRecognitionOfDeferredTaxAssetsOnCurrentYearTaxLosses1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effect From Recognition Of Deferred Tax Assets On Current Year Tax Losses1", "label": "Recognition of Deferred Tax Assets on Tax Loss Carryforwards from Prior Years", "terseLabel": "Recognition of Deferred Tax Assets on Tax Loss Carryforwards from Prior Years" } } }, "localname": "TaxEffectFromRecognitionOfDeferredTaxAssetsOnCurrentYearTaxLosses1", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxEffectFromRecognitionOfDeferredTaxAssetsOnTemporaryDifferences1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effect From Recognition Of Deferred Tax Assets On Temporary Differences1", "label": "Recognition of Deferred Tax Assets on Prior Year Temporary Differences", "terseLabel": "Recognition of Deferred Tax Assets on Prior Year Temporary Differences" } } }, "localname": "TaxEffectFromRecognitionOfDeferredTaxAssetsOnTemporaryDifferences1", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxEffectOfPriorYearAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect of prior year adjustments.", "label": "Tax effect of prior year adjustments", "negatedLabel": "Prior Year Taxes" } } }, "localname": "TaxEffectOfPriorYearAdjustments", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxEffectOfSharebasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect of share-based compensation.", "label": "Tax Effect of Share-based Compensation", "negatedLabel": "Share-based Payment" } } }, "localname": "TaxEffectOfSharebasedCompensation", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxEffectsOfPermanentDifferences": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effects Of Permanent Differences.", "label": "Tax Effects Of Permanent Differences", "terseLabel": "Permanent Differences" } } }, "localname": "TaxEffectsOfPermanentDifferences", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxLiabilitiesCurrentAndNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax liabilities, current and non-current", "label": "Tax liabilities, current and non-current", "negatedTerseLabel": "Tax liabilities, current and non-current" } } }, "localname": "TaxLiabilitiesCurrentAndNonCurrent", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "mor_TaxLossesCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Losses Carryforwards.", "label": "Tax Losses Carryforwards", "verboseLabel": "Total Tax Losses as of December\u00a031, 2020" } } }, "localname": "TaxLossesCarryforwards", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxLossesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tax Losses [Member]", "terseLabel": "Tax Losses [member]", "verboseLabel": "Tax Losses [Member]" } } }, "localname": "TaxLossesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "mor_TaxLossesRelativeToUSTaxGroup": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax losses relative to US tax group", "label": "Tax losses relative to US tax group", "terseLabel": "Tax losses relative to US tax group" } } }, "localname": "TaxLossesRelativeToUSTaxGroup", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "mor_TaxProvisionsAndCurrentAndNoncurrentOtherProvisions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax provisions and current and non-current other provisions.", "label": "Tax provisions and current and non-current other provisions", "negatedTerseLabel": "Tax provisions and current and non-current other provisions" } } }, "localname": "TaxProvisionsAndCurrentAndNoncurrentOtherProvisions", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "mor_TaxProvisionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Provisions [Line Items]", "label": "Tax Provisions [Line Items]", "terseLabel": "Tax Provisions [Line Items]" } } }, "localname": "TaxProvisionsLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "stringItemType" }, "mor_TaxProvisionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Provisions [Table]", "label": "Tax Provisions [Table]", "terseLabel": "Tax Provisions [Table]" } } }, "localname": "TaxProvisionsTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "stringItemType" }, "mor_TaxServiceFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax service fees", "label": "Tax service fees", "negatedTerseLabel": "Tax service fees" } } }, "localname": "TaxServiceFees", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "xbrltype": "monetaryItemType" }, "mor_TecDAXIndexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TecDAX index.", "label": "TecDAX Index [member]", "terseLabel": "TecDAX index [member]" } } }, "localname": "TecDAXIndexMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "xbrltype": "domainItemType" }, "mor_TechnicalEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Technical Equipment [Member]", "terseLabel": "Technical Equipment [Member]" } } }, "localname": "TechnicalEquipmentMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mor_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Text block [abstract]", "label": "Text block [abstract]", "terseLabel": "Text block [abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_ThereofForwardExchangeContractsUsedForHedging": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Thereof forward exchange contracts used for hedging", "label": "Thereof forward exchange contracts used for hedging", "terseLabel": "Thereof forward exchange contracts used for hedging" } } }, "localname": "ThereofForwardExchangeContractsUsedForHedging", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mor_ThroughProfitLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Through Profit / Loss", "label": "Through Profit / Loss [Member]", "terseLabel": "Through Profit / Loss [Member]" } } }, "localname": "ThroughProfitLossMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "mor_TradeAccountsPayable": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails": { "order": 2.0, "parentTag": "mor_AccountsPayableAndAccruedExpensesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Trade accounts payable.", "label": "Trade Accounts Payable", "terseLabel": "Trade Accounts Payable" } } }, "localname": "TradeAccountsPayable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "xbrltype": "monetaryItemType" }, "mor_TradeReceivablesAndContractAssets": { "auth_ref": [], "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Trade receivables and contract assets.", "label": "Trade receivables and contract assets", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeReceivablesAndContractAssets", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "mor_TransferOfAssignedLicenseRevenuesToRoyaltyPharma": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transfer of Assigned License Revenues to Royalty Pharma", "label": "Transfer of Assigned License Revenues to Royalty Pharma", "terseLabel": "Transfer of Assigned License Revenues to Royalty Pharma" } } }, "localname": "TransferOfAssignedLicenseRevenuesToRoyaltyPharma", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "mor_TreasurySharesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Shares [Line Items]", "label": "Treasury Shares [Line Items]", "terseLabel": "Treasury Shares [Line Items]" } } }, "localname": "TreasurySharesLineItems", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "mor_TreasurySharesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Shares [Table]", "label": "Treasury Shares [Table]", "terseLabel": "Treasury Shares [Table]" } } }, "localname": "TreasurySharesTable", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "mor_TreasuryStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Treasury stock, value", "label": "Treasury stock, value", "terseLabel": "Treasury stock, value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "mor_TwoThousandEighteenLongTermIncentiveProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Eighteen Long Term Incentive Program [member]", "label": "Two Thousand Eighteen Long Term Incentive Program [member]", "terseLabel": "2018 long-term incentive program [member]" } } }, "localname": "TwoThousandEighteenLongTermIncentiveProgramMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledLongtermIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "mor_TwoThousandNineteenLongTermIncentiveProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen long term incentive program", "label": "Two Thousand Nineteen Long Term Incentive Program [Member]", "terseLabel": "Two Thousand Nineteen Long Term Incentive Program [Member]" } } }, "localname": "TwoThousandNineteenLongTermIncentiveProgramMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "mor_TwoThousandSeventeenLongTermIncentiveProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen long term incentive program.", "label": "Two thousand seventeen long term incentive program [member]", "terseLabel": "2017 long-term incentive plan [member]" } } }, "localname": "TwoThousandSeventeenLongTermIncentiveProgramMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasurySharesDetails" ], "xbrltype": "domainItemType" }, "mor_TypeOfDebtInstrumentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of Debt Instrument", "label": "Type of Debt Instrument [Axis]", "terseLabel": "Type of Debt Instrument [Axis]" } } }, "localname": "TypeOfDebtInstrumentAxis", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "stringItemType" }, "mor_TypeOfDebtInstrumentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of Debt Instrument", "label": "Type of Debt Instrument [Domain]", "terseLabel": "Type of Debt Instrument [Domain]" } } }, "localname": "TypeOfDebtInstrumentDomain", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_USAAndCanadaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USA and Canada.", "label": "USA and canada [member]", "terseLabel": "USA and Canada [member]" } } }, "localname": "USAAndCanadaMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "xbrltype": "domainItemType" }, "mor_UnlimitedAndLimitedCarryForwardOfTaxLossesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unlimited And Limited Carry Forward of Tax Losses Abstract.", "label": "Unlimited And Limited Carry Forward of Tax Losses [Abstract]", "terseLabel": "Unlimited And Limited Carry Forward of Tax Losses [Abstract]" } } }, "localname": "UnlimitedAndLimitedCarryForwardOfTaxLossesAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_UnlimitedCarryForwardOfTaxLossesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unlimited Carry Forward Of Tax Losses (Member).", "label": "Unlimited Carry Forward Of Tax Losses [Member]", "terseLabel": "Unlimited Carry Forward Of Tax Losses [member]" } } }, "localname": "UnlimitedCarryForwardOfTaxLossesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "domainItemType" }, "mor_UnsecuredConvertibleBondMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured Convertible Bond", "label": "Unsecured Convertible Bond [Member]", "terseLabel": "Unsecured Convertible Bond [Member]" } } }, "localname": "UnsecuredConvertibleBondMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "xbrltype": "domainItemType" }, "mor_UnusedProvisionAmountsReversed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unused provision amounts reversed.", "label": "Unused provision amounts reversed", "terseLabel": "Unused Amounts Reversed" } } }, "localname": "UnusedProvisionAmountsReversed", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "mor_UpfrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront Payment", "label": "Upfront Payment", "terseLabel": "Upfront Payment" } } }, "localname": "UpfrontPayment", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "xbrltype": "monetaryItemType" }, "mor_UsefulLivesOfIntangibleAssetsIncludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Useful Lives Of Intangible Assets Including Goodwill [Abstract]", "terseLabel": "Useful Lives Of Intangible Assets Including Goodwill [Abstract]" } } }, "localname": "UsefulLivesOfIntangibleAssetsIncludingGoodwillAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_UtilizationOfTaxLosses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Utilization Of Tax Losses .", "label": "Utilization Of Tax Losses", "terseLabel": "Utilization Of Tax Losses" } } }, "localname": "UtilizationOfTaxLosses", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "xbrltype": "monetaryItemType" }, "mor_UtilizationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Utilizations", "label": "Utilizations [Member]", "terseLabel": "Utilizations [Member]" } } }, "localname": "UtilizationsMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "xbrltype": "domainItemType" }, "mor_WagesAndSalariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wages and Salaries", "label": "Wages and Salaries [Member]", "terseLabel": "Wages and Salaries [Member]" } } }, "localname": "WagesAndSalariesMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "xbrltype": "domainItemType" }, "mor_WeightedAverageCostOfCapitalBeforeTaxPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average cost of capital before tax percentage.", "label": "Weighted Average Cost of Capital Before Tax Percentage", "terseLabel": "WACC before Tax" } } }, "localname": "WeightedAverageCostOfCapitalBeforeTaxPercentage", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "xbrltype": "percentItemType" }, "mor_WeightedAverageNumberOfEquitySharesUsedInComputingEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of equity shares used in computing earnings per share.", "label": "Weighted Average Number of Equity Shares Used In Computing Earnings per Share [abstract]", "terseLabel": "Weighted Average Number of Equity Shares Used In Computing Earnings per Share [abstract]" } } }, "localname": "WeightedAverageNumberOfEquitySharesUsedInComputingEarningsPerShareAbstract", "nsuri": "http://www.morphosys.com/20221231", "xbrltype": "stringItemType" }, "mor_WeightedAverageNumberOfEquitySharesUsedInComputingEarningsPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of equity shares used in computing earnings per share basic and diluted.", "label": "Weighted average number of equity shares used in computing earnings per share basic and diluted", "terseLabel": "Shares Used in Computing Earnings per Share, Basic and Diluted" } } }, "localname": "WeightedAverageNumberOfEquitySharesUsedInComputingEarningsPerShareBasicAndDiluted", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "sharesItemType" }, "mor_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number Of Shares Outstanding Basic .", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Shares Used in Computing Earnings per Share, Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "mor_WeightedAverageNumberOfSharesOutstandingDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number Of Shares Outstanding Diluted .", "label": "Weighted Average Number Of Shares Outstanding Diluted", "terseLabel": "Shares Used in Computing Earnings per Share, Diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDiluted", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "xbrltype": "sharesItemType" }, "mor_WendyJohnsonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wendy Johnson.", "label": "Wendy Johnson [member]", "terseLabel": "Wendy Johnson [member]" } } }, "localname": "WendyJohnsonMember", "nsuri": "http://www.morphosys.com/20221231", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r10": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r100": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r110": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r120": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "30", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_30_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "30", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_30&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "23", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_23_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "9B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_9B_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r130": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Clause": "ix", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r140": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r150": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_115&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "m", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_m&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r160": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r170": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r180": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r190": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "11A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_11A_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r20": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r200": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r210": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r220": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r230": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "9", "Paragraph": "6.5.15", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_6.5.15&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r240": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39M", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r250": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_7&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_91_a&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39G", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39G_a&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39J", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J_a&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39J", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r259": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r26": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r260": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r261": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r262": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r263": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r264": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r265": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r266": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r267": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r268": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r269": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r27": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r270": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r271": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r272": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r273": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r274": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r275": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r276": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r277": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r278": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r279": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "14", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r28": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r280": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r281": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r282": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r283": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r284": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r285": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r286": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r287": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r288": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r289": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r29": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r290": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r291": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r292": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r293": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r294": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r295": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r296": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "IG23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r297": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r298": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r299": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r3": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r30": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r300": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r301": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r302": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r303": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r304": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r305": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r306": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r307": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r308": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG20C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r309": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r31": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r310": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r311": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r312": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r313": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r314": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "36", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_c&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r315": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r316": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r317": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG25", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG25_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r318": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r319": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r32": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r320": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r321": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r322": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r323": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r324": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r325": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r326": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r327": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r328": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r329": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r33": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r330": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r331": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r332": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r333": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r334": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r335": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r336": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r337": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r338": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r339": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r34": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r340": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r341": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r342": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r343": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r344": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r345": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r346": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r347": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r348": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r350": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r360": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r40": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r50": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r60": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r70": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r80": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "126", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "129", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_129_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "134", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_d_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "134", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r90": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_88&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" }